Zithromax and penicillin

September 18th, 2013 | No Comments

Buy zithromax pill

Some in the Hudson Valley were caught by surprise when there was a rare and buy zithromax pill unexpected earthquake in the area. Shortly before 4:30 p.m buy zithromax pill. On Thursday, Oct. 22, there was a 2.2 magnitude earthquake in Merritt Park reported near Fishkill in Dutchess County, according to officials.On Volcano buy zithromax pill Discovery, some residents said that they heard the quake, but couldn’t feel the ground shaking below them.“I thought it was construction work,” a Hopewell Junction resident reported.

€œ(It) sounded like concrete falling but more resounding. Didn’t feel buy zithromax pill a shake. Only heard sound for about two seconds then quick pause then sound for another one second.”A Putnam County resident in Mahopac said that it “sounded like our boiler kicked on and something was wrong with it, to the point I went into the basement to check it.” Earthquakes are a rarity in New York. According to Earthquake track, there have only been two reported in the past month, and 20 buy zithromax pill in the past year.

Click here to sign up for Daily Voice's free daily emails and news alerts..

Zithromax and penicillin

Zithromax
Noroxin
Long term side effects
250mg 12 tablet $17.99
400mg 30 tablet $39.99
Price per pill
No more than once a day
Twice a day
Buy with american express
Canadian pharmacy only
In online pharmacy

Start Preamble zithromax and penicillin Food and Drug Administration, HHS. Notice of availability. The Food and Drug Administration (FDA) is zithromax and penicillin announcing the availability of a revised draft guidance for industry entitled “Hospital and Health System Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act” (“revised draft guidance”). This revised draft guidance, when finalized, will describe how FDA intends to apply certain provisions of the Federal Food, Drug, and Cosmetic Act (FD&C Act) to human drug products compounded by State-licensed pharmacies that are not outsourcing facilities and distributed for use within a hospital or health system. First, it addresses the requirement that compounding be based on the receipt of a valid prescription order for an identified individual patient.

Second, it addresses the provision concerning compounded drug products that are essentially copies of a commercially available drug product zithromax and penicillin. This draft guidance revises the draft guidance issued in 2016 entitled, “Hospital and Health System Compounding Under the Federal Food, Drug, and Cosmetic Act” (“draft guidance”). FDA is revising the draft guidance to address stakeholder feedback and provide further clarification on policies regarding hospital and health system compounding. This revised draft guidance is not final nor is it in zithromax and penicillin effect at this time. Submit either electronic or written comments on the revised draft guidance by December 6, 2021 to ensure that the Agency considers your comment on this revised draft guidance before it begins work on the final version of the guidance.

Submit electronic or written comments on the proposed collection of information in the revised draft guidance by December 6, 2021. You may submit comments on any zithromax and penicillin guidance at any time as follows. Electronic Submissions Submit electronic comments in the following way. Start Printed Page 55848 • Federal eRulemaking Portal. Https://www.regulations.gov.

Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https://www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov. If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions”).

Written/Paper Submissions Submit written/paper submissions as follows. • Mail/Hand Delivery/Courier (for written/paper submissions). Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.” Instructions.

All submissions received must include the Docket No. FDA-2016-D-0271 for “Hospital and Health System Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act.” Received comments will be placed in the docket and, except for those submitted as “Confidential Submissions,” publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. And 4 p.m., Monday through Friday, 240-402-7500. • Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total.

One copy will include the information you claim to be confidential with a heading or cover note that states “THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.” The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as “confidential.” Any information marked as “confidential” will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at.

Https://www.govinfo.gov/​content/​pkg/​FR-2015-09-18/​pdf/​2015-23389.pdf. Docket. For access to the docket to read background documents or the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the “Search” box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500. You may submit comments on any guidance at any time (see 21 CFR 10.115(g)(5)).

Submit written requests for single copies of this revised draft guidance to the Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration, 10001 New Hampshire Ave., Hillandale Building, 4th Floor, Silver Spring, MD 20993-0002. Send one self-addressed adhesive label to assist that office in processing your request or include a fax number to which the revised draft guidance may be sent. See the SUPPLEMENTARY INFORMATION section for information on electronic access to the revised draft guidance. Start Further Info With regard to the revised draft guidance. Tracy Rupp, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg.

51, Silver Spring, MD 20993, 301-796-3100. With regard to the proposed collection of information. Domini Bean, Office of Operations, Food and Drug Administration, Three White Flint North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-5733, PRAStaff@fda.hhs.gov. End Further Info End Preamble Start Supplemental Information I. Background FDA is announcing the availability of a revised draft guidance for industry entitled “Hospital and Health System Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act.” Pharmacies located within a hospital, or standalone pharmacies that are part of a health system, frequently provide compounded drug products for administration within the hospital or health system.

Some of these compounders seek to compound under section 503A of the FD&C Act (21 U.S.C. 353a) and others have registered with FDA as outsourcing facilities and are subject to section 503B of the FD&C Act (21 U.S.C. 353b). Section 503A of the FD&C Act describes the conditions that must be satisfied for human drug products compounded by a licensed pharmacist in a State-licensed pharmacy or Federal facility, or by a licensed physician, to be exempt from the following three sections of the FD&C Act. Section 501(a)(2)(B) (21 U.S.C.

351(a)(2)(B)) (concerning current good manufacturing practice (CGMP) requirements). Section 502(f)(1) (21 U.S.C. 352(f)(1)) (concerning the labeling of drugs with adequate directions for use). And Section 505 (21 U.S.C. 355) (concerning the approval of drugs under new drug applications or abbreviated new drug applications).

This revised draft guidance proposes policies for FDA's application of certain provisions of section 503A of the FD&C Act to human drug products compounded by State-licensed pharmacies that are not outsourcing facilities and distributed for use within a hospital or health system. First, the revised draft guidance addresses the requirement that compounding be based on the receipt of a valid prescription order for an identified individual patient. Second, it addresses the provision concerning compounded drug products that are essentially copies of a commercially available drug product. This revised draft guidance does not apply to human drug products compounded by outsourcing facilities under section 503B of the FD&C Act, compounded drug products that are not distributed for use within a hospital or health system, or drug products compounded for use in animals. In the Federal Register of April 18, 2016 (81 FR 22610), FDA announced the availability of a draft guidance for industry entitled, “Hospital and Health System Compounding Under the Federal Food, Drug, and Cosmetic Act” Start Printed Page 55849 (“draft guidance”).

The draft guidance proposed new policies for the application of section 503A of the FD&C Act to drug products compounded by licensed pharmacists or physicians in State-licensed hospital or health system pharmacies. In particular, the draft guidance described certain circumstances under which FDA generally would not intend to take action if a hospital or health system pharmacy distributed compounded drug products without first receiving a patient-specific prescription or order. The comment period on the initial draft guidance ended on July 18, 2016. FDA received approximately 76 comments on the draft guidance. FDA is issuing a revised draft guidance with certain changes made in response to received comments or on its own initiative.

For example, the prescription requirement enforcement policy described in the revised draft guidance does not consider whether the drug products are distributed only to healthcare facilities that are located within a 1-mile radius of the compounding pharmacy (“1-mile radius policy”). Instead, the Agency is proposing a two-part, risk-based compliance policy. In addition, the revised draft guidance proposes new policies for hospital and health system pharmacies regarding the provision in section 503A of the FD&C Act which states that to qualify for the exemptions under section 503A of the FD&C Act, among other conditions, a drug product must be compounded by a licensed pharmacist or physician who does not compound regularly or in inordinate amounts any drug products that are essentially copies of a commercially available drug product. FDA is issuing this revised draft guidance to address stakeholders' feedback, reflect additional Agency consideration of the proposed policies, and enable the public to further review and comment before finalization. This revised draft guidance is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115).

The revised draft guidance, when finalized, will represent the current thinking of FDA on “Hospital and Health System Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act.” It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. II. Paperwork Reduction Act of 1995 Under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501-3521), Federal Agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor.

€œCollection of information” is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes Agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal Agencies to provide a 60-day notice in the Federal Register concerning each proposed collection of information before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information set forth in this document.

We are consolidating the information collection in the revised draft guidance with the information collections and approvals under OMB control number 0910-0800. With respect to the following collection of information, FDA invites comments on these topics. (1) Whether the proposed collection of information is necessary for the proper performance of FDA's functions, including whether the information will have practical utility. (2) the accuracy of FDA's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used. (3) ways to enhance the quality, utility, and clarity of the information to be collected.

And (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology. Human Drug Compounding Under Sections 503A and 503B the Federal Food, Drug, and Cosmetic Act OMB Control Number 0910-0800—Revision This notice solicits comments on certain information collections found in the revised draft guidance entitled “Hospital and Health System Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act” (“revised draft guidance”). This guidance, when finalized, will support implementation of the copies provisions of the 1997 Food and Drug Administration Modernization Act (FDAMA) (Pub. L. 105-115) discussed in section 503A of the FD&C Act, which were maintained by the 2013 Drug Quality and Security Act (DQSA) (Title I of Pub.

L. 113-54). For efficiency of Agency operations, we are revising OMB control number 0910-0800 to include information collections relating to the copies policies for hospital and health system pharmacies that are not outsourcing facilities, as proposed in the revised draft guidance document. As proposed in section III.B of the revised draft guidance, among other conditions, we generally would not intend to take action against a hospital or health system pharmacy that is not an outsourcing facility for compounding a drug product regularly or in inordinate amounts that is essentially a copy of a commercially available drug product, if the compounded drug product is administered only to patients within the hospital or health system and the pharmacy obtains from the prescriber a statement that. (1) Specifies a change between the compounded drug product and the commercially available drug product.

(2) indicates that the compounded drug product will be administered only to patients for whom the change produces a significant difference from the commercially available drug product. And (3) describes the intended patient population for the compounded drug product. In addition, the revised draft guidance specifies that the statement would be maintained in the hospital or health system pharmacy to address routine orders for patients for whom the change produces a significant difference, and a statement would be on file for each prescriber that covers each drug product that is compounded. As provided in section III.B of the revised draft guidance, except for the policy proposed above regarding the documentation of a prescriber's determination of significant difference, we propose to apply the policies described in the guidance, “Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act” (“503A copies guidance”) to drug products compounded by hospital and health system pharmacies that are not outsourcing facilities. As described in section III.B.2 of the 503A copies guidance, and proposed in the revised draft guidance to apply to hospital and health system pharmacies, if a compounder intends to rely on a prescriber determination of significant difference to establish that a compounded drug is not essentially a copy of a commercially available drug product, the compounder should ensure that the determination is documented on the prescription.

If a prescription Start Printed Page 55850 does not make clear that the prescriber made the determination required by section 503A(b)(2) of the FD&C Act, or a compounded drug is substituted for the commercially available drug product, the compounder can contact the prescriber and if the prescriber confirms it, make a notation on the prescription that the compounded drug product contains a change that makes a significant difference for the patient. The notations should be as specific as those described in the 503A copies guidance, and the date of the conversation with the prescriber should be included on the prescription. With respect to the determination of significant difference described above, we estimate that, annually, a total of approximately 3,075 hospital or health system pharmacies (table 1) will obtain a prescriber determination of significant difference. This estimate represents approximately half of the hospitals in the United States, including those that are in health systems. Of these, we estimate that approximately half (1,538) will have hospital or health system pharmacies that will follow the policy in the revised draft guidance, obtaining a statement of significant difference for the intended patient population, and approximately half (1,537) will have hospital or health system pharmacies that will follow the policy with respect to prescriber determination of significant difference in the 503A copies guidance, documenting the notation on the individual patient prescription.

This estimate assumes that most pharmacies in smaller hospitals and health systems will follow the policy in the 503A copies guidance because a prescriber determination of significant difference will not be routinely needed and can be most efficiently managed on a patient-by-patient basis. On the other hand, this estimate assumes that most pharmacies in larger hospitals and health systems will follow the policy in the revised draft guidance because the need for a prescriber determination of significant difference is more routinely necessary and, therefore, most efficiently managed with a statement of significant difference that is maintained in the hospital or health system pharmacy to address routine orders for patients for whom the change produces a significant difference. We estimate that, annually, approximately 1,538 hospital or health system pharmacies following the policy in the revised draft guidance will obtain approximately 30 statements of significant difference for compounded drug products, for a total of approximately 46,140 statements (table 1, row 1). We estimate that the consultation between the hospital or health system pharmacy and the prescriber to obtain the statement of significant difference will require approximately 5 minutes per statement (table 1, row 1). We estimate that, annually, approximately 1,537 hospital or health pharmacies following the policy in the 503A copies guidance will consult a prescriber to determine whether the prescriber has made a determination that the compounded drug product has a change that produces a significant difference for a patient as compared to the comparable commercially available drug and that the compounders will document this determination on approximately 76,850 prescription orders for compounded drug products (table 1, row 2).

We estimate that the consultation between the compounder and the prescriber and adding a notation to each prescription that does not already document this determination will take approximately 3 minutes per prescription order (table 1, row 2). The average burden per consultation and notation for pharmacies following the significant difference policy in the 503A copies guidance, compared to pharmacies following the significant difference policy in the revised draft guidance, is estimated to be less (3 minutes) because the significant difference determination described in the 503A copies policy is specific to one patient, whereas the statement of significant difference in the revised draft guidance describes the intended patient population. In addition, as described in section III.B.3 of the 503A copies guidance, and proposed in the revised draft guidance to apply to hospital and health system pharmacies, if the drug product was compounded because the approved drug product was not commercially available because it was on the FDA drug shortage list, the prescription or a notation on the prescription should note that it was on the drug shortage list and note the date the list was checked. We estimate that a total of approximately 4,613 hospital or health system pharmacies will document this information on approximately 922,600 prescription orders for compounded drug products (table 1, row 3). We estimate that checking FDA's drug shortage list and documenting this information will require approximately 2 minutes per prescription order (table 1, row 3).

With respect to maintaining records of the statement of significant difference proposed in section III.B of the revised draft guidance, we estimate that a total of approximately 1,538 hospital or health system pharmacies will maintain approximately 46,140 statements of significant difference (table 2, row 1). We estimate that maintaining the records will require approximately 2 minutes per record (table 2, row 1). With respect to maintaining records of the significant difference determination, as provided in section III.B.5 of the 503A copies guidance, we estimate that a total of approximately 1,537 hospital or health system pharmacies will maintain approximately 76,850 records (table 2, row 2). We estimate that maintaining records will require approximately 2 minutes per record (table 2, row 2). Also with respect to maintenance of records, as described in section III.B.5 of the 503A copies guidance, and proposed in the revised draft guidance to apply to hospital and health system pharmacies, compounders under section 503A should maintain records of (1) the frequency in which they have compounded drug products that are essentially copies of commercially available drug products and (2) the number of prescriptions that they have filled for compounded drug products that are essentially copies of commercially available drug products.

We estimate that a total of approximately 3,075 hospital or health system pharmacies will maintain approximately 61,500 records of prescriptions that they have filled for compounded drug products that are essentially copies of commercially available drug products (table 2, row 3). We estimate that maintaining the records will require approximately 2 minutes per record (table 2, row 3). We estimate the burden of this collection of information as follows. Start Printed Page 55851 Table 1—Estimated Annual Third-Party Disclosure Burden 1ActivityNumber of respondentsNumber of disclosures per respondentTotal annual disclosuresAverage burden per disclosureTotal hoursConsultation between the hospital or health system pharmacy and the prescriber to document the statement of significant difference (revised draft guidance)1,5383046,140.08 (5 minutes)3,691Consultation between the hospital or health system pharmacy and prescriber and the notation on the prescription documenting the prescriber's determination of significant difference (503A copies guidance)1,5375076,850.05 (3 minutes)3,843Hospital or health system pharmacy checking FDA's drug shortage list and documenting on the prescription that the drug is in shortage (503A copies guidance)4,613200922,600.03 (2 minutes)27,678Total35,2121  There are no capital costs or operating and maintenance costs associated with this collection of information. Table 2—Estimated Annual Recordkeeping Burden 1ActivityNumber of recordkeepersNumber of records per recordkeeperTotal annual recordsAverage burden per recordkeepingTotal hoursRecords of the statement of significant difference (revised draft guidance)1,5383046,140.03 (2 minutes)1,384Records of documentation of significant difference (503A copies guidance)1,5375076,850.03 (2 minutes)2,306Records of frequency and number of prescriptions filled for compounded drug products that are essentially a copy (503A copies guidance)3,0752061,500.03 (2 minutes)1,845Total5,5351  There are no capital costs or operating and maintenance costs associated with this collection of information.

IV. Electronic Access Persons with access to the internet may obtain an electronic version of the revised draft guidance at either https://www.fda.gov/​Drugs/​GuidanceComplianceRegulatoryInformation/​Guidances/​default.htm or https://www.regulations.gov. Start Signature Dated. October 4, 2021. Lauren K.

Roth, Associate Commissioner for Policy. End Signature End Supplemental Information [FR Doc. 2021-21970 Filed 10-6-21. 8:45 am]BILLING CODE 4164-01-PStart Preamble Centers for Medicare &. Medicaid Services, Health and Human Services (HHS).

Notice. The Centers for Medicare &. Medicaid Services (CMS) is announcing an opportunity for the public to comment on CMS' intention to collect information from the public. Under the Paperwork Reduction Act of 1995 (the PRA), federal agencies are required to publish notice in the Federal Register concerning each proposed collection of information (including each proposed extension or reinstatement of an existing collection of information) and to allow 60 days for public comment on the proposed action. Interested persons are invited to send comments regarding our burden estimates or any other aspect of this collection of information, including the necessity and utility of the proposed information collection for the proper performance of the agency's functions, the accuracy of the estimated burden, ways to enhance the quality, utility, and clarity of the information to be collected, and the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

Comments must be received by October 19, 2021. When commenting, please reference the document identifier or OMB control number. To be assured consideration, comments and recommendations must be submitted in any one of the following ways. 1. Electronically.

You may send your comments electronically to http://www.regulations.gov. Follow the instructions for “Comment or Submission” or “More Search Options” to find the information collection document(s) that are accepting comments. 2. By regular mail. You may mail written comments to the following address.

CMS, Office of Strategic Operations and Regulatory Affairs, Division of Regulations Development, Attention. Document Identifier/OMB Control Number. __, Room C4-26-05, 7500 Security Boulevard, Baltimore, Maryland 21244-1850. To obtain copies of a supporting statement and any related forms for the proposed collection(s) summarized in this notice, you may make your request using one of following. 1.

Access CMS' website address at website address at https://www.cms.gov/​Regulations-and-Guidance/​Legislation/​PaperworkReductionActof1995/​PRA-Listing.html. Start Further Info William N. Parham at (410) 786-4669. End Further Info End Preamble Start Supplemental Information Contents This notice sets out a summary of the use and burden associated with the following information collections. More detailed information can be found in each collection's supporting statement and associated materials (see ADDRESSES).

CMS-10280 Home Health Change of Care Notice CMS-1557 Survey Report Form for Clinical Laboratory Improvement Amendments (CLIA) and Supporting Regulations CMS-3070G-I ICF/IID Survey Report Form and Supporting Regulations Under the PRA (44 U.S.C. 3501-3520), federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. The term “collection of information” is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA requires federal agencies to publish a 60-day notice in the Federal Register concerning each proposed collection of information, including each proposed extension or reinstatement of an existing collection of information, before submitting the collection to OMB for approval.

To comply with this requirement, CMS is publishing this notice. Information Collection 1. Type of Information Collection Request. Extension of a currently approved collection. Title of the Information Collection.

Home Health Change of Care Notice. Use. The purpose of the Home Health Change of Care Notice (HHCCN) is to notify original Medicare beneficiaries receiving home health care benefits of plan of care changes. Home health agencies (HHAs) are required to provide written notice to Original Medicare beneficiaries under various circumstances involving the reduction or termination of items and/or services consistent with Home Health Agencies Conditions of Participation (COPs). The home health COP requirements are set forth in § 1891[42 U.S.C.

1395bbb] of the Social Security Act (the Act). The implementing regulations under 42 CFR 484.10(c) specify that Medicare patients receiving HHA services have rights. The patient has the right to be informed, in advance about the care to be furnished, and of any changes in the care to be furnished. The HHA must advise the patient in advance of the disciplines that will furnish care, and the frequency of visits proposed to be furnished. The HHA must advise the patient in advance of any change in the plan of care before the change is made.” Notification is required for covered and non-covered services listed in the plan of care (POC).

The beneficiary will use the information provided to decide whether or not to pursue alternative options to continue receiving the care noted on the HHCCN. Form Number. CMS-10280 (OMB control number. 0938-1196). Frequency.

Yearly. Affected Public. Private Sector (Business or other for-profits, Not-for-Profit Institutions). Number of Respondents. 11,157.

Total Annual Responses. 12,385,108. Total Annual Hours. 824,848. (For policy questions regarding this collection contact Jennifer McCormick at 410-786-2852.) 2.

Type of Information Collection Request. Extension of a currently approved collection. Title of Information Collection. Survey Report Form for Clinical Laboratory Improvement Amendments (CLIA) and Supporting Regulations. Use.

The form is used to report surveyor findings during a CLIA survey. For each type of survey conducted (i.e., initial certification, recertification, validation, complaint, addition/deletion of specialty/subspecialty, transfusion fatality investigation, or revisit inspections) the Survey Report Form incorporates the requirements specified in the CLIA regulations. Form Number. CMS-1557 (OMB control number. 0938-0544).

Frequency. Biennially. Affected Public. Private sector (Business or other for-profit and Not-for-profit institutions, State, Local or Tribal Governments and Federal Government). Number of Respondents.

15,975. Total Start Printed Page 46855Annual Responses. 7,988. Total Annual Hours. 3,994.

(For policy questions regarding this collection contact Kathleen Todd at 410-786-3385). 3. Type of Information Collection Request. Revision of a currently approved collection. Title of Information Collection.

ICF/IID Survey Report Form and Supporting Regulations. Use. The information collected with forms 3070G, CMS-3070H and CMS-3070I is used by the surveyors from the State Survey Agencies (SAs) to determine the level of compliance with the ICF/IID Conditions of Participation (CoPs) necessary to participate in the Medicare/Medicaid program and to report any non-compliance with the ICF/IID CoPs to the Federal government. These forms summarize the survey team characteristics, facility characteristics, client population, and the special needs of clients. These forms are used in conjunction with the CMS regulation text and additional surveyor aids such as the CMS interpretive guidelines and probes.

The CMS-3070G-I forms serves as coding worksheets, designed to facilitate data entry and retrieval into the Automated Survey Processing Environment Suite (ASPEN) in the State and at the CMS regional offices. Form Number. CMS-3070G-I (OMB control number. 0938-0062). Frequency.

Reporting—Yearly. Affected Public. Business or other for-profits and Not-for-profit institutions. Number of Respondents. 5,758.

Total Annual Responses. 5,758. Total Annual Hours. 17,274. (For policy questions regarding this collection contact Caroline Gallaher at 410-786-8705.) Start Signature Dated.

August 17, 2021. William N. Parham, III Director, Paperwork Reduction Staff, Office of Strategic Operations and Regulatory Affairs. End Signature End Supplemental Information [FR Doc. 2021-17908 Filed 8-19-21.

Start Preamble Home Page Food and Drug buy zithromax pill Administration, HHS. Notice of availability. The Food and Drug Administration (FDA) is announcing the availability of a revised draft guidance for industry entitled “Hospital and Health System Compounding Under Section 503A buy zithromax pill of the Federal Food, Drug, and Cosmetic Act” (“revised draft guidance”).

This revised draft guidance, when finalized, will describe how FDA intends to apply certain provisions of the Federal Food, Drug, and Cosmetic Act (FD&C Act) to human drug products compounded by State-licensed pharmacies that are not outsourcing facilities and distributed for use within a hospital or health system. First, it addresses the requirement that compounding be based on the receipt of a valid prescription order for an identified individual patient. Second, it addresses the provision concerning compounded drug products that are essentially copies of a buy zithromax pill commercially available drug product.

This draft guidance revises the draft guidance issued in 2016 entitled, “Hospital and Health System Compounding Under the Federal Food, Drug, and Cosmetic Act” (“draft guidance”). FDA is revising the draft guidance to address stakeholder feedback and provide further clarification on policies regarding hospital and health system compounding. This revised draft guidance is not final nor buy zithromax pill is it in effect at this time.

Submit either electronic or written comments on the revised draft guidance by December 6, 2021 to ensure that the Agency considers your comment on this revised draft guidance before it begins work on the final version of the guidance. Submit electronic or written comments on the proposed collection of information in the revised draft guidance by December 6, 2021. You may submit comments on any guidance at any buy zithromax pill time as follows.

Electronic Submissions Submit electronic comments in the following way. Start Printed Page 55848 • Federal eRulemaking Portal. Https://www.regulations.gov.

Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https://www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process.

Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov. If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions”). Written/Paper Submissions Submit written/paper submissions as follows.

• Mail/Hand Delivery/Courier (for written/paper submissions). Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.” Instructions. All submissions received must include the Docket No. FDA-2016-D-0271 for “Hospital and Health System Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act.” Received comments will be placed in the docket and, except for those submitted as “Confidential Submissions,” publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m.

And 4 p.m., Monday through Friday, 240-402-7500. • Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total.

One copy will include the information you claim to be confidential with a heading or cover note that states “THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.” The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management Staff.

If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as “confidential.” Any information marked as “confidential” will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at. Https://www.govinfo.gov/​content/​pkg/​FR-2015-09-18/​pdf/​2015-23389.pdf.

Docket. For access to the docket to read background documents or the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the “Search” box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500.

You may submit comments on any guidance at any time (see 21 CFR 10.115(g)(5)). Submit written requests for single copies of this revised draft guidance to the Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration, 10001 New Hampshire Ave., Hillandale Building, 4th Floor, Silver Spring, MD 20993-0002. Send one self-addressed adhesive label to assist that office in processing your request or include a fax number to which the revised draft guidance may be sent.

See the SUPPLEMENTARY INFORMATION section for information on electronic access to the revised draft guidance. Start Further Info With regard to the revised draft guidance. Tracy Rupp, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg.

51, Silver Spring, MD 20993, 301-796-3100. With regard to the proposed collection of information. Domini Bean, Office of Operations, Food and Drug Administration, Three White Flint North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-5733, PRAStaff@fda.hhs.gov.

End Further Info End Preamble Start Supplemental Information I. Background FDA is announcing the availability of a revised draft guidance for industry entitled “Hospital and Health System Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act.” Pharmacies located within a hospital, or standalone pharmacies that are part of a health system, frequently provide compounded drug products for administration within the hospital or health system. Some of these compounders seek to compound under section 503A of the FD&C Act (21 U.S.C.

353a) and others have registered with FDA as outsourcing facilities and are subject to section 503B of the FD&C Act (21 U.S.C. 353b). Section 503A of the FD&C Act describes the conditions that must be satisfied for human drug products compounded by a licensed pharmacist in a State-licensed pharmacy or Federal facility, or by a licensed physician, to be exempt from the following three sections of the FD&C Act.

Section 501(a)(2)(B) (21 U.S.C. 351(a)(2)(B)) (concerning current good manufacturing practice (CGMP) requirements). Section 502(f)(1) (21 U.S.C.

352(f)(1)) (concerning the labeling of drugs with adequate directions for use). And Section 505 (21 U.S.C. 355) (concerning the approval of drugs under new drug applications or abbreviated new drug applications).

This revised draft guidance proposes policies for FDA's application of certain provisions of section 503A of the FD&C Act to human drug products compounded by State-licensed pharmacies that are not outsourcing facilities and distributed for use within a hospital or health system. First, the revised draft guidance addresses the requirement that compounding be based on the receipt of a valid prescription order for an identified individual patient. Second, it addresses the provision concerning compounded drug products that are essentially copies of a commercially available drug product.

This revised draft guidance does not apply to human drug products compounded by outsourcing facilities under section 503B of the FD&C Act, compounded drug products that are not distributed for use within a hospital or health system, or drug products compounded for use in animals. In the Federal Register of April 18, 2016 (81 FR 22610), FDA announced the availability of a draft guidance for industry entitled, “Hospital and Health System Compounding Under the Federal Food, Drug, and Cosmetic Act” Start Printed Page 55849 (“draft guidance”). The draft guidance proposed new policies for the application of section 503A of the FD&C Act to drug products compounded by licensed pharmacists or physicians in State-licensed hospital or health system pharmacies.

In particular, the draft guidance described certain circumstances under which FDA generally would not intend to take action if a hospital or health system pharmacy distributed compounded drug products without first receiving a patient-specific prescription or order. The comment period on the initial draft guidance ended on July 18, 2016. FDA received approximately 76 comments on the draft guidance.

FDA is issuing a revised draft guidance with certain changes made in response to received comments or on its own initiative. For example, the prescription requirement enforcement policy described in the revised draft guidance does not consider whether the drug products are distributed only to healthcare facilities that are located within a 1-mile radius of the compounding pharmacy (“1-mile radius policy”). Instead, the Agency is proposing a two-part, risk-based compliance policy.

In addition, the revised draft guidance proposes new policies for hospital and health system pharmacies regarding the provision in section 503A of the FD&C Act which states that to qualify for the exemptions under section 503A of the FD&C Act, among other conditions, a drug product must be compounded by a licensed pharmacist or physician who does not compound regularly or in inordinate amounts any drug products that are essentially copies of a commercially available drug product. FDA is issuing this revised draft guidance to address stakeholders' feedback, reflect additional Agency consideration of the proposed policies, and enable the public to further review and comment before finalization. This revised draft guidance is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115).

The revised draft guidance, when finalized, will represent the current thinking of FDA on “Hospital and Health System Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act.” It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. II.

Paperwork Reduction Act of 1995 Under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501-3521), Federal Agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. €œCollection of information” is defined in 44 U.S.C.

3502(3) and 5 CFR 1320.3(c) and includes Agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal Agencies to provide a 60-day notice in the Federal Register concerning each proposed collection of information before submitting the collection to OMB for approval.

To comply with this requirement, FDA is publishing notice of the proposed collection of information set forth in this document. We are consolidating the information collection in the revised draft guidance with the information collections and approvals under OMB control number 0910-0800. With respect to the following collection of information, FDA invites comments on these topics.

(1) Whether the proposed collection of information is necessary for the proper performance of FDA's functions, including whether the information will have practical utility. (2) the accuracy of FDA's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used. (3) ways to enhance the quality, utility, and clarity of the information to be collected.

And (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology. Human Drug Compounding Under Sections 503A and 503B the Federal Food, Drug, and Cosmetic Act OMB Control Number 0910-0800—Revision This notice solicits comments on certain information collections found in the revised draft guidance entitled “Hospital and Health System Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act” (“revised draft guidance”). This guidance, when finalized, will support implementation of the copies provisions of the 1997 Food and Drug Administration Modernization Act (FDAMA) (Pub.

L. 105-115) discussed in section 503A of the FD&C Act, which were maintained by the 2013 Drug Quality and Security Act (DQSA) (Title I of Pub. L.

113-54). For efficiency of Agency operations, we are revising OMB control number 0910-0800 to include information collections relating to the copies policies for hospital and health system pharmacies that are not outsourcing facilities, as proposed in the revised draft guidance document. As proposed in section III.B of the revised draft guidance, among other conditions, we generally would not intend to take action against a hospital or health system pharmacy that is not an outsourcing facility for compounding a drug product regularly or in inordinate amounts that is essentially a copy of a commercially available drug product, if the compounded drug product is administered only to patients within the hospital or health system and the pharmacy obtains from the prescriber a statement that.

(1) Specifies a change between the compounded drug product and the commercially available drug product. (2) indicates that the compounded drug product will be administered only to patients for whom the change produces a significant difference from the commercially available drug product. And (3) describes the intended patient population for the compounded drug product.

In addition, the revised draft guidance specifies that the statement would be maintained in the hospital or health system pharmacy to address routine orders for patients for whom the change produces a significant difference, and a statement would be on file for each prescriber that covers each drug product that is compounded. As provided in section III.B of the revised draft guidance, except for the policy proposed above regarding the documentation of a prescriber's determination of significant difference, we propose to apply the policies described in the guidance, “Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act” (“503A copies guidance”) to drug products compounded by hospital and health system pharmacies that are not outsourcing facilities. As described in section III.B.2 of the 503A copies guidance, and proposed in the revised draft guidance to apply to hospital and health system pharmacies, if a compounder intends to rely on a prescriber determination of significant difference to establish that a compounded drug is not essentially a copy of a commercially available drug product, the compounder should ensure that the determination is documented on the prescription.

If a prescription Start Printed Page 55850 does not make clear that the prescriber made the determination required by section 503A(b)(2) of the FD&C Act, or a compounded drug is substituted for the commercially available drug product, the compounder can contact the prescriber and if the prescriber confirms it, make a notation on the prescription that the compounded drug product contains a change that makes a significant difference for the patient. The notations should be as specific as those described in the 503A copies guidance, and the date of the conversation with the prescriber should be included on the prescription. With respect to the determination of significant difference described above, we estimate that, annually, a total of approximately 3,075 hospital or health system pharmacies (table 1) will obtain a prescriber determination of significant difference.

This estimate represents approximately half of the hospitals in the United States, including those that are in health systems. Of these, we estimate that approximately half (1,538) will have hospital or health system pharmacies that will follow the policy in the revised draft guidance, obtaining a statement of significant difference for the intended patient population, and approximately half (1,537) will have hospital or health system pharmacies that will follow the policy with respect to prescriber determination of significant difference in the 503A copies guidance, documenting the notation on the individual patient prescription. This estimate assumes that most pharmacies in smaller hospitals and health systems will follow the policy in the 503A copies guidance because a prescriber determination of significant difference will not be routinely needed and can be most efficiently managed on a patient-by-patient basis.

On the other hand, this estimate assumes that most pharmacies in larger hospitals and health systems will follow the policy in the revised draft guidance because the need for a prescriber determination of significant difference is more routinely necessary and, therefore, most efficiently managed with a statement of significant difference that is maintained in the hospital or health system pharmacy to address routine orders for patients for whom the change produces a significant difference. We estimate that, annually, approximately 1,538 hospital or health system pharmacies following the policy in the revised draft guidance will obtain approximately 30 statements of significant difference for compounded drug products, for a total of approximately 46,140 statements (table 1, row 1). We estimate that the consultation between the hospital or health system pharmacy and the prescriber to obtain the statement of significant difference will require approximately 5 minutes per statement (table 1, row 1).

We estimate that, annually, approximately 1,537 hospital or health pharmacies following the policy in the 503A copies guidance will consult a prescriber to determine whether the prescriber has made a determination that the compounded drug product has a change that produces a significant difference for a patient as compared to the comparable commercially available drug and that the compounders will document this determination on approximately 76,850 prescription orders for compounded drug products (table 1, row 2). We estimate that the consultation between the compounder and the prescriber and adding a notation to each prescription that does not already document this determination will take approximately 3 minutes per prescription order (table 1, row 2). The average burden per consultation and notation for pharmacies following the significant difference policy in the 503A copies guidance, compared to pharmacies following the significant difference policy in the revised draft guidance, is estimated to be less (3 minutes) because the significant difference determination described in the 503A copies policy is specific to one patient, whereas the statement of significant difference in the revised draft guidance describes the intended patient population.

In addition, as described in section III.B.3 of the 503A copies guidance, and proposed in the revised draft guidance to apply to hospital and health system pharmacies, if the drug product was compounded because the approved drug product was not commercially available because it was on the FDA drug shortage list, the prescription or a notation on the prescription should note that it was on the drug shortage list and note the date the list was checked. We estimate that a total of approximately 4,613 hospital or health system pharmacies will document this information on approximately 922,600 prescription orders for compounded drug products (table 1, row 3). We estimate that checking FDA's drug shortage list and documenting this information will require approximately 2 minutes per prescription order (table 1, row 3).

With respect to maintaining records of the statement of significant difference proposed in section III.B of the revised draft guidance, we estimate that a total of approximately 1,538 hospital or health system pharmacies will maintain approximately 46,140 statements of significant difference (table 2, row 1). We estimate that maintaining the records will require approximately 2 minutes per record (table 2, row 1). With respect to maintaining records of the significant difference determination, as provided in section III.B.5 of the 503A copies guidance, we estimate that a total of approximately 1,537 hospital or health system pharmacies will maintain approximately 76,850 records (table 2, row 2).

We estimate that maintaining records will require approximately 2 minutes per record (table 2, row 2). Also with respect to maintenance of records, as described in section III.B.5 of the 503A copies guidance, and proposed in the revised draft guidance to apply to hospital and health system pharmacies, compounders under section 503A should maintain records of (1) the frequency in which they have compounded drug products that are essentially copies of commercially available drug products and (2) the number of prescriptions that they have filled for compounded drug products that are essentially copies of commercially available drug products. We estimate that a total of approximately 3,075 hospital or health system pharmacies will maintain approximately 61,500 records of prescriptions that they have filled for compounded drug products that are essentially copies of commercially available drug products (table 2, row 3).

We estimate that maintaining the records will require approximately 2 minutes per record (table 2, row 3). We estimate the burden of this collection of information as follows. Start Printed Page 55851 Table 1—Estimated Annual Third-Party Disclosure Burden 1ActivityNumber of respondentsNumber of disclosures per respondentTotal annual disclosuresAverage burden per disclosureTotal hoursConsultation between the hospital or health system pharmacy and the prescriber to document the statement of significant difference (revised draft guidance)1,5383046,140.08 (5 minutes)3,691Consultation between the hospital or health system pharmacy and prescriber and the notation on the prescription documenting the prescriber's determination of significant difference (503A copies guidance)1,5375076,850.05 (3 minutes)3,843Hospital or health system pharmacy checking FDA's drug shortage list and documenting on the prescription that the drug is in shortage (503A copies guidance)4,613200922,600.03 (2 minutes)27,678Total35,2121  There are no capital costs or operating and maintenance costs associated with this collection of information.

Table 2—Estimated Annual Recordkeeping Burden 1ActivityNumber of recordkeepersNumber of records per recordkeeperTotal annual recordsAverage burden per recordkeepingTotal hoursRecords of the statement of significant difference (revised draft guidance)1,5383046,140.03 (2 minutes)1,384Records of documentation of significant difference (503A copies guidance)1,5375076,850.03 (2 minutes)2,306Records of frequency and number of prescriptions filled for compounded drug products that are essentially a copy (503A copies guidance)3,0752061,500.03 (2 minutes)1,845Total5,5351  There are no capital costs or operating and maintenance costs associated with this collection of information. IV. Electronic Access Persons with access to the internet may obtain an electronic version of the revised draft guidance at either https://www.fda.gov/​Drugs/​GuidanceComplianceRegulatoryInformation/​Guidances/​default.htm or https://www.regulations.gov.

Start Signature Dated. October 4, 2021. Lauren K.

Roth, Associate Commissioner for Policy. End Signature End Supplemental Information [FR Doc. 2021-21970 Filed 10-6-21.

8:45 am]BILLING CODE 4164-01-PStart Preamble Centers for Medicare &. Medicaid Services, Health and Human Services (HHS). Notice.

The Centers for Medicare &. Medicaid Services (CMS) is announcing an opportunity for the public to comment on CMS' intention to collect information from the public. Under the Paperwork Reduction Act of 1995 (the PRA), federal agencies are required to publish notice in the Federal Register concerning each proposed collection of information (including each proposed extension or reinstatement of an existing collection of information) and to allow 60 days for public comment on the proposed action.

Interested persons are invited to send comments regarding our burden estimates or any other aspect of this collection of information, including the necessity and utility of the proposed information collection for the proper performance of the agency's functions, the accuracy of the estimated burden, ways to enhance the quality, utility, and clarity of the information to be collected, and the use of automated collection techniques or other forms of information technology to minimize the information collection burden. Comments must be received by October 19, 2021. When commenting, please reference the document identifier or OMB control number.

To be assured consideration, comments and recommendations must be submitted in any one of the following ways. 1. Electronically.

You may send your comments electronically to http://www.regulations.gov. Follow the instructions for “Comment or Submission” or “More Search Options” to find the information collection document(s) that are accepting comments. 2.

By regular mail. You may mail written comments to the following address. CMS, Office of Strategic Operations and Regulatory Affairs, Division of Regulations Development, Attention.

Document Identifier/OMB Control Number. __, Room C4-26-05, 7500 Security Boulevard, Baltimore, Maryland 21244-1850. To obtain copies of a supporting statement and any related forms for the proposed collection(s) summarized in this notice, you may make your request using one of following.

1. Access CMS' website address at website address at https://www.cms.gov/​Regulations-and-Guidance/​Legislation/​PaperworkReductionActof1995/​PRA-Listing.html. Start Further Info William N.

Parham at (410) 786-4669. End Further Info End Preamble Start Supplemental Information Contents This notice sets out a summary of the use and burden associated with the following information collections. More detailed information can be found in each collection's supporting statement and associated materials (see ADDRESSES).

CMS-10280 Home Health Change of Care Notice CMS-1557 Survey Report Form for Clinical Laboratory Improvement Amendments (CLIA) and Supporting Regulations CMS-3070G-I ICF/IID Survey Report Form and Supporting Regulations Under the PRA (44 U.S.C. 3501-3520), federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. The term “collection of information” is defined in 44 U.S.C.

3502(3) and 5 CFR 1320.3(c) and includes agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA requires federal agencies to publish a 60-day notice in the Federal Register concerning each proposed collection of information, including each proposed extension or reinstatement of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, CMS is publishing this notice.

Information Collection 1. Type of Information Collection Request. Extension of a currently approved collection.

Title of the Information Collection. Home Health Change of Care Notice. Use.

The purpose of the Home Health Change of Care Notice (HHCCN) is to notify original Medicare beneficiaries receiving home health care benefits of plan of care changes. Home health agencies (HHAs) are required to provide written notice to Original Medicare beneficiaries under various circumstances involving the reduction or termination of items and/or services consistent with Home Health Agencies Conditions of Participation (COPs). The home health COP requirements are set forth in § 1891[42 U.S.C.

1395bbb] of the Social Security Act (the Act). The implementing regulations under 42 CFR 484.10(c) specify that Medicare patients receiving HHA services have rights. The patient has the right to be informed, in advance about the care to be furnished, and of any changes in the care to be furnished.

The HHA must advise the patient in advance of the disciplines that will furnish care, and the frequency of visits proposed to be furnished. The HHA must advise the patient in advance of any change in the plan of care before the change is made.” Notification is required for covered and non-covered services listed in the plan of care (POC). The beneficiary will use the information provided to decide whether or not to pursue alternative options to continue receiving the care noted on the HHCCN.

Form Number. CMS-10280 (OMB control number. 0938-1196).

Private Sector (Business or other for-profits, Not-for-Profit Institutions). Number of Respondents. 11,157.

Total Annual Responses. 12,385,108. Total Annual Hours.

824,848. (For policy questions regarding this collection contact Jennifer McCormick at 410-786-2852.) 2. Type of Information Collection Request.

Extension of a currently approved collection. Title of Information Collection. Survey Report Form for Clinical Laboratory Improvement Amendments (CLIA) and Supporting Regulations.

Use. The form is used to report surveyor findings during a CLIA survey. For each type of survey conducted (i.e., initial certification, recertification, validation, complaint, addition/deletion of specialty/subspecialty, transfusion fatality investigation, or revisit inspections) the Survey Report Form incorporates the requirements specified in the CLIA regulations.

Form Number. CMS-1557 (OMB control number. 0938-0544).

Private sector (Business or other for-profit and Not-for-profit institutions, State, Local or Tribal Governments and Federal Government). Number of Respondents. 15,975.

Total Start Printed Page 46855Annual Responses. 7,988. Total Annual Hours.

3,994. (For policy questions regarding this collection contact Kathleen Todd at 410-786-3385). 3.

Type of Information Collection Request. Revision of a currently approved collection. Title of Information Collection.

ICF/IID Survey Report Form and Supporting Regulations. Use. The information collected with forms 3070G, CMS-3070H and CMS-3070I is used by the surveyors from the State Survey Agencies (SAs) to determine the level of compliance with the ICF/IID Conditions of Participation (CoPs) necessary to participate in the Medicare/Medicaid program and to report any non-compliance with the ICF/IID CoPs to the Federal government.

These forms summarize the survey team characteristics, facility characteristics, client population, and the special needs of clients. These forms are used in conjunction with the CMS regulation text and additional surveyor aids such as the CMS interpretive guidelines and probes. The CMS-3070G-I forms serves as coding worksheets, designed to facilitate data entry and retrieval into the Automated Survey Processing Environment Suite (ASPEN) in the State and at the CMS regional offices.

Form Number. CMS-3070G-I (OMB control number. 0938-0062).

Frequency. Reporting—Yearly. Affected Public.

Business or other for-profits and Not-for-profit institutions. Number of Respondents. 5,758.

Total Annual Responses. 5,758. Total Annual Hours.

17,274. (For policy questions regarding this collection contact Caroline Gallaher at 410-786-8705.) Start Signature Dated. August 17, 2021.

William N. Parham, III Director, Paperwork Reduction Staff, Office of Strategic Operations and Regulatory Affairs. End Signature End Supplemental Information [FR Doc.

2021-17908 Filed 8-19-21. 8:45 am]BILLING CODE 4120-01-P.

What if I miss a dose?

If you miss a dose, take it as soon as you can. If it is almost time for your next dose, take only that dose. Do not take double or extra doses. There should be an interval of at least 12 hours between doses.

Generic zithromax cost

UC Davis and two other universities have generic zithromax cost been awarded a $2.3 million grant from the National Institutes of Health to train and empower community health workers in research best practices, which could help reduce disparities related to the ongoing buy antibiotics zithromax. An NIH grant will allow UC Davis Health to train community health workers to help with research efforts to reduce health disparitiesThe grant from the NIH’s National Center for Advancing Translational Sciences is shared by the UC Davis Clinical and Translational Science Center (CTSC) and the Center generic zithromax cost for Reducing Health Disparities (CRHD), the University of Michigan, and the University of Florida. All three universities do extensive work in promoting health equity among Latinx and Black populations.The award acknowledges the increasing role that community health workers play in research to engage individuals from underserved communities.“We have been successfully training community health workers for many years to help diverse populations improve their health, and now we’ll have an opportunity to take that training to the next level, to formally teach the essentials of research to community health workers,” said Sergio Aguilar-Gaxiola, director of the CRHD and also director of the community engagement program of the CTSC. As with most gatherings nowadays, the training will be held online.Community health workers, sometimes known generic zithromax cost as promotoras de salud, are frontline public health workers who are trusted members of the community or have an unusually close understanding of the community they serve.

Sometimes they are embedded within generic zithromax cost underserved communities. In recent years, they have taken on a critical role in research for their ability to reduce barriers in translation, particularly in in the area of health disparities.The grant’s timing allows Spanish-speaking community health workers to be trained in critical research like contact tracing to help slow the spread of buy antibiotics, Aguilar-Gaxiola said.Latinos in California are infected with buy antibiotics at a rate more than three times higher than whites, according to the California Department of Public Health. Latinos, who are 39% of California’s population, generic zithromax cost make up 60% of buy antibiotics cases. Also, nearly 80% of buy antibiotics related generic zithromax cost deaths in the 35-49 age group are Latinx, while this age group represents 41.5% of the California population.

In the same age group, whites represent 7.8% of the deaths and 32.5% of the population.“This particular grant could not be more timely because of the dire need to have this workforce of promotoras or community health workers to potentially help with contact tracing, which is much needed in hard-to-reach populations,” Aguilar-Gaxiola said. €œPromotoras are in the ideal position of using their cultural and linguistic skills to reach their communities and help slow the spread of the disease.”Grant will develop “champions” among peer mentorsIn addition to training community health workers, the grant also seeks to:Provide standardized education in research best practices for community health workersReduce barriers to accessibility of competency-based training and tools for training community health workers onlineEmpower select community health workers to become training “champions” to serve as peer mentors and facilitate the generic zithromax cost training of their colleagues at community sitesThe principal investigators are Aguilar-Gaxiola. Susan Murphy, an associate professor of physical medicine and rehabilitation at generic zithromax cost Michigan Medicine and Linda B. Cottler, a dean’s professor of epidemiology and director of community engagement of the University of Florida Clinical and Translational Science Institute.“This grant will allow us to enable community health workers to better support research within their community,” Murphy said.

€œThis is especially important in underserved communities where quality and translation of generic zithromax cost clinical research are hampered due to health disparities.”The three investigators’ institutions will serve as the first training hubs for the program.UC Davis Health also will work closely with partners that can assist in outreach and recruitment, including the Mexican Consulate in Sacramento, Health Education Council, Rio Vista CARE and other organizations. Community health workers and community members in California, Michigan and Florida will be engaged in content generation, as well as provide feedback on the training and its implementation.“Community health workers understand the needs of their community and are an incredibly valuable resource, especially when it comes to engaging their community members in research that could help us reduce health disparities in the future,” Cottler said..

UC Davis and two other universities have been https://gbs2018.com/how-much-does-propecia-cost/ awarded a $2.3 million grant from the National Institutes of Health to train and empower community health workers in research best practices, which could help reduce disparities related to the ongoing buy zithromax pill buy antibiotics zithromax. An NIH grant will allow UC Davis Health to train community health workers to help with research efforts to reduce health disparitiesThe grant from the NIH’s National Center for Advancing Translational Sciences is shared by the UC Davis Clinical and Translational Science Center (CTSC) and the Center for Reducing Health Disparities (CRHD), the University of Michigan, buy zithromax pill and the University of Florida. All three universities do extensive work in promoting health equity among Latinx and Black populations.The award acknowledges the increasing role that community health workers play in research to engage individuals from underserved communities.“We have been successfully training community health workers for many years to help diverse populations improve their health, and now we’ll have an opportunity to take that training to the next level, to formally teach the essentials of research to community health workers,” said Sergio Aguilar-Gaxiola, director of the CRHD and also director of the community engagement program of the CTSC.

As with most gatherings nowadays, the training will be held online.Community health workers, sometimes known as promotoras de salud, are frontline public health workers who are trusted members buy zithromax pill of the community or have an unusually close understanding of the community they serve. Sometimes they are embedded buy zithromax pill within underserved communities. In recent years, they have taken on a critical role in research for their ability to reduce barriers in translation, particularly in in the area of health disparities.The grant’s timing allows Spanish-speaking community health workers to be trained in critical research like contact tracing to help slow the spread of buy antibiotics, Aguilar-Gaxiola said.Latinos in California are infected with buy antibiotics at a rate more than three times higher than whites, according to the California Department of Public Health.

Latinos, who are 39% of buy zithromax pill California’s population, make up 60% of buy antibiotics cases. Also, nearly 80% of buy antibiotics related deaths in the 35-49 age group are Latinx, buy zithromax pill while this age group represents 41.5% of the California population. In the same age group, whites represent 7.8% of the deaths and 32.5% of the population.“This particular grant could not be more timely because of the dire need to have this workforce of promotoras or community health workers to potentially help with contact tracing, which is much needed in hard-to-reach populations,” Aguilar-Gaxiola said.

€œPromotoras are in the ideal position of using their cultural and linguistic skills to reach their communities and help slow the spread of the disease.”Grant will develop “champions” among peer mentorsIn addition to training community health workers, the grant also buy zithromax pill seeks to:Provide standardized education in research best practices for community health workersReduce barriers to accessibility of competency-based training and tools for training community health workers onlineEmpower select community health workers to become training “champions” to serve as peer mentors and facilitate the training of their colleagues at community sitesThe principal investigators are Aguilar-Gaxiola. Susan Murphy, an associate professor of physical medicine and rehabilitation at Michigan Medicine and Linda buy zithromax pill B. Cottler, a dean’s professor of epidemiology and director of community engagement of the University of Florida Clinical and Translational Science Institute.“This grant will allow us to enable community health workers to better support research within their community,” Murphy said.

€œThis is especially important buy zithromax pill in underserved communities where quality and translation of clinical research are hampered due to health disparities.”The three investigators’ institutions will serve as the first training hubs for the program.UC Davis Health also will work closely with partners that can assist in outreach and recruitment, including the Mexican Consulate in Sacramento, Health Education Council, Rio Vista CARE and other organizations. Community health workers and community members in California, Michigan and Florida will be engaged in content generation, as well as provide feedback on the training and its implementation.“Community health workers understand the needs of their community and are an incredibly valuable resource, especially when it comes to engaging their community members in research that could help us reduce health disparities in the future,” Cottler said..

Zithromax cost without insurance

The 7th annual National browse around this site Apprenticeship Week is zithromax cost without insurance Nov. 15-21!. NAW is a celebration where industry, labor, equity, workforce, education and government leaders host events zithromax cost without insurance to showcase the successes and value of Registered Apprenticeship. This year will focus on how apprenticeships area rebuilding our economy, advancing racial and gender equity and supporting underserved communities. Registered Apprenticeship, a proven and industry-driven training model, provides a critical talent pipeline for our economy.

Apprenticeships are helping address some of our nation’s pressing workforce challenges, zithromax cost without insurance from responding to critical supply chain demands and supporting a clean energy workforce, to modernizing our cybersecurity response, addressing public health issues and rebuilding our country’s infrastructure. Want to learn more host your own event?. Check out our resources. Over the past six years, stakeholders have zithromax cost without insurance hosted more than 5,000 events – with more than 470,000 attendees – in all 50 states. Register your event today so we can include it on our interactive map!.

We look forward to celebrating with you, and don’t forget to join the conversation on social media using the hashtag #NAW2021. John Ladd is the administrator of the department's Office of Apprenticeship.En españolThis zithromax cost without insurance summer, the Biden-Harris administration’s American Rescue Plan Act increased the 2021 Child Tax Credit (CTC). This historic support – the largest ever credit – is helping families and children struggling to recover financially from the buy antibiotics zithromax. The full benefit is now $300 per month, or $3,600 for the year, and any family with children 17 or under who are tax dependents and have a valid Social Security number (regardless of the parents’ immigration status) can access it. Many families automatically received this benefit zithromax cost without insurance.

Those who haven't received the benefits can easily and quickly apply for them. Accessing this benefit is fast and simple. Here’s what families interested zithromax cost without insurance in applying for the credit need to know. There is no minimum income required to get the credit for tax year 2021. Even families who had little to no reported income can be eligible for the full $300 a month.

These funds can be used in any way to support zithromax cost without insurance the wellbeing of children — child care, education supports, housing and more. Mixed status families can access this needed support as long as their children hold valid Social Security numbers and are 17 or under. DACA youth are also eligible. Although parents are not required to have a social security number, they must zithromax cost without insurance have an Individual Taxpayer Identification Number to claim the credit for their eligible children. The support is significant, with many families eligible for the full annual amount of $3,600.

Parents making little to no income, married couples making $150,000 per year or less, or heads of households making up to $112,500 are eligible to receive the full CTC benefit. Families with higher zithromax cost without insurance incomes may still be eligible for smaller amounts. There is still time for families to receive this support. Eligible families began getting payments in monthly installments in mid-July and will continue receiving those payments through December 2021. When families file their taxes in 2022, they will get the remaining CTC benefit they didn’t zithromax cost without insurance get through the monthly installments.

The payments will come directly to you. If you have a bank account, you can sign up for direct deposit of your CTC monthly payments. If not, provide the mailing zithromax cost without insurance address where you’d like the payments sent. Don’t let your child and family miss out on this historic support. To claim your credit, visit https://www.getctc.org/en.

To learn more about the credit, zithromax cost without insurance including who is eligible and how to apply, join @WB_DOL for a Twitter chat on Oct. 28, from 1 to 2 p.m. ET, using the hashtag #CTCchat. Analilia Mejia zithromax cost without insurance is the deputy director of the U.S. Department of Labor’s Women’s Bureau.

Follow the bureau on Twitter. @WB_DOL. 5 Cosas que Debe Saber Sobre el Crédito Tributario por Hijos Analilia Mejía Este verano, la Ley del Plan de Rescate Estadounidense (American Rescue Plan) de la Administración Biden-Harris aumentó la cantidad del Crédito Tributario por Hijos (CTC) 2021, brindando el apoyo crediticio más grande de la historia para auxiliar a familias con niños luchando para recuperarse financieramente de la pandemia de buy antibiotics. Ahora, el beneficio total es de $300 por mes, o $3,600 por año, y puede recibirlo cualquier familia con hijos de 17 años o menos que sean dependientes a efectos de impuestos y tengan un número valido de Seguro Social (independientemente del estado migratorio de los padres). Muchas familias ya han recibido este beneficio automáticamente.

Aquellos que no han hecho pueden solicitarlo fácilmente. Acceder a este beneficio es rápido y sencillo. Esto es lo que deben saber las familias interesadas en solicitar el crédito. No se requiere un ingreso mínimo para obtener el crédito para el año fiscal 2021. Incluso las familias que reportaron poco o ningún ingreso pueden ser elegibles para el total de $300 al mes.

Estos fondos se pueden utilizar de cualquier manera en apoyo al bienestar de los niños. Cuidado infantil, apoyo educativo, vivienda y más. Las familias de estatus mixto pueden acceder a este apoyo necesario siempre que sus hijos tengan números validos de Seguro Social y 17 años o menos. Los jóvenes de DACA también son elegibles. Aunque los padres no están obligados a tener un número de Seguro Social, si deben tener un Número de Identificación de Contribuyente Individual para reclamar el crédito para sus hijos elegibles.

El apoyo es significativo, con muchas familias elegibles para la cantidad anual completa de $3,600. Padres que ganan poco o nada, parejas casadas que ganan $150,000 por año o menos, o cabezas de familia que ganan hasta $112,500 son elegibles para recibir el beneficio completo del CTC. Incluso familias con ingresos más altos pueden ser elegibles para cantidades menores. Todavía hay tiempo para que las familias reciban este apoyo. Las familias elegibles comenzaron a mediados de julio a recibir los pagos en cuotas mensuales y continuarán recibiéndolos hasta diciembre de 2021.

Cuando las familias presenten sus impuestos en 2022, obtendrán el beneficio restante del CTC que no recibieron por cuotas mensuales. Los pagos le llegarán directamente a usted. Si tiene una cuenta bancaria puede registrarse para que sus pagos mensuales del CTC se ingresen por depósito directo. Si no es el caso, provea la dirección postal a la que desea que se envíen los pagos. No permita que su hijo y familia dejen de recibir este apoyo sin precedentes.

Para reclamar su crédito, visite https://www.getctc.org/es. Para más información, incluida elegibilidad y cómo aplicar, únase a @WB_DOL para una charla por Twitter el 28 de octubre, de 1 a 2 p.m. Hora del Este, usando #CTCchat. Analilia Mejia es la subdirectora de la Oficina de Mujeres del Departamento de Trabajo de EE.UU. Siga la oficina en Twitter.

The 7th annual http://www.arrco-agirc.fr/propecia-finasteride-price-in-canada/ National buy zithromax pill Apprenticeship Week is Nov. 15-21!. NAW is a buy zithromax pill celebration where industry, labor, equity, workforce, education and government leaders host events to showcase the successes and value of Registered Apprenticeship. This year will focus on how apprenticeships area rebuilding our economy, advancing racial and gender equity and supporting underserved communities.

Registered Apprenticeship, a proven and industry-driven training model, provides a critical talent pipeline for our economy. Apprenticeships are helping address some of our nation’s pressing workforce challenges, from buy zithromax pill responding to critical supply chain demands and supporting a clean energy workforce, to modernizing our cybersecurity response, addressing public health issues and rebuilding our country’s infrastructure. Want to learn more host your own event?. Check out our resources.

Over the buy zithromax pill past six years, stakeholders have hosted more than 5,000 events – with more than 470,000 attendees – in all 50 states. Register your event today so we can include it on our interactive map!. We look forward to celebrating with you, and don’t forget to join the conversation on social media using the hashtag #NAW2021. John Ladd is the administrator of the department's Office of Apprenticeship.En españolThis summer, the Biden-Harris administration’s American Rescue Plan Act increased the 2021 Child Tax Credit (CTC) buy zithromax pill.

This historic support – the largest ever credit – is helping families and children struggling to recover financially from the buy antibiotics zithromax. The full benefit is now $300 per month, or $3,600 for the year, and any family with children 17 or under who are tax dependents and have a valid Social Security number (regardless of the parents’ immigration status) can access it. Many families automatically buy zithromax pill received this benefit. Those who haven't received the benefits can easily and quickly apply for them.

Accessing this benefit is fast and simple. Here’s what families interested in applying for buy zithromax pill the credit need to know. There is no minimum income required to get the credit for tax year 2021. Even families who had little to no reported income can be eligible for the full $300 a month.

These funds can be used in any way to support the wellbeing of children buy zithromax pill — child care, education supports, housing and more. Mixed status families can access this needed support as long as their children hold valid Social Security numbers and are 17 or under. DACA youth are also eligible. Although parents are not required to have a social security number, they must have an Individual Taxpayer Identification Number to claim buy zithromax pill the credit for their eligible children.

The support is significant, with many families eligible for the full annual amount of $3,600. Parents making little to no income, married couples making $150,000 per year or less, or heads of households making up to $112,500 are eligible to receive the full CTC benefit. Families with higher incomes may still be eligible buy zithromax pill for smaller amounts. There is still time for families to receive this support.

Eligible families began getting payments in monthly installments in mid-July and will continue receiving those payments through December 2021. When families file their taxes in 2022, they will get the remaining CTC benefit they didn’t get through the monthly buy zithromax pill installments. The payments will come directly to you. If you have a bank account, you can sign up for direct deposit of your CTC monthly payments.

If not, provide the mailing address where you’d like buy zithromax pill the payments sent. Don’t let your child and family miss out on this historic support. To claim your credit, visit https://www.getctc.org/en. To learn more about the credit, including who is eligible and how to apply, join @WB_DOL for buy zithromax pill a Twitter chat on Oct.

28, from 1 to 2 p.m. ET, using the hashtag #CTCchat. Analilia Mejia is the deputy director of buy zithromax pill the U.S. Department of Labor’s Women’s Bureau.

Follow the bureau on Twitter. @WB_DOL. 5 Cosas que Debe Saber Sobre el Crédito Tributario por Hijos Analilia Mejía Este verano, la Ley del Plan de Rescate Estadounidense (American Rescue Plan) de la Administración Biden-Harris aumentó la cantidad del Crédito Tributario por Hijos (CTC) 2021, brindando el apoyo crediticio más grande de la historia para auxiliar a familias con niños luchando para recuperarse financieramente de la pandemia de buy antibiotics. Ahora, el beneficio total es de $300 por mes, o $3,600 por año, y puede recibirlo cualquier familia con hijos de 17 años o menos que sean dependientes a efectos de impuestos y tengan un número valido de Seguro Social (independientemente del estado migratorio de los padres).

Muchas familias ya han recibido este beneficio automáticamente. Aquellos que no han hecho pueden solicitarlo fácilmente. Acceder a este beneficio es rápido y sencillo. Esto es lo que deben saber las familias interesadas en solicitar el crédito.

No se requiere un ingreso mínimo para obtener el crédito para el año fiscal 2021. Incluso las familias que reportaron poco o ningún ingreso pueden ser elegibles para el total de $300 al mes. Estos fondos se pueden utilizar de cualquier manera en apoyo al bienestar de los niños. Cuidado infantil, apoyo educativo, vivienda y más.

Las familias de estatus mixto pueden acceder a este apoyo necesario siempre que sus hijos tengan números validos de Seguro Social y 17 años o menos. Los jóvenes de DACA también son elegibles. Aunque los padres no están obligados a tener un número de Seguro Social, si deben tener un Número de Identificación de Contribuyente Individual para reclamar el crédito para sus hijos elegibles. El apoyo es significativo, con muchas familias elegibles para la cantidad anual completa de $3,600.

Padres que ganan poco o nada, parejas casadas que ganan $150,000 por año o menos, o cabezas de familia que ganan hasta $112,500 son elegibles para recibir el beneficio completo del CTC. Incluso familias con ingresos más altos pueden ser elegibles para cantidades menores. Todavía hay tiempo para que las familias reciban este apoyo. Las familias elegibles comenzaron a mediados de julio a recibir los pagos en cuotas mensuales y continuarán recibiéndolos hasta diciembre de 2021.

Cuando las familias presenten sus impuestos en 2022, obtendrán el beneficio restante del CTC que no recibieron por cuotas mensuales. Los pagos le llegarán directamente a usted. Si tiene una cuenta bancaria puede registrarse para que sus pagos mensuales del CTC se ingresen por depósito directo. Si no es el caso, provea la dirección postal a la que desea que se envíen los pagos.

No permita que su hijo y familia dejen de recibir este apoyo sin precedentes. Para reclamar su crédito, visite https://www.getctc.org/es. Para más información, incluida elegibilidad y cómo aplicar, únase a @WB_DOL para una charla por Twitter el 28 de octubre, de 1 a 2 p.m. Hora del Este, usando #CTCchat.

Analilia Mejia es la subdirectora de la Oficina de Mujeres del Departamento de Trabajo de EE.UU. Siga la oficina en Twitter. @WB_DOL..

Azithromycin zithromax 1000mg

N/A 2020-03-11 2026-03-11 N/A 2028-03-11 amifampridine how to get a zithromax prescription from your doctor (supplied as amifampridine phosphate) 232685 Firdapse Kye Pharmaceuticals azithromycin zithromax 1000mg Inc. N/A 2020-07-31 2026-07-31 N/A 2028-07-31 anthrax immune globulin (human) 200446 Anthrasil Emergent BioSolutions Canada Inc. N/A 2017-11-06 2023-11-06 Yes 2026-05-06 antihemophilic factor (recombinant BDD), Fc fusion protein 163447 Eloctate Sanofi-Aventis Canada Inc.

N/A 2014-08-22 2020-08-22 Yes 2023-02-22 antihemophilic factor (recombinant), pegylated azithromycin zithromax 1000mg 189709 Adynovate Takeda Canada Inc. N/A 2016-11-17 2022-11-17 Yes 2025-05-17 antihemophilic factor (recombinant, B-domain deleted, pegylated) (also known as damoctocog alfa pegol) 210935 Jivi Bayer Inc. N/A 2018-10-18 2024-10-18 Yes 2027-04-18 antihemophilic factor (recombinant, B-domain deleted) (also known as simoctocog alfa) 169551 Nuwiq Octapharma Pharmazeutika Produktionsges.m.b.H N/A 2014-10-23 2020-10-23 Yes 2023-04-23 antihemophilic factor VIII (recombinant), singlechain (also known as lonoctocog alfa) 190891 Afstyla CSL Behring Canada Inc.

N/A 2016-12-12 2022-12-12 Yes 2025-06-12 anthrax antigen azithromycin zithromax 1000mg fiate 212387 Biothrax Emergent Biodefense Operations Lansing LLC N/A 2018-12-13 2024-12-13 N/A 2026-12-13 antihemophilic factor VIII (recombinant, B-domain truncated), PEGylated (turoctocog alfa pegol) 218531 Esperoct Novo Nordisk Canada Inc. N/A 2019-07-04 2025-07-04 Yes 2028-01-04 apalutamide 211942 Erleada Janssen Inc. N/A 2018-07-03 2024-07-03 N/A 2026-07-03 apremilast 169862 Otezla Amgen Canada Inc.

N/A 2014-11-12 2020-11-12 N/A 2022-11-12 azithromycin zithromax 1000mg asfotase alfa 179340 Strensiq Alexion Pharma International Sàrl N/A 2015-08-14 2021-08-14 Yes 2024-02-14 asunaprevir 172617 Sunvepra Bristol-Myers Squibb Canada N/A 2016-03-09 2022-03-09 N/A 2024-03-09 atezolizumab 196843 Tecentriq Hoffmann-La Roche Limited N/A 2017-04-12 2023-04-12 N/A 2025-04-12 avelumab 204052 Bavencio EMD Serono, a Division of EMD Inc., Canada N/A 2017-12-18 2023-12-18 N/A 2025-12-18 axicabtagene ciloleucel 218389 Yescarta Gilead Sciences Canada Inc N/A 2019-02-13 2025-02-13 N/A 2027-02-13 azelastine hydrochloride 169604 Dymista Meda Pharmaceuticals Ltd. N/A 2014-10-23 2020-10-23 Yes 2023-04-23 baloxavir marboxil 227361 Xofluza Hoffmann-La Roche Limited N/A 2020-02-19 2026-02-19 Yes 2028-08-19 baricitinib 193687 Olumiant Eli Lilly Canada Inc. N/A 2018-08-17 2024-08-17 N/A 2026-08-17 bazedoxifene acetate 160681 Duavive Pfizer Canada Inc.

N/A 2014-10-23 azithromycin zithromax 1000mg 2020-10-23 N/A 2022-10-23 benralizumab 204008 Fasenra AstraZeneca Canada Inc. N/A 2018-02-22 2024-02-22 Yes 2026-08-22 bepotastine besilate 179294 Bepreve Bausch and Lomb Incorporated N/A 2016-07-27 2022-07-27 Yes 2025-01-27 bictegravir 203718 Biktarvy Gilead Sciences Canada, Inc. N/A 2018-07-10 2024-07-10 Yes 2027-01-10 bilastine 184231 Blexten Aralez Pharmaceutials Canada Inc.

N/A 2016-04-21 2022-04-21 Yes 2024-10-21 binimetinib 237410 azithromycin zithromax 1000mg Mektovi Pfizer Canada ULC N/A 2021-03-02 2027-03-02 N/A 2029-03-02 blinatumomab 181723 Blincyto Amgen Canada Incorporated N/A 2015-12-22 2021-12-22 Yes 2024-06-22 bosutinib 152211 Bosulif Pfizer Canada Inc. N/A 2014-03-07 2020-03-07 N/A 2022-03-07 botulism antitoxin heptavalen C/ D/ F/ G - (equine) 190645 Bat Emergent BioSolutions Inc. N/A 2016-12-08 2022-12-08 Yes 2025-06-08 brexpiprazole 192684 Rexulti Otsuka Pharmaceutical Co.

Ltd. N/A 2017-02-16 2023-02-16 Yes 2025-08-16 brexucabtagene autoleucel 246355 Tecartus Gilead Sciences Canada, Inc. N/A 2021-06-08 2027-06-08 N/A 2029-06-08 brigatinib 210369 Alunbrig Takeda Canada Incorporated N/A 2018-07-26 2024-07-26 N/A 2026-07-26 brivaracetam 183355 Brivlera UCB Canada Incorporated N/A 2016-03-09 2022-03-09 Yes 2024-09-09 brodalumab 195317 Siliq Bausch Health, Canada Inc.

N/A 2018-03-06 2024-03-06 N/A 2026-03-06 brolucizumab 226224 Beovu Novartis Pharmaceuticals Canada Inc. N/A 2020-03-12 2026-03-12 N/A 2028-03-12 bromfenac sodium sesquihydrate 171657 Prolensa Bausch &. Lomb Incorporated N/A 2015-03-26 2021-03-26 N/A 2023-03-26 burosumab 216239 Crysvita Kyowa Kirin Limited N/A 2018-12-05 2024-12-05 Yes 2027-06-05 cabotegravir sodium 227315 Vocabria ViiV Healthcare ULC N/A 2020-03-18 2026-03-18 N/A 2028-03-18 cabotegravir 227315 Cabenuva ViiV Healthcare ULC N/A 2020-03-18 2026-03-18 N/A 2028-03-18 cabozantinib (supplied as cabozantinib (S)-malate) 206230 Cabometyx Ipsen Biopharmaceuticals Canada Inc.

N/A 2018-09-14 2024-09-14 N/A 2026-09-14 calcifediol 205392 Rayaldee Vifor Fresenius Medical Care Renal Pharma Ltd N/A 2018-07-10 2024-07-10 N/A 2026-07-10 canagliflozin 157505 Invokana Janssen Inc. InvokametInvokamet XR 2014-05-23 2020-05-23 N/A 2022-05-23 caplacizumab 230001 Cablivi Sanofi-Aventis Canada Inc. N/A 2020-02-28 2026-02-28 N/A 2028-02-28 carfilzomib 184479 Kyprolis Amgen Canada Inc.

N/A 2016-01-15 2022-01-15 N/A 2024-01-15 carglumic acid 171358 Carbaglu Recordati Rare Diseases N/A 2015-04-10 2021-04-10 Yes 2023-10-10 cedazuridine 234610 Inqovi Otsuka Pharmaceutical Co., Ltd. N/A 2020-07-07 2026-07-07 N/A 2028-07-07 ceftolozane 178006 Zerbaxa Merck Canada Inc. N/A 2015-09-30 2021-09-30 N/A 2023-09-30 cemiplimab 218718 Libtayo Sanofi-Aventis Canada Inc.

N/A 2019-04-10 2025-04-10 N/A 2027-04-10 cenegermin 218145 Oxervate Dompé farmaceutici S.p.A. N/A 2019-02-08 2025-02-08 N/A 2027-02-08 ceritinib 175702 Zykadia Novartis Pharmaceuticals Canada Inc. N/A 2015-03-27 2021-03-27 N/A 2023-03-27 cerliponase alfa 216539 Brineura Biomarin International Limited N/A 2018-12-19 2024-12-19 Yes 2027-06-19 coagulation factor IX (recombinant), albumin fusion protein (rIX-FP) 180793 Idelvion CSL Behring Canada Inc.

N/A 2016-01-26 2022-01-26 Yes 2024-07-26 coagulation factor IX (recombinant), pegylated (nonacog beta pegol) 201114 Rebinyn Novo Nordisk Canada Inc. N/A 2017-11-29 2023-11-29 Yes 2026-05-29 coagulation factor IX, Fc fusion protein 163614 Alprolix Sanofi-Aventis Canada Inc. N/A 2014-03-20 2020-03-20 Yes 2022-09-20 cobimetinib 182788 Cotellic Hoffmann-La Roche Limited N/A 2016-02-22 2022-02-22 N/A 2024-02-22 crisaborole 206906 Eucrisa Pfizer Canada Inc.

N/A 2018-06-07 2024-06-07 Yes 2026-12-07 cysteamine bitartrate 191347 Procysbi Horizon Pharma Ireland Ltd. N/A 2017-06-13 2023-06-13 Yes 2025-12-13 daclatasvir 172616 Daklinza Bristol-Myers Squibb Canada N/A 2015-08-13 2021-08-13 N/A 2023-08-13 daclizumab beta 190458 Zinbryta Biogen Canada Inc. N/A 2016-12-08 2022-12-08 N/A 2024-12-08 dacomitinib 214572 Vizimpro Pfizer Canada Inc.

N/A 2019-02-26 2025-02-26 N/A 2027-02-26 dalbavancin (supplied as dalbavancin hydrochloride) 212390 Xydalba Cipher Pharmaceuticals Inc. N/A 2018-09-04 2024-09-04 N/A 2026-09-04 dapagliflozin propanediol 160877 Forxiga AstraZeneca Canada Inc. XigduoQtern 2014-12-12 2020-12-12 N/A 2022-12-12 daratumumab 187648 Darzalex Janssen Inc.

Darzalex SC 2016-06-29 2022-06-29 N/A 2024-06-29 darolutamide 226146 Nubeqa Bayer Inc. N/A 2020-02-20 2026-02-20 N/A 2028-02-20 deferiprone 162924 Ferriprox Chiesi Canada Corp. N/A 2015-02-13 2021-02-13 Yes 2023-08-13 defibrotide sodium 200808 Defitelio Jazz Pharmaceuticals Ireland Limited N/A 2017-07-10 2023-07-10 Yes 2026-01-10 difluprednate 154517 Durezol Novartis Pharmaceuticals Canada Inc.

N/A 2013-11-04 2019-11-04 Yes 2022-05-04 dimethyl fumarate 154776 Tecfidera Biogen Idec Canada Inc. N/A 2013-04-03 2019-04-03 Yes 2021-10-03 dinutuximab 212066 Unituxin United Therapeutics Corporation N/A 2018-11-28 2024-11-28 Yes 2027-05-28 dolutegravir sodium 161084 Tivicay ViiV Healthcare ULC TriumeqJulucaDovato 2013-10-31 2019-10-31 Yes 2022-05-01 doravirine 211293 Pifeo Merck Canada Inc. Delstrigo 2018-10-12 2024-10-12 N/A 2026-10-12 dulaglutide 168671 Trulicity Eli Lilly Canada Inc.

N/A 2015-11-10 2021-11-10 N/A 2023-11-10 dupilumab 201285 Dupixent Sanofi-Aventis Canada Inc. N/A 2017-11-30 2023-11-30 Yes 2026-05-30 durvalumab 202953 Imfinzi AstraZeneca Canada Inc. N/A 2017-11-03 2023-11-03 N/A 2025-11-03 edaravone 214391 Radicava Mitsubishi Tanabe Pharma Corporation N/A 2018-10-03 2024-10-03 N/A 2026-10-03 edoxaban 187363 Lixiana Servier Canada Inc.

N/A 2016-11-04 2022-11-04 N/A 2024-11-04 efinaconazole 159416 Jublia Bausch Health, Canada Inc. N/A 2013-10-02 2019-10-02 N/A 2021-10-02 elagolix 209513 Orilissa AbbVie Corporation N/A 2018-10-05 2024-10-05 N/A 2026-10-05 elexacaftor 246955 Trikafta Vertex Pharmaceuticals (Canada) Incorporated N/A 2021-06-18 2027-06-18 Yes 2029-12-18 eliglustat tartrate 183050 Cerdelga Genzyme Canada, A division of Sanofi-aventis Canada Inc. N/A 2017-04-21 2023-04-21 N/A 2025-04-21 elosulfase alfa 170340 Vimizim Biomarin International Limited N/A 2014-07-02 2020-07-02 Yes 2023-01-02 elotuzumab 188144 Empliciti Bristol-Myers Squibb Canada N/A 2016-06-21 2022-06-21 N/A 2024-06-21 eluxadoline 190162 Viberzi Allergan inc.

N/A 2017-01-26 2023-01-26 N/A 2025-01-26 emicizumab 212635 Hemlibra Hoffmann-La Roche Limited N/A 2018-08-02 2024-08-02 Yes 2027-02-02 empagliflozin 162552 Jardiance Boehringer Ingelheim (Canada) Ltd. SynjardyGlyxambi 2015-07-23 2021-07-23 N/A 2023-07-23 enasidenib mesylate 217033 Idhifa Celgene Inc. N/A 2019-02-06 2025-02-06 N/A 2027-02-06 encorafenib 237413 Braftovi Pfizer Canada ULC N/A 2021-03-02 2027-03-02 N/A 2029-03-02 entrectinib 227517 Rozlytrek Hoffmann-La Roche Limited N/A 2020-02-10 2026-02-10 Yes 2028-08-10 eptinezumab 233288 Vyepti Lundbeck Canada Inc.

N/A 2021-01-11 2027-01-11 N/A 2029-01-11 erdafitinib 224529 Balversa Janssen Inc. N/A 2019-10-25 2025-10-25 N/A 2027-10-25 erenumab 208607 Aimovig Novartis Pharmaceuticals Canada Inc. N/A 2018-08-01 2024-08-01 N/A 2026-08-01 ertugliflozin 204724 Steglatro Merck Canada Inc.

SteglujanSegluromet 2018-05-09 2024-05-09 N/A 2026-05-09 eslicarbazepine acetate 165665 Aptiom Sunovion Pharmaceuticals Canada Inc. N/A 2014-07-08 2020-07-08 Yes 2023-01-08 estetrol monohydrate 236197 Nextstellis Searchlight Pharma Inc. N/A 2021-03-05 2027-03-05 N/A 2029-03-05 evolocumab 178234 Repatha Amgen Canada Inc.

N/A 2015-09-10 2021-09-10 Yes 2024-03-10 fedratinib (supplied as fedratinib hydrochloride) 229866 Inrebic Celgene Inc. N/A 2020-07-27 2026-07-27 N/A 2028-07-27 ferric pyrophosphate citrate 239850 Triferic Avnu Rockwell Medical Inc. N/A 2021-04-22 2027-04-22 Yes 2029-10-22 finafloxacin 172450 Xtoro MerLion Pharmaceuticals GmbH N/A 2016-03-11 2022-03-11 Yes 2024-09-11 flibanserin 189352 Addyi Searchlight Pharma Inc.

N/A 2018-02-27 2024-02-27 N/A 2026-02-27 florbetaben (18F) 193105 Neuraceq Isologic Innovative Radiopharmaceuticals Ltd. N/A 2017-02-22 2023-02-22 N/A 2025-02-22 follitropin delta 188743 Rekovelle Ferring Inc. N/A 2018-03-22 2024-03-22 N/A 2026-03-22 fostamatinib (supplied as fostamatinib disodium) 232078 Tavalisse Rigel Pharmaceuticals Inc.

N/A 2020-11-19 2026-11-19 N/A 2028-11-19 fremanezumab 226828 Ajovy Teva Canada Limited N/A 2020-04-09 2026-04-09 N/A 2028-04-09 gadoterate meglumine 186333 Dotarem Guerbet N/A 2016-11-26 2022-11-26 Yes 2025-05-26 galcanezumab 219521 Emgality Eli Lilly Canada Inc. N/A 2019-07-30 2025-07-30 N/A 2027-07-30 galsulfase 159020 Naglazyme BioMarin Pharmaceutical Inc. N/A 2013-09-16 2019-09-16 Yes 2022-03-16 gemtuzumab ozogamicin 223091 Mylotarg Pfizer Canada ULC N/A 2019-11-28 2025-11-28 Yes 2028-05-28 gilteritinib fumarate 227918 Xospata Astellas Pharma Canada Inc.

N/A 2019-12-23 2025-12-23 N/A 2027-12-23 givosiran (supplied as givosiran sodium) 237194 Givlaari Alnylam Netherlands B.V.. N/A 2020-10-09 2026-10-09 N/A 2028-10-09 glasdegib 225793 Daurismo Pfizer Canada ULC N/A 2020-04-28 2026-04-28 N/A 2028-04-28 glecaprevir, pibrentasvir 202233 Maviret AbbVie Corporation N/A 2017-08-16 2023-08-16 Yes 2026-02-16 glycerol phenylbutyrate 174219 Ravicti Horizon Pharma Ireland Ltd. N/A 2016-03-18 2022-03-18 Yes 2024-09-18 grazoprevir, elbasvir 185866 Zepatier Merck Canada Inc.

N/A 2016-01-19 2022-01-19 N/A 2024-01-19 guanfacine hydrochloride 150741 Intuniv XR Takeda Canada Inc. N/A 2013-07-05 2019-07-05 Yes 2022-01-05 guselkumab 200590 Tremfya Janssen Inc. N/A 2017-11-10 2023-11-10 N/A 2025-11-10 haemagglutinin strain A (H5N1) 115398 Arepanrix H5N1 ID Biomedical Corporation of Quebec N/A 2013-02-13 2019-02-13 Yes 2021-08-13 hemin 212276 Panhematin Recordati Rare Diseases Canada Inc.

N/A 2018-07-13 2024-07-13 N/A 2026-07-13 ibrutinib 174029 Imbruvica Janssen Inc. N/A 2014-11-17 2020-11-17 Yes 2023-05-17 icatibant acetate 162918 Firazyr Takeda Canada Inc. N/A 2014-06-04 2020-06-04 Yes 2022-12-04 icosapent ethyl 227235 Vascepa HLS Therapeutics Inc.

N/A 2019-12-30 2025-12-30 N/A 2027-12-30 idarucizumab 182503 Praxbind Boehringer Ingelheim (Canada) Ltd N/A 2016-04-29 2022-04-29 N/A 2024-04-29 idecabtagene vicleucel 244266 Abecma Celgene Inc. N/A 2021-05-26 2027-05-26 N/A 2029-05-26 idelalisib 172652 Zydelig Gilead Sciences Canada Inc. N/A 2015-03-27 2021-03-27 N/A 2023-03-27 inotersen sodium 214274 Tegsedi Akcea Therapeutics Inc.

N/A 2018-10-03 2024-10-03 N/A 2026-10-03 inotuzumab ozogamicin 204077 Besponsa Pfizer Canada Inc. N/A 2018-03-15 2024-03-15 N/A 2026-03-15 insulin degludec 198124 Tresiba Novo Nordisk Canada Inc. Xultophy 2017-08-25 2023-08-25 Yes 2026-02-25 ioflupane (123I) 201481 Datscan GE Healthcare Canada Inc.

N/A 2017-12-07 2023-12-07 N/A 2025-12-07 iron isomaltoside 1000 193890 Monoferric Pharmacosmos A/S N/A 2018-06-22 2024-06-22 N/A 2026-06-22 isatuximab 229245 Sarclisa Sanofi-Aventis Canada Inc. N/A 2020-04-29 2026-04-29 N/A 2028-04-29 isavuconazole (supplied as isavuconazonium sulfate) 208919 Cresemba Avir Pharma Inc. N/A 2018-12-19 2024-12-19 N/A 2026-12-19 ivabradine hydrochloride 166949 Lancora Servier Canada Inc.

N/A 2016-12-23 2022-12-23 Yes 2025-06-23 ivermectin 172733 Rosiver Galderma Canada Inc. N/A 2015-04-22 2021-04-22 N/A 2023-04-22 ixazomib (supplied as ixazomib citrate) 190498 Ninlaro Takeda Canada Inc. N/A 2016-08-04 2022-08-04 N/A 2024-08-04 ixekizumab 184993 Taltz Eli Lilly Canada Inc.

N/A 2016-05-25 2022-05-25 Yes 2024-11-25 lanadelumab 213920 Takhzyro Takeda Canada Inc. N/A 2018-09-19 2024-09-19 Yes 2027-03-19 larotrectinib (supplied as larotrectinib sulfate) 219998 Vitrakvi Bayer Inc. N/A 2019-07-10 2025-07-10 Yes 2028-01-10 latanoprostene bunod 211732 Vyzulta Bausch &.

Lomb Incorporated N/A 2018-12-27 2024-12-27 N/A 2026-12-27 ledipasvir 173180 Harvoni Gilead Sciences Canada Inc. N/A 2014-10-15 2020-10-15 Yes 2023-04-15 lefamulin acetate 233292 Xenleta Sunovion Pharmaceuticals Canada Inc. N/A 2020-07-10 2026-07-10 N/A 2028-07-10 lemborexant 231286 Dayvigo Eisai Limited N/A 2020-11-04 2026-11-04 N/A 2028-11-04 lenvatinib mesylate 180877 Lenvima Eisai Limited N/A 2015-12-22 2021-12-22 N/A 2023-12-22 letermovir 204165 Prevymis Merck Canada Inc.

N/A 2017-11-01 2023-11-01 N/A 2025-11-01 levomilnacipran hydrochloride 167319 Fetzima Allergan Inc. N/A 2015-05-08 2021-05-08 N/A 2023-05-08 lifitegrast 199810 Xiidra Novartis Pharmaceuticals Canada Inc. N/A 2017-12-22 2023-12-22 N/A 2025-12-22 linaclotide 161056 Constella Forest Laboratories Canada Inc.

N/A 2013-12-02 2019-12-02 N/A 2021-12-02 lixisenatide 193862 Adlyxine Sanofi-aventis Canada Inc. Soliqua 2017-05-25 2023-05-25 N/A 2025-05-25 lomitapide mesylate 160385 Juxtapid Aegerion Pharmaceuticals Canada Ltd. N/A 2014-02-04 2020-02-04 N/A 2022-02-04 lorlatinib 215733 Lorbrena Pfizer Canada ULC N/A 2019-02-22 2025-02-22 N/A 2027-02-22 lubiprostone 179333 Amitiza Sucampo Pharma Americas LLC N/A 2015-10-14 2021-10-14 N/A 2023-10-14 lumacaftor 181715 Orkambi Vertex Pharmaceuticals (Canada) Incorporated N/A 2016-01-26 2022-01-26 Yes 2024-07-26 luspatercept 236441 Reblozyl Celgene Inc.

N/A 2020-09-25 2026-09-25 N/A 2028-09-25 lutetium177 Lu oxodotreotide 217184 Lutathera Advanced Accelerator Applications USA, Inc. N/A 2019-01-09 2025-01-09 N/A 2027-01-09 macitentan 161372 Opsumit Janssen Inc. N/A 2013-11-06 2019-11-06 Yes 2022-05-06 mecasermin 235023 Increlex Ipsen Biopharmaceuticals Canada Inc.

N/A 2020-12-17 2026-12-17 Yes 2029-06-17 mepolizumab 179850 Nucala GlaxoSmithKline Inc. N/A 2015-12-03 2021-12-03 Yes 2024-06-03 midostaurin 201101 Rydapt Novartis Pharmaceuticals Canada Inc. N/A 2017-07-21 2023-07-21 Yes 2026-01-21 mifepristone 160063 Mifegymiso Linepharma International Limited N/A 2015-07-29 2021-07-29 Yes 2024-01-29 migalastat hydrochloride 196956 Galafold Amicus Therapeutics UK LTD N/A 2017-09-05 2023-09-05 N/A 2025-09-05 modified vaccinia zithromax (ankara-bavarian nordic) 144762 Imvamune Bavarian Nordic A/S N/A 2013-11-21 2019-11-21 N/A 2021-11-21 naloxegol oxalate 167790 Movantik Knight Therapeutics Inc.

N/A 2015-06-02 2021-06-02 N/A 2023-06-02 necitumumab 193689 Portrazza Eli Lilly Canada Inc. N/A 2017-03-16 2023-03-16 N/A 2025-03-16 neisseria meningitidis serogroup A polysaccharide, neisseria meningitidis serogroup C polysaccharide, neisseria meningitidis serogroup W-135 polysaccharide, neisseria meningitidis serogroup Y polysaccharide, conjugated to tetanus toxoid carrier protein 154290 Nimenrix Pfizer Canada Inc. N/A 2013-03-05 2019-03-05 Yes 2021-09-05 neisseria meningitidis serogroup B recombinant lipoprotein 2086 (rLP2086) subfamily A and Neisseria meningitidis serogroup B recombinant lipoprotein 2086 (rLP2086) subfamily B 195550 Trumenba Pfizer Canada Inc.

N/A 2017-10-05 2023-10-05 Yes 2026-04-05 neratinib maleate 218224 Nerlynx Knight Therapeutics Inc. N/A 2019-07-16 2025-07-16 N/A 2027-07-16 netupitant 196495 Akynzeo Elvium Life Sciences N/A 2017-09-28 2023-09-28 N/A 2025-09-28 nintedanib (supplied as nintedanib esilate) 176043 Ofev Boehringer Ingelheim (Canada) Ltd N/A 2015-06-25 2021-06-25 N/A 2023-06-25 niraparib 216792 Zejula GlaxoSmithKline Inc. N/A 2019-06-27 2025-06-27 N/A 2027-06-27 nivolumab 180828 Opdivo Bristol-Myers-Squibb Canada N/A 2015-09-25 2021-09-25 Yes 2024-03-25 nusinersen 200070 Spinraza Biogen Canada Inc.

N/A 2017-06-29 2023-06-29 Yes 2025-12-29 obeticholic acid 198418 Ocaliva Intercept Pharmaceuticals Inc. N/A 2017-05-24 2023-05-24 N/A 2025-05-24 obiltoxaximab 230825 Anthim Elusys Therapeutics, Inc. N/A 2020-07-30 2026-07-30 N/A 2028-07-30 obinutuzumab 168227 Gazyva Hoffmann-La Roche Limited N/A 2014-11-25 2020-11-25 N/A 2022-11-25 ocrelizumab 198094 Ocrevus Hoffmann-La Roche Limited N/A 2017-08-14 2023-08-14 N/A 2025-08-14 ocriplasmin 161356 Jetrea ThromboGenics N.V.

N/A 2013-08-13 2019-08-13 N/A 2021-08-13 olaparib 182823 Lynparza AstraZeneca Canada Inc. N/A 2016-04-29 2022-04-29 N/A 2024-04-29 olaratumab 203478 Lartruvo Eli Lilly Canada Inc. N/A 2017-11-23 2023-11-23 N/A 2025-11-23 ombitasvir, paritaprevir, dasabuvir sodium 174739 Holkira Pak Abbvie Corporation Technivie 2014-12-22 2020-12-22 N/A 2022-12-22 onasemnogene abeparvovec 239719 Zolgensma Novartis Pharmaceuticals Canada Inc.

N/A 2020-12-15 2026-12-15 Yes 2029-06-15 osimertinib mesylate 188171 Tagrisso AstraZeneca Canada Inc. N/A 2016-07-05 2022-07-05 N/A 2024-07-05 ozanimod (supplied as ozanimod hydrochloride) 232761 Zeposia Celgene Inc. N/A 2020-10-02 2026-10-02 N/A 2028-10-02 ozenoxacin 192925 Ozanex Ferrer Internacional, S.A.

N/A 2017-05-01 2023-05-01 Yes 2025-11-01 palbociclib 182048 Ibrance Pfizer Canada Inc. N/A 2016-03-16 2022-03-16 N/A 2024-03-16 pasireotide diaspartate 145005 Signifor Novartis Pharmaceuticals Canada Inc. Signifor Lar 2013-09-23 2019-09-23 N/A 2021-09-23 patiromer sorbitex calcium 210368 Veltassa Vifor Fresenius Medical Care Renal Pharma Ltd.

N/A 2018-10-03 2024-10-03 N/A 2026-10-03 patisiran (as patisiran sodium) 221896 Onpattro Alnylam Netherlands B.V. N/A 2019-06-07 2025-06-07 N/A 2027-06-07 peginterferon beta-1a 166974 Plegridy Biogen Idec Canada Inc. N/A 2015-08-10 2021-08-10 N/A 2023-08-10 pembrolizumab 175884 Keytruda Merck Canada Inc.

N/A 2015-05-19 2021-05-19 Yes 2023-11-19 peramivir 191280 Rapivab BioCryst Pharmaceuticals Inc. N/A 2017-01-05 2023-01-05 N/A 2025-01-05 perampanel 153747 Fycompa Eisai Limited N/A 2013-04-04 2019-04-04 Yes 2021-10-04 pitolisant hydrochloride 238175 Wakik Endo Ventures Ltd. N/A 2021-05-25 2027-05-25 N/A 2029-05-25 plecanatide 215288 Trulance Bausch Health, Canada Inc.

N/A 2019-10-10 2025-10-10 N/A 2027-10-10 polatuzumab vedotin 232303 Polivy Hoffmann-La Roche Limited N/A 2020-07-09 2026-07-09 N/A 2028-07-09 polidocanol 177359 Varithena Provensis Ltd. N/A 2015-08-04 2021-08-04 N/A 2023-08-04 pomalidomide 165891 Pomalyst Celgene Inc. N/A 2014-01-20 2020-01-20 Yes 2022-07-20 pralatrexate 207545 Folotyn Servier Canada Inc.

N/A 2018-10-26 2024-10-26 N/A 2026-10-26 pralsetinib 243731 Gavreto Hoffmann-La Roche Limited N/A 2021-06-30 2027-06-30 N/A 2029-06-30 prasterone 198822 Intrarosa Endoceutics Inc. N/A 2019-11-01 2025-11-01 N/A 2027-11-01 ponatinib hydrochloride 165121 Iclusig Ariad Pharmaceuticals Inc. N/A 2015-04-02 2021-04-02 N/A 2023-04-02 ponesimod 239537 Ponvory Janssen Inc.

N/A 2021-04-28 2027-04-28 N/A 2029-04-28 propiverine hydrochloride 188323 Mictoryl / Mictoryl Pediatric Duchesnay Inc. N/A 2017-01-05 2023-01-05 Yes 2025-07-05 radium - 223 dichloride 161312 Xofigo Bayer Inc. N/A 2013-12-12 2019-12-12 N/A 2021-12-12 ramucirumab 176810 Cyramza Eli Lilly Canada Inc.

N/A 2015-07-16 2021-07-16 N/A 2023-07-16 ravulizumab 217955 Ultomiris Alexion Pharma GmbH N/A 2019-08-28 2025-08-28 N/A 2027-08-28 recombinant haemagglutinin protein-strain A (H1N1) recombinant haemagglutinin protein-strain A (H3N2) recombinant haemagglutinin protein-strain B (Victoria) recombinant haemagglutinin protein-strain B (Yamagata) 235672 Supemtek Sanofi Pasteur Limited N/A 2021-01-14 2027-01-14 N/A 2029-01-14 recombinant human papillomazithromax types 31, 33, 45, 52 and 58 170006 Gardasil 9 Merck Canada Inc. N/A 2015-02-05 2021-02-05 Yes 2023-08-05 recombinant neisseria meningitidis group B NHBA fusion protein, recombinant neisseria meningitidis group B NadA protein, recombinant neisseria meningitidis group B FHBP fusion protein, outer membrane vesicle (neisseria meningitidis group B NZ98/254 strain) 147275 Bexsero GlaxoSmithKline Inc. N/A 2013-12-06 2019-12-06 Yes 2022-06-06 recombinant porcine factor VIII (antihemophilic factor (recombinant), porcine sequence) 177290 Obizur Takeda Canada Inc.

N/A 2015-10-14 2021-10-14 N/A 2023-10-14 regorafenib monohydrate 157970 Stivarga Bayer Inc. N/A 2013-03-11 2019-03-11 Yes 2021-09-11 remdesivir 240551 Veklury Gilead Sciences Canada, Inc. N/A 2020-07-27 2026-07-27 N/A 2028-07-27 reslizumab 185873 Cinqair Teva Canada Limited N/A 2016-07-20 2022-07-20 Yes 2025-01-20 ribociclib (supplied as ribociclib succinate) 203884 Kisqali Novartis Pharmaceuticals Canada Inc.

N/A 2018-03-02 2024-03-02 N/A 2026-03-02 rifaximin 161256 Zaxine Salix Pharmaceuticals Inc. N/A 2013-08-13 2019-08-13 N/A 2021-08-13 riociguat 162761 Adempas Bayer Inc. N/A 2013-09-19 2019-09-19 N/A 2021-09-19 ripretinib 234688 Qinlock Deciphera Pharmaceuticals, LLC N/A 2020-06-19 2026-06-19 N/A 2028-06-19 risankizumab 215753 Skyrizi AbbVie Corporation N/A 2019-04-17 2025-04-17 N/A 2027-04-17 risdiplam 242373 Evrysdi Hoffman-La Roche Limited N/A 2021-04-14 2027-04-14 Yes 2029-10-14 romidepsin 152293 Istodax Celgene Inc.

N/A 2013-10-16 2019-10-16 N/A 2021-10-16 romosozumab 197713 Evenity Amgen Canada Inc. N/A 2019-06-17 2025-06-17 N/A 2027-06-17 rupatadine (supplied as rupatadine fumarate) 186488 Rupall Medexus Pharmaceuticals Inc. N/A 2016-07-20 2022-07-20 Yes 2025-01-20 sacubitril 182734 Entresto Novartis Pharmaceuticals Canada Inc.

N/A 2015-10-02 2021-10-02 N/A 2023-10-02 safinamide (as safinamide mesylate) 207115 Onstryv Valeo Pharma Inc. N/A 2019-01-10 2025-01-10 N/A 2027-01-10 sarilumab 191745 Kevzara Sanofi-aventis Canada Inc. N/A 2017-01-12 2023-01-12 N/A 2025-01-12 satralizumab 233642 Enspryng Hoffmann-La Roche Limited N/A 2020-06-01 2026-06-01 Yes 2028-12-01 sebelipase alfa 204085 Kanuma Alexion Pharma GmbH N/A 2017-12-15 2023-12-15 Yes 2026-06-15 secukinumab 170732 Cosentyx Novartis Pharmaceuticals Canada Inc.

N/A 2015-02-27 2021-02-27 Yes 2023-08-27 selexipag 182114 Uptravi Janssen Inc. N/A 2016-01-20 2022-01-20 N/A 2024-01-20 selpercatinib 243748 Retevmo Loxo Oncology Inc. N/A 2021-06-15 2027-06-15 Yes 2029-12-15 semaglutide 202059 Ozempic Novo Nordisk Canada Inc.

Rybelsus 2018-01-04 2024-01-04 N/A 2026-01-04 siltuximab 174291 Sylvant EUSA Pharma (UK) Limited N/A 2014-12-03 2020-12-03 N/A 2022-12-03 simeprevir 164021 Galexos Janssen Inc. N/A 2013-11-18 2019-11-18 N/A 2021-11-18 siponimod 223225 Mayzent Novartis Pharmaceuticals Canada Inc. N/A 2020-02-20 2026-02-20 N/A 2028-02-20 sodium zirconium cyclosilicate 218799 Lokelma AstraZeneca Canada Inc.

N/A 2019-07-25 2025-07-25 N/A 2027-07-25 sofosbuvir 165043 Sovaldi Gilead Sciences Canada Inc. HarvoniEpclusaVosevi 2013-12-13 2019-12-13 N/A 2021-12-13 solriamfetol hydrochloride 237511 Sunosi Jazz Pharmaceuticals Ireland Ltd. N/A 2021-05-13 2027-05-13 N/A 2029-11-13 sonidegib phosphate 229407 Odomzo Sun Pharma Global FZE N/A 2020-06-12 2026-06-12 N/A 2028-06-12 sucroferric oxyhydroxide 201492 Velphoro Vifor Fresenius Medical Care Renal Pharma Ltd.

N/A 2018-01-05 2024-01-05 N/A 2026-01-05 sugammadex sodium 180385 Bridion Merck Canada Inc. N/A 2016-02-05 2022-02-05 N/A 2024-02-05 suvorexant 196367 Belsomra Merck Canada Inc. N/A 2018-11-29 2024-11-29 N/A 2026-11-29 tafamidis meglumine 228368 Vyndaqel Pfizer Canada ULC Vyndamax 2020-01-20 2026-01-20 N/A 2028-01-20 tafluprost 165596 Saflutan Purdue Pharma N/A 2014-05-26 2020-05-26 N/A 2022-05-26 talazoparib (supplied as talazoparib tosylate) 220584 Talzenna Pfizer Canada ULC N/A 2019-09-06 2025-09-06 N/A 2027-09-06 taliglucerase alfa 140854 Elelyso Pfizer Canada Inc.

N/A 2014-05-29 2020-05-29 Yes 2022-11-29 tedizolid phosphate 173603 Sivextro Merck Canada Inc. N/A 2015-03-17 2021-03-17 N/A 2023-03-17 teduglutide 180223 Revestive Takeda Canada Inc. N/A 2015-09-04 2021-09-04 Yes 2024-03-04 telotristat ethyl (as telotristat etiprate) 208730 Xermelo Ipsen Biopharmaceuticals Canada Inc.

N/A 2018-10-10 2024-10-10 N/A 2026-10-10 tenapanor hydrochloride 224850 Ibsrela Knight Therapeutics Inc. N/A 2020-04-15 2026-04-15 N/A 2028-04-15 tenofovir alafenamide hemifumarate 181399 Genvoya Gilead Sciences Canada Inc. DescovyOdefseyVemlidySymtuzaBiktarvy 2015-11-27 2021-11-27 Yes 2024-05-27 tepotinib (supplied as tepotinib hydrochloride) 242300 Tepmetko EMD Serono, a Division of EMD Inc., Canada N/A 2021-05-27 2027-05-27 N/A 2029-05-27 teriflunomide 160646 Aubagio Genzyme Canada a division of Sanofi-aventis Canada Inc.

N/A 2013-11-14 2019-11-14 Yes 2022-05-14 tesamorelin 131836 Egrifta Theratechnologies Inc. N/A 2014-04-29 2020-04-29 N/A 2022-04-29 tezacaftor 211292 Symdeko Vertex Pharmaceuticals (Canada) Incorporated N/A 2018-06-27 2024-06-27 Yes 2026-12-27 tildrakizumab 224036 Ilumya Sun Pharma Global FZE N/A 2021-05-19 2027-05-19 N/A 2029-05-19 tisagenlecleucel 213547 / 213698 Kymriah Novartis Pharmaceuticals Canada Inc. N/A 2018-09-05 2024-09-05 Yes 2027-03-05 tofacitinib 154642 Xeljanz Pfizer Canada Inc.

N/A 2014-04-17 2020-04-17 Yes 2022-10-17 trametinib 157665 Mekinist Novartis Pharmaceuticals Canada Inc. N/A 2013-07-18 2019-07-18 N/A 2021-07-18 trastuzumab deruxtecan 242104 Enhertu AstraZeneca Canada Inc. N/A 2021-04-15 2027-04-15 N/A 2029-04-15 trastuzumab emtansine 162414 Kadcyla Hoffmann-La Roche Limited N/A 2013-09-11 2019-09-11 N/A 2021-09-11 trifarotene 221945 Aklief Galderma Canada Inc.

N/A 2019-11-25 2025-11-25 Yes 2028-05-25 tipiracil hydrochloride 205852 Lonsurf Taiho Pharma Canada Inc. N/A 2018-01-25 2024-01-25 N/A 2026-01-25 triheptanoin 242196 Dojolvi Uagenyx Pharmaceutical Inc. N/A 2021-02-15 2027-02-15 Yes 2029-08-15 tucatinib 235295 Tukysa Seagen Inc.

N/A 2020-06-05 2026-06-05 N/A 2028-06-05 turoctocog alfa 170796 Zonovate Novo Nordisk Canada Inc. N/A 2014-12-08 2020-12-08 Yes 2023-06-08 umeclidinium bromide 161585 Anoro Ellipta GlaxoSmithKline Inc. Incruse Ellipta 2013-12-23 2019-12-23 N/A 2021-12-23 upadacitinib 223734 Rinvoq AbbVie Corporation N/A 2019-12-23 2025-12-23 N/A 2027-12-23 varicella-zoster zithromax glycoprotein E (gE) 200244 Shingrix GlaxoSmithKline Inc.

N/A 2017-10-13 2023-10-13 N/A 2025-10-13 vedolizumab 169414 Entyvio Takeda Canada Inc. N/A 2015-01-29 2021-01-29 Yes 2023-07-29 velpatasvir 190521 Epclusa Gilead Sciences Canada Inc. Vosevi 2016-07-11 2022-07-11 Yes 2025-01-11 venetoclax 190761 Venclexta AbbVie Corporation N/A 2016-09-30 2022-09-30 N/A 2024-09-30 vernakalant hydrochloride 190817 Brinavess Cipher Pharmaceuticals Inc.

N/A 2017-03-13 2023-03-13 N/A 2025-03-13 vilanterol trifenatate 157301 Breo Ellipta GlaxoSmithKline Inc. Anoro ElliptaTrelegy Ellipta 2013-07-03 2019-07-03 Yes 2022-01-03 vilazodone hydrochloride 176820 Viibryd Allergan Inc. N/A 2015-07-16 2021-07-16 Yes 2024-01-16 von willebrand factor (recombinant) (vonicog alfa) 213188 Vonvendi Takeda Canada Inc.

N/A 2019-01-10 2025-01-10 N/A 2027-01-10 vorapaxar sulfate 179320 Zontivity Toprol Acquisition LLC N/A 2016-05-13 2022-05-13 N/A 2024-05-13 voretigene neparvovec 233097 Luxturna Novartis Pharmaceuticals Canada Inc. N/A 2020-10-13 2026-10-13 Yes 2029-04-13 vortioxetine hydrobromide 159019 Trintellix Lundbeck Canada Inc. N/A 2014-10-22 2020-10-22 Yes 2023-04-22 voxilaprevir 202324 Vosevi Gilead Sciences Canada Inc.

N/A 2017-08-16 2023-08-16 N/A 2025-08-16 zanubrutinib 242748 Brukinsa BeiGene Switzerland GmbH N/A 2021-03-01 2027-03-01 N/A 2029-03-01On this page June 2021Product Monograph Brand Safety Updates June 2021(PDF, 101 KB, 4 pages) June 2021 Brand Name Submission Number Ingredient(s) Manufacturer Contraindications Warnings &. Precautions Serious Warnings &. Precautions Adverse Reactions Drug Interactions Dosage &.

Administration Overdosage Consumer Information Altace HCT 246597 Hydrochlorothiazide, Ramipril Bausch Health, Canada Inc No Yes No Yes No No No Yes Aspirin 81 mg, Aspirin 81 mg Quick Chews, Aspirin Regular Strength, Aspirin Extra Strength 248124 Acetylsalicylic Acid Bayer Inc No Yes No Yes Yes No No No Bricanyl Turbuhaler 239089 Terbutaline Sulfate AstraZeneca Canada Inc Yes Yes No No No No No Yes Cellcept, Cellcept I.V. 248429 Mycophenolate Mofetil Hoffmann-La Roche Limited No Yes No No No No No Yes Cipro XL 248371 Ciprofloxacin Hydrochloride Bayer Inc Yes No No No No Yes No Yes Cipro, Cipro Oral Suspension 248370 Ciprofloxacin Hydrochloride Bayer Inc Yes No No No No Yes No Yes Clozaril 247538 Clozapine HLS Therapeutics Inc No Yes Yes No No Yes No Yes Combogesic 248697 Ibuprofen, Acetaminophen Biosyent Pharma Inc No No No Yes No Yes No No Efudex 246337 Fluorouracil Bausch Health, Canada Inc Yes Yes Yes Yes Yes Yes Yes Yes Epclusa 247195 Velpatasvir, Sofosbuvir Gilead Sciences Canada Inc No No No Yes No No No Yes Erleada 241210 Apalutamide Janssen Inc No Yes No Yes No Yes No Yes Harvoni 247194 Ledipasvir, Sofosbuvir Gilead Sciences Canada Inc No No No Yes No No No Yes Hemangiol 247151 Propranolol Hcl Pierre Fabre Dermo-Cosmetique Canada Inc No Yes No Yes No No No Yes Idamycin PFS 249085 Idarubicin Hcl Pfizer Canada ULC No No No Yes No No No Yes Imbruvica 248172 Ibrutinib Janssen Inc No Yes No Yes No No No Yes Inderal-LA 248972 Propranolol Hcl Pfizer Canada ULC No No No Yes No No No Yes Jakavi 247787 Ruxolitinib Phosphate Novartis Pharmaceuticals Canada Inc No Yes No Yes No No No Yes Lorbrena 247174 Lorlatinib Pfizer Canada ULC No Yes No Yes No Yes No Yes Lynparza 249369 Olaparib AstraZeneca Canada Inc No No No Yes No No No Yes Manerix 246047 Moclobemide Bausch Health, Canada Inc Yes Yes No Yes Yes Yes Yes Yes Maxidol Liquid Gels 248432 Naproxen Sodium Bayer Inc No No No Yes No No No Yes Nerlynx 242449 Neratinib Maleate Knight Therapeutics Inc No Yes No Yes Yes Yes No Yes Ofev 241747 Nintedanib Boehringer Ingelheim (Canada) Ltd Ltee No Yes No No Yes No No Yes Orgalutran 248614 Ganirelix Acetate Organon Canada Inc Yes Yes No Yes No Yes No Yes Pat-Galantamine ER 248978 Galantamine Hydrobromide Janssen Inc No Yes No Yes No Yes No Yes Piqray 248616 Alpelisib Novartis Pharmaceuticals Canada Inc No Yes No Yes No No No Yes Ralivia 246159 Tramadol Hcl Bausch Health, Canada Inc No Yes No Yes No No Yes Yes Retrovir (AZT) 249459 Zidovudine ViiV Healthcare ULC No Yes Yes No Yes Yes Yes Yes Rinvoq 241253 Upadacitinib Abbvie Corporation No Yes No Yes No Yes No Yes Rivotril 245341 Clonazepam Hoffmann-La Roche Limited No Yes Yes Yes Yes Yes No Yes Rydapt 247829 Midostaurin Novartis Pharmaceuticals Canada Inc No No No Yes No No No Yes Sandoz Zopiclone Tablet 247527 Zopiclone Sandoz Canada Incorporated No Yes Yes Yes No Yes No Yes Sovaldi 247196 Sofosbuvir Gilead Sciences Canada Inc No No No Yes No No No Yes Synalar 247002 Fluocinolone Acetonide Bausch Health, Canada Inc No Yes No Yes No No No Yes Tapazole 246350 Methimazole Paladin Labs Inc No Yes No No No No Yes Yes Toviaz 248542 Fesoterodine Fumarate Pfizer Canada ULC Yes Yes No Yes Yes Yes No No Trileptal 247670 Oxcarbazepine Novartis Pharmaceuticals Canada Inc No Yes No No No Yes No Yes Valium 245343 Diazepam Hoffmann-La Roche Limited No Yes Yes Yes Yes Yes No Yes Vaseretic 247516 Enalapril Maleate, Hydrochlorothiazide Organon Canada Inc No Yes No No Yes No No Yes Vasotec 247519 Enalapril Maleate Organon Canada Inc No Yes No No Yes No No Yes Wellbutrin XL 247849 Bupropion Hcl Bausch Health, Canada Inc Yes Yes No Yes Yes Yes Yes Yes Zyban 247564 Bupropion Hcl Bausch Health, Canada Inc Yes Yes No Yes Yes Yes Yes Yes Zyvoxam 248930 Linezolid Pfizer Canada ULC No Yes No Yes No Yes No Yes May 2021Product Monograph Brand Safety Updates May 2021(PDF, 90 KB, 2 pages) May 2021 Brand Name Submission Number Ingredient(s) Manufacturer Contraindications Warnings &. Precautions Serious Warnings &.

Precautions Adverse Reactions Drug Interactions Dosage &. Administration Overdosage Consumer Information Afinitor, Afinitor Disperz 247570 Everolimus Novartis Pharmaceuticals Canada Inc No Yes No Yes No No No Yes Androcur, Androcur Depot 245903 Cyproterone Acetate Bayer Inc No Yes No Yes No No No Yes Apo-Clobazam 245505 Clobazam Apotex Inc No Yes Yes Yes Yes Yes No Yes Ativan 245317 Lorazepam Pfizer Canada ULC No Yes Yes Yes Yes Yes No Yes Aubagio 247354 Teriflunomide Sanofi Genzyme, A Division of Sanofi-Aventis Canada Inc No No No Yes No No No Yes Biktarvy 240953 Emtricitabine, Bictegravir Sodium, Tenofovir Alafenamide Hemifumarate Gilead Sciences Canada Inc No Yes No Yes No Yes No Yes Ceftriaxone Sodium for Injection 246728 Ceftriaxone Sodium Teva Canada Limited No No No Yes No No No Yes Depakene 247699 Valproic Acid BGP Pharma ULC No Yes No Yes No No No Yes Diastat 245322 Diazepam Valeant Pharmaceuticals North America Llc No Yes Yes Yes Yes Yes No Yes Diazepam Injection USP 245324 Diazepam Sandoz Canada Incorporated Yes Yes Yes Yes Yes Yes No Yes Epival 247581 Divalproex Sodium BGP Pharma ULC No Yes No Yes No No No Yes Eucrisa 240171 Crisaborole Pfizer Canada ULC No No No No Yes No No Yes Lorazepam Injection USP 245339 Lorazepam Sandoz Canada Incorporated No Yes Yes Yes Yes Yes No Yes Mayzent 245078 Siponimod Novartis Pharmaceuticals Canada Inc No Yes No Yes No No No Yes Ofev 247352 Nintedanib Boehringer Ingelheim (Canada) Ltd Ltee No Yes No Yes Yes Yes Yes Yes Prinivil 247696 Lisinopril Merck Canada Inc No Yes No No Yes No No Yes Sevorane AF 246821 Sevoflurane Abbvie Corporation No Yes No Yes No No No Yes Soliqua 247226 Lixisenatide, Insulin Glargine Sanofi-Aventis Canada Inc No Yes No Yes No Yes No Yes Tegretol 247229 Carbamazepine Novartis Pharmaceuticals Canada Inc Yes Yes Yes Yes Yes Yes Yes Yes Toloxin 246803 Digoxin Pendopharm Division of Pharmascience Inc No No No No No Yes No Yes Topamax 247698 Topiramate Janssen Inc Yes Yes No No Yes Yes Yes Yes Trelegy Ellipta 240101 Umeclidinium Bromide, Fluticasone Furoate, Vilanterol Trifenatate GlaxoSmithKline Inc Yes Yes No Yes Yes Yes Yes Yes Vitrakvi 241249 Larotrectinib Sulfate Bayer Inc No Yes No Yes Yes Yes No No Vosevi 247191 Voxilaprevir, Velpatasvir, Sofosbuvir Gilead Sciences Canada Inc No No No Yes No No No Yes Xanax,Xanax TS 245344 Alprazolam Upjohn Canada ULC No Yes Yes Yes Yes Yes No Yes Xylocard 246218 Lidocaine Hcl Aspen Pharmacare Canada Inc. Yes Yes No No No Yes Yes Yes April 2021Product Monograph Brand Safety Updates April 2021(PDF, 84.6 KB, 2 pages) April 2021 Brand Name Submission Number Ingredient(s) Manufacturer Contraindications Warnings &.

Precautions Serious Warnings &. Precautions Adverse Reactions Drug Interactions Dosage &. Administration Overdosage Consumer Information Avalide 246609 Hydrochlorothiazide, Irbesartan Sanofi-Aventis Canada Inc No Yes No Yes No No No Yes Avapro 246866 Irbesartan Sanofi-Aventis Canada Inc No No No Yes No No No Yes Docetaxel Injection USP 246984 Docetaxel Pfizer Canada ULC No Yes Yes Yes No No No Yes Duodopa 245733 Levodopa, Carbidopa Monohydrate AbbVie Corporation No Yes No No No Yes No Yes Hydromorphone Hydrochloride Injection USP 237401 Hydromorphone Hcl Sandoz Canada Incorporated No No No No No Yes Yes No Iressa 246584 Gefitinib AstraZeneca Canada Inc No No No Yes No No No Yes Kazano 243901 Metformin Hcl, Alogliptin Benzoate Takeda Canada Inc No No No Yes No No No Yes Naproxen Capsules200 Mg 245549 Naproxen Catalent Ontario Limited No Yes No Yes Yes No No Yes Nesina 243900 Alogliptin Benzoate Takeda Canada Inc No Yes No Yes No No No Yes Nexplanon 247049 Etonogestrel Organon Canada Inc.

No Yes No No No No No Yes Opsumit 246750 Macitentan Janssen Inc No No No No Yes No No Yes Reactine Fast Melt Junior 246339 Cetirizine Hydrochloride McNeil Consumer Healthcare Division of Johnson &. Johnson Inc No No No No No No No Yes Sandostatin, Sandostatin LAR 247160 Octreotide Novartis Pharmaceuticals Canada Inc No No No Yes No No Yes No Seroquel, Seroquel XR >246849 Quetiapine Fumarate AstraZeneca Canada Inc No Yes Yes Yes Yes Yes No Yes Sinemet 246915 Carbidopa Monohydrate, Levodopa Organon Canada Inc. No No No No No Yes No Yes Vosevi >245142 Voxilaprevir, Velpatasvir, Sofosbuvir Gilead Sciences Canada Inc No Yes No Yes No No No Yes Xeloda 247293 Capecitabine Hoffmann La Roche Limited No No No Yes No No No Yes Zenhale 239493 Formoterol Fumarate Dihydrate, Mometasone Furoate Organon Canada Inc.

No Yes No Yes No Yes No Yes March 2021Product Monograph Brand Safety Updates March 2021(PDF, 108 KB, 3 pages) March 2021 Brand Name Submission Number Ingredient(s) Manufacturer Contraindications Warnings &. Precautions Serious Warnings &. Precautions Adverse Reactions Drug Interactions Dosage &.

Administration Overdosage Consumer Information Abilify Maintena 237149 Aripiprazole Otsuka Pharmaceutical Co Ltd No Yes No No No Yes No Yes Accuretic 244863 Hydrochlorothiazide, Quinapril Hcl Pfizer Canada ULC No Yes No Yes No No No Yes Aldactazide 25, Aldactazide 50 244911 Hydrochlorothiazide, Spironolactone Pfizer Canada ULC No Yes No Yes No No No Yes Alunbrig 237680 Brigatinib Takeda Canada Inc No Yes No Yes No No No Yes Asacol 245536 Mesalazine Allergan Inc No Yes No Yes Yes No No Yes Asacol 800 245722 Mesalazine Allergan Inc No Yes No Yes Yes No No Yes Balversa 245919 Erdafitinib Janssen Inc No No No No Yes No No No Belsomra 244781 Suvorexant Merck Canada Inc No Yes No Yes No No No Yes Buscopan 245198 Hyoscine Butylbromide Sanofi Consumer Health Inc Yes Yes No No No No Yes Yes Cellcept 245034 Mycophenolate Mofetil Hydrochloride, Mycophenolate Mofetil Hoffmann La Roche Limited No No No Yes No No No Yes Children's Advil 244560 Ibuprofen GlaxoSmithkKine Consumer Healthcare ULC No Yes No No No Yes No Yes Cymbalta 245810 Duloxetine Hcl Eli Lilly Canada Inc No Yes No No No No No Yes Flovent HFA, Flovent Diskus 243742 Fluticasone Propionate GlaxoSmithkKine Inc No Yes No Yes No Yes Yes Yes Gemcitabine Injection 245820 Gemcitabine Hcl Pfizer Canada ULC No Yes No Yes No No No No Glatect 244549 Glatiramer Acetate Pharmascience Inc No Yes No Yes No No No Yes Glyxambi 243907 Linagliptin, Empagliflozin Boehringer Ingelheim (Canada) Ltd Ltee No No No Yes No No No Yes Imbruvica 238064 Ibrutinib Janssen Inc No Yes No Yes Yes No No Yes Invanz 245199 Ertapenem Sodium Merck Canada Inc No No No Yes No No No Yes Jentadueto 243906 Metformin Hcl, Linagliptin Boehringer Ingelheim (Canada) Ltd Ltee No No No Yes No No No Yes Jorveza 238101 Budesonide Avir Pharma Inc No No No Yes No Yes No Yes Lynparza 246316 Olaparib AstraZeneca Canada Inc No Yes No Yes No No No Yes Maviret 245141 Pibrentasvir, Glecaprevir Abbvie Corporation Yes Yes No Yes No No No Yes Mekinist 245843 Trametinib Novartis Pharmaceuticals Canada Inc No Yes No Yes No No No Yes Motrin Liquid Gels 200 Mg, Motrin Liquid Gels 400 Mg 244305 Ibuprofen McNeil Consumer Healthcare Division of Johnson &. Johnson Inc No Yes No No No No No Yes Neupro 245289 Rotigotine UCB Canada Inc No Yes No Yes No No No Yes Nolvadex-D 243317 Tamoxifen Citrate AstraZeneca Canada Inc Yes Yes No Yes Yes No No No Octostim 244562 Desmopressin Acetate Ferring Inc Yes Yes No Yes Yes Yes Yes Yes Onbrez Breezhaler 245077 Indacaterol Maleate Novartis Pharmaceuticals Canada Inc No Yes No Yes Yes No No Yes Onpattro 245256 Patisiran Sodium Alnylam Netherlands B.V. No Yes No Yes No No No Yes PMS-Methadone 241778 Methadone Hydrochloride Paladin Labs Inc Yes Yes Yes Yes Yes Yes Yes Yes Prevacid, Prevacid Fastab 241989 Lansoprazole Takeda Pharmaceuticals America Inc No Yes No Yes No No No No Radicava 245593 Edaravone Mitsubishi Tanabe Pharma Corporation No No No No No Yes No No Sandoz Methylphenidate SR 244991 Methylphenidate Hcl Sandoz Canada Incorporated No Yes No Yes No Yes No Yes Sandoz Perindopril Erbumine/Indapamide LD, Sandoz Perindopril Erbumine/Indapamide, Sandoz Perindopril Erbumine/Indapamide HD 244537 Indapamide, Perindopril Erbumine Sandoz Canada Incorporated Yes Yes No Yes Yes No No Yes Septra Injection 245929 Trimethoprim, Sulfamethoxazole Aspen Pharmacare Canada Inc.

No Yes Yes Yes No No No Yes Serevent Diskus 243734 Salmeterol Xinafoate GlaxoSmithKline Inc Yes Yes No Yes Yes Yes No Yes Solu-Medrol, Solu-Medrol Act-O-Vials 245362 Methylprednisolone Pfizer Canada ULC No Yes No No No No No No Somatuline Autogel 245315 Lanreotide Ipsen Biopharmaceuticals Canada Inc Yes Yes Yes Yes Yes Yes No Yes Tafinlar 245834 Dabrafenib Novartis Pharmaceuticals Canada Inc No Yes No Yes No No No Yes Thalomid 244994 Thalidomide Celgene Inc No Yes No Yes No No No Yes Trintellix 237793 Vortioxetine Hydrobromide Lundbeck Canada Inc No Yes No Yes No No No Yes Viibryd 237588 Vilazodone Hydrochloride Allergan Inc No Yes No Yes No Yes No No Vocabria, Cabenuva 238803 Rilpivirine, Cabotegravir ViiV Healthcare ULC Yes Yes No Yes Yes Yes No Yes Zepatier 245140 Grazoprevir, Elbasvir Merck Canada Inc No Yes No Yes No No No Yes February 2021Product Monograph Brand Safety Updates February 2021(PDF, 83 KB, 2 pages) February 2021 Brand Name Submission Number Ingredient(s) Manufacturer Contraindications Warnings &. Precautions Serious Warnings &. Precautions Adverse Reactions Drug Interactions Dosage &.

Administration Overdosage Consumer Information Abilify 242200 Aripiprazole Otsuka Pharmaceutical Co Ltd No Yes No Yes No No No Yes Aleve Caplets 243112 Naproxen Sodium Bayer Inc No No No No No Yes No Yes Aubagio 243821 Teriflunomide Sanofi Genzyme, A Division of Sanofi-Aventis Canada Inc No Yes No Yes No No No Yes Belkyra 242465 Deoxycholic Acid Kythera Biopharmaceuticals Inc No Yes No Yes No No No Yes Biktarvy 237235 Emtricitabine, Bictegravir Sodium, Tenofovir Alafenamide Hemifumarate Gilead Sciences Canada Inc No No No Yes No No No Yes Bridion 237151 Sugammadex Merck Canada Inc No Yes No Yes No No No No Clobex Spray 244309 Clobetasol Propionate Galderma Canada Inc Yes Yes No Yes No Yes Yes Yes Definity 242706 Perflutren Lantheus MI Canada Inc No Yes No No No No No No Depo-Medrol 245381 Methylprednisolone Acetate Pfizer Canada ULC No No No No No Yes No No Diflucan One 244031 Fluconazole Pfizer Canada ULC No No No No Yes No No Yes Metadol 241772 Methadone Hydrochloride Paladin Labs Inc No Yes No Yes Yes Yes No Yes Metadol-D 241773 Methadone Hydrochloride Paladin Labs Inc No Yes No Yes Yes Yes No Yes Mycobutin 244143 Rifabutin Pfizer Canada ULC No Yes No Yes No No No Yes Myleran 243043 Busulfan Aspen Pharmacare Canada Inc. No Yes No Yes No No No Yes Ninlaro 244191 Ixazomib Citrate Takeda Canada Inc No No No No No No Yes Yes Pomalyst 243491 Pomalidomide Celgene Inc No Yes Yes Yes Yes Yes Yes Yes Revatio 237407 Sildenafil Citrate Upjohn Canada ULC No No No Yes No No No No Sabril 244467 Vigabatrin Lundbeck Pharmaceuticals LLC No Yes No No No Yes No No Salofalk 242059 Mesalazine Aptalis Pharma Canada ULC No Yes No Yes Yes Yes No Yes Salofalk 242468 Mesalazine Aptalis Pharma Canada ULC No Yes No Yes Yes No No Yes Salofalk 242774 Mesalazine Aptalis Pharma Canada ULC No Yes No Yes Yes No No Yes Seasonale 245618 Levonorgestrel, Ethinyl Estradiol Teva Canada Limited Yes Yes Yes No No No No Yes Seasonique 245619 Levonorgestrel, Ethinyl Estradiol Teva Canada Limited Yes Yes Yes No No No No Yes Stieva-A 244142 Tretinoin GlaxoSmithKline Inc No Yes No No No Yes No Yes Symbicort Turbuhaler 244507 Formoterol Fumarate Dihydrate, Budesonide AstraZeneca Canada Inc No Yes No Yes Yes Yes Yes Yes Teveten Plus 244660 Hydrochlorothiazide, Eprosartan Mesylate BGP Pharma ULC No Yes No Yes No No No Yes Trajenta 243905 Linagliptin Boehringer Ingelheim (Canada) Ltd Ltee No No No Yes No No No Yes Trintellix 243819 Vortioxetine Hydrobromide Lundbeck Canada Inc No Yes No Yes Yes No No Yes Vfend 243931 Voriconazole Pfizer Canada ULC Yes No No No Yes No No Yes January 2021Product Monograph Brand Safety Updates January 2021(PDF, 83 KB, 2 pages) January 2021 Brand Name Submission Number Ingredient(s) Manufacturer Contraindications Warnings &. Precautions Serious Warnings &.

Precautions Adverse Reactions Drug Interactions Dosage &. Administration Overdosage Consumer Information Addyi 229727 Flibanserin Searchlight Pharma Inc Yes Yes Yes Yes Yes Yes No Yes Aptivus 242983 Tipranavir Boehringer Ingelheim (Canada) Ltd Ltee No No No No Yes Yes No Yes Entocort Enema 242607 Budesonide Tillotts Pharma GmbH Yes Yes No No Yes Yes Yes Yes Fycompa 235549 Perampanel Eisai Limited No Yes No No Yes No No No Kyleena 243730 Levonorgestrel Bayer Inc No Yes No No No Yes No Yes Kyprolis 237196 Carfilzomib Amgen Canada Inc No Yes No Yes No Yes No Yes Micardis Plus 242123 Telmisartan, Hydrochlorothiazide Boehringer Ingelheim (Canada) Ltd Ltee Yes No No Yes Yes No No No Monistat Derm Cream 242581 Miconazole Nitrate Insight Pharmaceuticals LLC No Yes Yes No No No Yes Yes Omnipaque 180, Omnipaque 240, Omnipaque 300, Omnipaque 350 242219 Iohexol GE Healthcare Canada Inc No No No No No Yes No Yes Retin-A 235656 Tretinoin Bausch Health, Canada Inc. Yes Yes No Yes No Yes No Yes Rozlytrek 242028 Entrectinib Hoffmann La Roche Limited No No No Yes No Yes No Yes Sinemet 240018 Carbidopa, Levodopa Merck Canada Inc No No No No No Yes No No Tagrisso 243288 Osimertinib Mesylate AstraZeneca Canada Inc No Yes No Yes No Yes No Yes Tivicay 235583 Dolutegravir Sodium ViiV Healthcare ULC No Yes No Yes Yes Yes No Yes Trelstar 239594 Triptorelin Pamoate Knight Therapeutics Inc.

No No No No No No No Yes Venclexta 243474 Venetoclax Abbvie Corporation No Yes No No No Yes No Yes Xarelto 234756 Rivaroxaban Bayer Inc Yes Yes No Yes Yes Yes Yes Yes Xylac 243159 Loxapine Succinate Pendopharm Division of Pharmascience Inc No Yes Yes Yes Yes Yes No Yes Ziagen 243476 Abacavir Sulfate ViiV Healthcare ULC No No No No Yes No No Yes Zytiga 244273 Abiraterone Acetate Janssen Inc No Yes No Yes No No No Yes December 2020Product Monograph Brand Safety Updates December 2020(PDF, 103 KB, 3 pages) December 2020 Brand Name Submission Number Ingredient(S) Manufacturer Contraindications Warnings &. Precautions Serious Warnings &. Precautions Adverse Reactions Drug Interactions Dosage &.

Administration Overdosage Consumer Information Abilify Maintena 242346 Aripiprazole Otsuka Pharmaceutical Co Ltd No Yes No Yes No No No No Accel-Sevelamer 239213 Sevelamer Carbonate Accel Pharma Inc No Yes No No No Yes Yes Yes Adderall XR 241496 Amphetamine Aspartate, Dextroamphetamine Saccharate, Amphetamine Sulfate, Dextroamphetamine Sulfate Takeda Canada Inc No Yes No No Yes No No Yes Advagraf 241431 Tacrolimus Astellas Pharma Canada Inc No No No No Yes No No Yes Asmanex Twisthaler 241482 Mometasone Furoate Merck Canada Inc No Yes No No No Yes Yes Yes Biktarvy 242750 Emtricitabine, Bictegravir Sodium, Tenofovir Alafenamide Hemifumarate Gilead Sciences Canada Inc No No No Yes No No No Yes Caduet 241827 Atorvastatin Calcium, Amlodipine Besylate Upjohn Canada ULC Yes Yes No No Yes No No Yes Caripul 241742 Epoprostenol Sodium Janssen Inc No Yes No No No No No Yes Dexilant 241999 Dexlansoprazole Takeda Canada Inc No Yes No Yes No No No No Duotrav PQ 242431 Travoprost, Timolol Maleate Novartis Pharmaceuticals Canada Inc No No No Yes No No No Yes Erythrocin I.V. 241362 Erythromycin Lactobionate Amdipharm Limited Yes Yes Yes Yes Yes No No Yes Gilenya 242144 Fingolimod Hydrochloride Novartis Pharmaceuticals Canada Inc No Yes No Yes Yes Yes No Yes Idhifa 242218 Enasidenib Mesylate Celgene Inc No No No No Yes No No No Imbruvica 235706 Ibrutinib Janssen Inc No Yes No Yes No Yes No Yes Invanz 238455 Ertapenem Sodium Merck Canada Inc No Yes No No No No No Yes Invega 241812 Paliperidone Janssen Inc No Yes No Yes No No No Yes Invega Sustenna 241862 Paliperidone Palmitate Janssen Inc No Yes No Yes No No No Yes Invega Trinza 241830 Paliperidone Palmitate Janssen Inc No Yes No Yes No No No Yes Keppra 242697 Levetiracetam UCB Canada Inc No Yes No Yes No No No Yes Kisqali 237555 Ribociclib Succinate Novartis Pharmaceuticals Canada Inc No No No Yes No No No No Lenvima 242453 Lenvatinib Mesylate Eisai Limited No Yes No Yes Yes Yes No Yes Lipitor 241951 Atorvastatin Calcium Upjohn Canada ULC Yes Yes No No Yes No No Yes Luvox 238347 Fluvoxamine Maleate BGP Pharma ULC No Yes No No No No No No Mavenclad 238626 Cladribine EMD Serono a Division of EMD Inc Canada Yes Yes No No No No No Yes Moviprep 238575 Polyethylene Glycol 3350, Sodium Chloride, Potassium Chloride, Ascorbic Acid, Sodium Ascorbate, Sodium Sulfate Anhydrous Aralez Pharmaceuticals Canada Inc No Yes No No No No No Yes Olmetec 241065 Olmesartan Medoxomil Merck Canada Inc Yes Yes No Yes Yes No No Yes Olmetec Plus 241145 Hydrochlorothiazide, Olmesartan Medoxomil Merck Canada Inc Yes Yes No No Yes No Yes Yes Onivyde 243509 Irinotecan Sucrose Octasulfate Servier Canada Inc No Yes No No No No No Yes Onstryv 242236 Safinamide Valeo Pharma Inc No No No Yes No No No Yes Pantoloc 242003 Pantoprazole Takeda Canada Inc No Yes No Yes No No No No Pediapred 243283 Prednisolone Sodium Phosphate Sanofi-Aventis Canada Inc No Yes No Yes No No No Yes Prograf 241489 Tacrolimus Astellas Pharma Canada Inc No No No No Yes Yes No Yes Prolensa 238790 Bromfenac Sodium Sesquihydrate Bausch &. Lomb Inc No Yes No Yes No No No Yes Remeron 242352 Mirtazapine Merck Canada Inc No Yes No Yes No No No Yes Remeron RD 242354 Mirtazapine Merck Canada Inc No Yes No Yes No No No Yes Rexulti 242419 Brexpiprazole Otsuka Pharmaceutical Co Ltd No Yes No Yes No No No Yes Rifadin 241843 Rifampin Sanofi-Aventis Canada Inc No No No No Yes No No Yes Risperdal 241861 Risperidone Janssen Inc No Yes No Yes No No No Yes Risperdal Consta 241839 Risperidone Janssen Inc No Yes No Yes No No No Yes Stribild 238174 Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat, Elvitegravir Gilead Sciences Canada Inc Yes No No No No No No Yes Tecta 242002 Pantoprazole Magnesium Takeda Canada Inc No Yes No Yes No No No No Teva-Loperamide 240985 Loperamide Hcl Teva Canada Limited No Yes No No No No Yes Yes Uam 241841 Tramadol Hcl Janssen Inc No Yes No Yes No No No Yes November 2020Product Monograph Brand Safety Updates November 2020(PDF, 91 KB, 2 pages) November 2020 Brand Name Submission Number Ingredient(S) Manufacturer Contraindications Warnings &.

Precautions Serious Warnings &. Precautions Adverse Reactions Drug Interactions Dosage &. Administration Overdosage Consumer Information Adlyxine 240740 Lixisenatide Sanofi-Aventis Canada Inc No No No No No Yes No Yes Advil Cold &.

Sinus Convenience Pack 240564 Ibuprofen, Pseudoephedrine Hcl, Chlorpheniramine Maleate GlaxoSmithKline Consumer Healthcare Inc Yes Yes No No Yes No No Yes Advil Day/Night Convenience Pack 240575 Ibuprofen, Diphenhydramine Hcl GlaxoSmithKline Consumer Healthcare Inc Yes Yes No Yes Yes No Yes Yes Auro-Cefixime 239750 Cefixime Auro Pharma Inc No Yes No No No No No Yes Avalide 241361 Hydrochlorothiazide, Irbesartan Sanofi-Aventis Canada Inc No Yes No Yes Yes No No Yes Avapro 241360 Irbesartan Sanofi-Aventis Canada Inc No Yes No Yes Yes No No Yes Azarga 242484 Timolol Maleate, Brinzolamide Novartis Pharmaceuticals Canada Inc No Yes No Yes No No No Yes Carbaglu 227936 Carglumic Acid Recordati Rare Diseases No Yes No Yes Yes Yes Yes Yes Claritin Kids Rapid Dissolve 228699 Loratadine Bayer Inc No No No No No Yes No Yes Cold + Sinus Daytime Cold + Sinus Nighttime 239435 Ibuprofen, Pseudoephedrine Hcl Vita Health Products Inc Yes Yes Yes No Yes No No Yes Depakene 242654 Valproic Acid BGP Pharma ULC No Yes No No No No No Yes Descovy 234525 Emtricitabine, Tenofovir Alafenamide Gilead Sciences Canada Inc No Yes Yes Yes No Yes No Yes Epclusa 233923 Velpatasvir, Sofosbuvir Gilead Sciences Canada Inc No Yes No Yes No Yes No Yes Epival 242651 Divalproex Sodium BGP Pharma ULC No Yes No No No No No Yes Erleada 241921 Apalutamide Janssen Inc No No No Yes No No No Yes Genvoya 238172 Emtricitabine, Tenofovir Alafenamide Hemifumarate, Cobicistat, Elvitegravir Gilead Sciences Canada Inc Yes No No No Yes No No Yes Jakavi 241484 Ruxolitinib Phosphate Novartis Pharmaceuticals Canada Inc No Yes No Yes Yes No No Yes Lolo 238799 Ethinyl Estradiol, Norethindrone Acetate Allergan Inc No No No No No Yes No Yes Lonsurf 235999 Tipiracil Hydrochloride, Trifluridine Taiho Pharma Canada, Inc. No Yes No Yes No Yes No Yes Lupron, Lupron Depot 241744 Leuprolide Acetate Abbvie Corporation Yes Yes Yes Yes Yes Yes Yes Yes Micro+6 Concentrate 237994 Manganese Sulfate, Chromic Chloride, Cupric Sulfate, Selenious Acid, Zinc Sulfate Heptahydrate, Sodium Iodide Sandoz Canada Incorporated No Yes No No No Yes Yes No Mirena 243721 Levonorgestrel Bayer Inc No Yes No No No Yes No Yes PMS-Fluticasone Propionate/Salmeterol DPI 242762 Fluticasone Propionate, Salmeterol Xinafoate Pharmascience Inc No No No No No No No Yes Ravicti 241398 Glycerol Phenylbutyrate Horizon Therapeutics Ireland DAC No No No No No No No Yes Rydapt 241284 Midostaurin Novartis Pharmaceuticals Canada Inc No Yes No No No Yes No No Sandostatin LAR, Sandostatin 240998 Octreotide, Octreotide Acetate Novartis Pharmaceuticals Canada Inc No Yes No Yes Yes Yes No Yes Sandoz Metoprolol SR 240568 Metoprolol Tartrate Sandoz Canada Incorporated No No No No Yes No No Yes Sofracort 240569 Dexamethasone Sodium Metasulphobenzoate, Gramicidin, Framycetin Sulfate Sanofi-Aventis Canada Inc Yes Yes No Yes Yes No Yes Yes Tagrisso 242157 Osimertinib Mesylate AstraZeneca Canada Inc No No No Yes No No No Yes Tasigna 242015 Nilotinib Hydrochloride Monohydrate Novartis Pharmaceuticals Canada Inc No No No Yes No No No Yes Tiazac XC 238542 Diltiazem Hcl Valeant Canada LP Valeant Canada S.E.C. Yes Yes No Yes No No Yes Yes Xarelto 233166 Rivaroxaban Bayer Inc No Yes No Yes No Yes No Yes Zytiga 241627 Abiraterone Acetate Janssen Inc No Yes No Yes Yes No No Yes October 2020Product Monograph Brand Safety Updates October 2020(PDF, 70KB, 1 page) October 2020 Brand Name Submission Number Ingredient(S) Manufacturer Contraindications Warnings &.

Precautions Serious Warnings &. Precautions Adverse Reactions Drug Interactions Dosage &. Administration Overdosage Consumer Information Aubagio 239626 Teriflunomide Sanofi Genzyme, A Division of Sanofi-Aventis Canada Inc No Yes No Yes Yes No No Yes Elmiron 239842 Pentosan Polysulfate Sodium Janssen Inc Yes Yes Yes Yes No No No Yes Ibuprofen Liquid Filled Capsules, Extra Strength Ibuprofen Liquid Filled Capsules 240415 Ibuprofen Apotex Inc Yes Yes No No Yes No No Yes Imovane 240565 Zopiclone Sanofi-Aventis Canada Inc Yes Yes Yes Yes Yes No No Yes Ketalar 238402 Ketamine Hydrochloride ERFA Canada 2012 Inc Yes Yes No Yes No Yes No No Kisqali 233623 Ribociclib Succinate Novartis Pharmaceuticals Canada Inc No Yes No Yes No Yes No No Maviret 234362 Pibrentasvir, Glecaprevir Abbvie Corporation No No No No No Yes No No Plavix 239831 Clopidogrel Bisulfate Sanofi-Aventis Canada Inc No Yes No No Yes No No Yes Prezcobix 240107 Darunavir Ethanolate, Cobicistat Janssen Inc No No No No Yes No No Yes Prezista 240039 Darunavir Ethanolate Janssen Inc No No No No Yes No No Yes Renagel 238457 Sevelamer Hydrochloride Sanofi-Aventis Canada Inc No Yes No Yes No No No Yes Renvela 238461 Sevelamer Carbonate Sanofi-Aventis Canada Inc No Yes No Yes No No No Yes Salazopyrin, Salazopyrin En-Tabs 239257 Sulfasalazine Pfizer Canada ULC No No No Yes No No No No Symtuza 240432 Darunavir Ethanolate, Emtricitabine, Cobicistat, Tenofovir Alafenamide Hemifumarate Janssen Inc No No No No Yes No No Yes Tagrisso 234607 Osimertinib Mesylate AstraZeneca Canada Inc No Yes No Yes No Yes No No Talzenna 234108 Talazoparib Pfizer Canada ULC No Yes No Yes Yes Yes No No Tenormin 239845 Atenolol AstraZeneca Canada Inc No Yes No No No No No No Teva-Mexiletine 238065 Mexiletine Hcl Teva Canada Limited No Yes No No No No No No Twynsta 239007 Telmisartan, Amlodipine Besylate Boehringer Ingelheim (Canada) Ltd Ltee Yes Yes No Yes Yes No Yes Yes Zejula 237670 Niraparib GlaxoSmithKline Inc No Yes No Yes Yes Yes No Yes Zerbaxa 238477 Ceftolozane Sulfate, Tazobactam Sodium Merck Canada Inc No Yes No No No No No Yes Zofran, Zofran ODT 240200 Ondansetron Hydrochloride Dihydrate Novartis Pharmaceuticals Canada Inc No Yes No No No No No Yes September 2020Product Monograph Brand Safety Updates September 2020(PDF, 72 KB, 1 page) September 2020 Brand Name Submission Number Ingredient(s) Manufacturer Contraindications Warnings &.

Precautions Serious Warnings &. Precautions Adverse Reactions Drug Interactions Dosage &. Administration Overdosage Consumer Information Aubagio 231739 Teriflunomide Sanofi Genzyme, A Division of Sanofi-Aventis Canada Inc No Yes No Yes No No No Yes Dovato 233469 Dolutegravir, Lamivudine ViiV Healthcare ULC No No No Yes No No No No Heartburn Control 238026 Omeprazole Apotex Inc Yes Yes No Yes Yes Yes Yes Yes Imbruvica 233164 Ibrutinib Janssen Inc No Yes No No No Yes No No Incruse Ellipta 222505 Umeclidinium Bromide GlaxoSmithKline Inc No No No No No No No Yes Narcan Nasal Spray 234832 Naloxone Hcl Adapt Pharma Operations Limited No No No No No No No Yes Plaquenil 238801 Hydroxychloroquine Sulfate Sanofi-Aventis Canada Inc Yes Yes No Yes Yes Yes Yes Yes Saphris 238694 Asenapine Merck Canada Inc No Yes No No No No No No Soliqua 232504 Lixisenatide, Insulin Glargine Sanofi-Aventis Canada Inc No No No Yes No Yes No Yes Synthroid 238350 Levothyroxine Sodium BGP Pharma ULC Yes Yes No No Yes Yes No Yes Targin 237753 Naloxone Hcl, Oxycodone Hcl Purdue Pharma Yes Yes Yes Yes Yes Yes Yes Yes Venclexta 234504 Venetoclax Abbvie Corporation No No No Yes No Yes No No Zytiga 236834 Abiraterone Acetate Janssen Inc No No No Yes No No No No August 2020Product Monograph Brand Safety Updates August 2020(PDF, 82 KB, 2 pages) August 2020 Brand Name Submission Number Ingredient(s) Manufacturer Contraindications Warnings &.

Precautions Serious Warnings &. Precautions Adverse Reactions Drug Interactions Dosage &. Administration Overdosage Consumer Information Brilinta 231818 Ticagrelor AstraZeneca Canada Inc No Yes No Yes No Yes No Yes Butrans 237701 Buprenorphine Purdue Pharma Yes Yes Yes Yes Yes Yes Yes Yes Clinimix E, Clinimix 239475 Nitrogen, Amino Acids, Dextrose Baxter Corporation No Yes No No No Yes No No Codeine Contin 237940 Codeine, Codeine Sulfate Purdue Pharma Yes Yes Yes Yes Yes Yes Yes Yes Epuris 238793 Isotretinoin Cipher Pharmaceuticals Inc No Yes No Yes No No No No Hepsera 236397 Adefovir Dipivoxil Gilead Sciences Canada Inc No Yes No No Yes No No Yes Invokamet 232307 Metformin Hcl, Canagliflozin Janssen Inc No Yes No Yes No Yes No Yes Lokelma 231794 Sodium Zirconium Cyclosilicate AstraZeneca Canada Inc No Yes No Yes No Yes No Yes Lotriderm 237862 Betamethasone Dipropionate, Clotrimazole Merck Canada Inc Yes Yes No Yes Yes Yes Yes Yes Lynparza 235698 Olaparib AstraZeneca Canada Inc No Yes No Yes Yes No No Yes Mezavant 238836 Mesalazine Shire Pharma Canada ULC No No No Yes No No Yes Yes Mirapex 234378 Pramipexole Dihydrochloride Monohydrate Boehringer Ingelheim (Canada) Ltd Ltee No Yes No Yes No Yes No Yes MS Contin 237930 Morphine Sulfate Purdue Pharma Yes Yes Yes Yes Yes Yes Yes Yes MS IR 237978 Morphine Sulfate Purdue Pharma Yes Yes Yes Yes Yes Yes Yes Yes Otezla 233030 Apremilast Amgen Canada Inc No Yes No Yes No Yes No Yes Oxy.IR 237807 Oxycodone Hcl Purdue Pharma Yes Yes Yes Yes Yes Yes Yes Yes Oxyneo 237808 Oxycodone Hcl Purdue Pharma Yes Yes Yes Yes Yes Yes Yes Yes Sonovue 231944 Sulfur Hexafluoride Bracco Imaging Canada No Yes No Yes No Yes No No Sprycel 229858 Dasatinib Bristol-Myers Squibb Canada No Yes No Yes Yes Yes No Yes Sudafed Sinus Advance 237300 Ibuprofen, Pseudoephedrine Hcl McNeil Consumer Healthcare Division of Johnson &.

Johnson Inc No Yes No No No No No Yes Symdeko 237289 Tezacaftor, Ivacaftor Vertex Pharmaceuticals (Canada) Incorporated No Yes No No No No No No Uniphyl 237977 Theophylline Purdue Pharma No Yes No No No Yes No Yes Zydelig 240413 Idelalisib Gilead Sciences Canada Inc No Yes Yes Yes No No No Yes Zytram XL 237703 Tramadol Hcl Purdue Pharma Yes Yes Yes Yes Yes Yes Yes Yes July 2020Product Monograph Brand Safety Updates July 2020(PDF, 77.9 KB, 2 pages) July 2020 Brand Name Submission Number Ingredient(s) Manufacturer Contraindications Warnings and Precautions Serious Warnings and Precautions Adverse Reactions Drug Interactions Dosage and Administration Overdosage Consumer Information Diflucan 237806 Fluconazole Pfizer Canada Inc No No No No Yes No No Yes Dilaudid 237679 Hydromorphone Hcl Purdue Pharma Yes Yes Yes Yes Yes Yes Yes Yes Enstilar 237303 Betamethasone Dipropionate, Calcipotriol Monohydrate Leo Pharma Inc No Yes No Yes No Yes No Yes Hydromorph Contin 237700 Hydromorphone Hcl Purdue Pharma Yes Yes Yes Yes Yes Yes Yes Yes Ninlaro 236958 Ixazomib Citrate Takeda Canada Inc No Yes No Yes No No No Yes Oxaliplatin 236783 Oxaliplatin Pfizer Canada ULC Yes Yes No Yes No No No Yes Precedex 237805 Dexmedetomidine Pfizer Canada ULC No No No Yes No No No No Protopic 237801 Tacrolimus Leo Pharma Inc No Yes No No No Yes No Yes Singulair 230733 Montelukast Sodium Merck Canada Inc No Yes Yes Yes No Yes No Yes Smofkabiven Electrolyte Free, Smofkabiven Extra Nitrogen Electrolyte Free 230307 Fish Oil, Phenylalanine, Valine, Methionamine, Tyrosine, Threonine, Nitrogen, Dextrose, Glycine, Histidine, Isoleucine, Proline, Arginine, Lysine, Alanine, Serine, Olive Oil, Tryptophan, Leucine, Soybean Oil, Taurine, Medium-Chain Triglycerides Fresenius Kabi Canada Ltd No No No No No Yes No Yes Smofkabiven, Smofkabiven Extra Nitrogen 230147 Fish Oil, Phenylalanine, Valine, Methionamine, Tyrosine, Threonine, Nitrogen, Dextrose, Glycine, Histidine, Isoleucine, Proline, Magnesium Sulfate, Potassium Chloride, Alanine, Arginine, Sodium Glycerophosphate, Lysine, Calcium Chloride Dihydrate, Serine, Olive Oil, Tryptophan, Sodium Acetate Trihydrate, Zinc Sulfate Heptahydrate, Leucine, Soybean Oil, Taurine, Medium-Chain Triglycerides Fresenius Kabi Canada Ltd No No No No No Yes No Yes Suboxone 229217 Buprenorphine Hydrochloride, Naloxone Hydrochloride Dihydrate Indivior UK Limited No Yes Yes Yes No Yes No Yes Teveten 237726 Eprosartan Mesylate BGP Pharma ULC No Yes No No Yes No No Yes Teveten Plus 237724 Hydrochlorothiazide, Eprosartan Mesylate BGP Pharma ULC No Yes No No Yes No No Yes Tiazac 237804 Diltiazem Hcl Valeant Canada LP Valeant Canada S.E.C. No Yes No Yes No No Yes Yes Vfend 237769 Voriconazole Pfizer Canada ULC Yes Yes Yes Yes Yes No No Yes Wellbutrin SR 237178 Bupropion Hcl Valeant Canada LP Valeant Canada S.E.C. No Yes No Yes No No Yes Yes Wellbutrin XL 237179 Bupropion Hcl Valeant Canada LP Valeant Canada S.E.C.

N/A 2015-07-15 2021-07-15 N/A 2023-07-15 alectinib hydrochloride buy zithromax pill 189442 Alecensaro Hoffmann-La Roche Limited N/A 2016-09-29 2022-09-29 N/A 2024-09-29 alirocumab 183116 http://www.em-centre-bischheim.ac-strasbourg.fr/les-parcours/lundi-mars/ Praluent Sanofi-aventis Canada Inc. N/A 2016-04-11 2022-04-11 N/A 2024-04-11 alogliptin benzoate 158335 Nesina Takeda Canada Inc. KazanoOseni 2013-11-27 2019-11-27 N/A 2021-11-27 alpelisib 226941 Piqray Novartis Pharmaceuticals Canada Inc.

N/A 2020-03-11 2026-03-11 N/A 2028-03-11 amifampridine (supplied as amifampridine phosphate) 232685 buy zithromax pill Firdapse Kye Pharmaceuticals Inc. N/A 2020-07-31 2026-07-31 N/A 2028-07-31 anthrax immune globulin (human) 200446 Anthrasil Emergent BioSolutions Canada Inc. N/A 2017-11-06 2023-11-06 Yes 2026-05-06 antihemophilic factor (recombinant BDD), Fc fusion protein 163447 Eloctate Sanofi-Aventis Canada Inc.

N/A 2014-08-22 2020-08-22 Yes 2023-02-22 buy zithromax pill antihemophilic factor (recombinant), pegylated 189709 Adynovate Takeda Canada Inc. N/A 2016-11-17 2022-11-17 Yes 2025-05-17 antihemophilic factor (recombinant, B-domain deleted, pegylated) (also known as damoctocog alfa pegol) 210935 Jivi Bayer Inc. N/A 2018-10-18 2024-10-18 Yes 2027-04-18 antihemophilic factor (recombinant, B-domain deleted) (also known as simoctocog alfa) 169551 Nuwiq Octapharma Pharmazeutika Produktionsges.m.b.H N/A 2014-10-23 2020-10-23 Yes 2023-04-23 antihemophilic factor VIII (recombinant), singlechain (also known as lonoctocog alfa) 190891 Afstyla CSL Behring Canada Inc.

N/A 2016-12-12 buy zithromax pill 2022-12-12 Yes 2025-06-12 anthrax antigen fiate 212387 Biothrax Emergent Biodefense Operations Lansing LLC N/A 2018-12-13 2024-12-13 N/A 2026-12-13 antihemophilic factor VIII (recombinant, B-domain truncated), PEGylated (turoctocog alfa pegol) 218531 Esperoct Novo Nordisk Canada Inc. N/A 2019-07-04 2025-07-04 Yes 2028-01-04 apalutamide 211942 Erleada Janssen Inc. N/A 2018-07-03 2024-07-03 N/A 2026-07-03 apremilast 169862 Otezla Amgen Canada Inc.

N/A 2014-11-12 2020-11-12 N/A 2022-11-12 asfotase alfa 179340 Strensiq Alexion Pharma International Sàrl N/A 2015-08-14 2021-08-14 Yes 2024-02-14 asunaprevir 172617 Sunvepra Bristol-Myers Squibb Canada N/A 2016-03-09 2022-03-09 N/A 2024-03-09 atezolizumab 196843 Tecentriq Hoffmann-La Roche Limited N/A 2017-04-12 buy zithromax pill 2023-04-12 N/A 2025-04-12 avelumab 204052 Bavencio EMD Serono, a Division of EMD Inc., Canada N/A 2017-12-18 2023-12-18 N/A 2025-12-18 axicabtagene ciloleucel 218389 Yescarta Gilead Sciences Canada Inc N/A 2019-02-13 2025-02-13 N/A 2027-02-13 azelastine hydrochloride 169604 Dymista Meda Pharmaceuticals Ltd. N/A 2014-10-23 2020-10-23 Yes 2023-04-23 baloxavir marboxil 227361 Xofluza Hoffmann-La Roche Limited N/A 2020-02-19 2026-02-19 Yes 2028-08-19 baricitinib 193687 Olumiant Eli Lilly Canada Inc. N/A 2018-08-17 2024-08-17 N/A 2026-08-17 bazedoxifene acetate 160681 Duavive Pfizer Canada Inc.

N/A 2014-10-23 2020-10-23 N/A 2022-10-23 benralizumab 204008 Fasenra AstraZeneca Canada Inc buy zithromax pill. N/A 2018-02-22 2024-02-22 Yes 2026-08-22 bepotastine besilate 179294 Bepreve Bausch and Lomb Incorporated N/A 2016-07-27 2022-07-27 Yes 2025-01-27 bictegravir 203718 Biktarvy Gilead Sciences Canada, Inc. N/A 2018-07-10 2024-07-10 Yes 2027-01-10 bilastine 184231 Blexten Aralez Pharmaceutials Canada Inc.

N/A 2016-04-21 2022-04-21 Yes 2024-10-21 binimetinib 237410 Mektovi Pfizer Canada ULC N/A 2021-03-02 2027-03-02 N/A 2029-03-02 blinatumomab 181723 Blincyto Amgen Canada Incorporated N/A 2015-12-22 2021-12-22 Yes 2024-06-22 bosutinib 152211 Bosulif Pfizer buy zithromax pill Canada Inc. N/A 2014-03-07 2020-03-07 N/A 2022-03-07 botulism antitoxin heptavalen C/ D/ F/ G - (equine) 190645 Bat Emergent BioSolutions Inc. N/A 2016-12-08 2022-12-08 Yes 2025-06-08 brexpiprazole 192684 Rexulti Otsuka Pharmaceutical Co.

Ltd. N/A 2017-02-16 2023-02-16 Yes 2025-08-16 brexucabtagene autoleucel 246355 Tecartus Gilead Sciences Canada, Inc. N/A 2021-06-08 2027-06-08 N/A 2029-06-08 brigatinib 210369 Alunbrig Takeda Canada Incorporated N/A 2018-07-26 2024-07-26 N/A 2026-07-26 brivaracetam 183355 Brivlera UCB Canada Incorporated N/A 2016-03-09 2022-03-09 Yes 2024-09-09 brodalumab 195317 Siliq Bausch Health, Canada Inc.

N/A 2018-03-06 2024-03-06 N/A 2026-03-06 brolucizumab 226224 Beovu Novartis Pharmaceuticals Canada Inc. N/A 2020-03-12 2026-03-12 N/A 2028-03-12 bromfenac sodium sesquihydrate 171657 Prolensa Bausch &. Lomb Incorporated N/A 2015-03-26 2021-03-26 N/A 2023-03-26 burosumab 216239 Crysvita Kyowa Kirin Limited N/A 2018-12-05 2024-12-05 Yes 2027-06-05 cabotegravir sodium 227315 Vocabria ViiV Healthcare ULC N/A 2020-03-18 2026-03-18 N/A 2028-03-18 cabotegravir 227315 Cabenuva ViiV Healthcare ULC N/A 2020-03-18 2026-03-18 N/A 2028-03-18 cabozantinib (supplied as cabozantinib (S)-malate) 206230 Cabometyx Ipsen Biopharmaceuticals Canada Inc.

N/A 2018-09-14 2024-09-14 N/A 2026-09-14 calcifediol 205392 Rayaldee Vifor Fresenius Medical Care Renal Pharma Ltd N/A 2018-07-10 2024-07-10 N/A 2026-07-10 canagliflozin 157505 Invokana Janssen Inc. InvokametInvokamet XR 2014-05-23 2020-05-23 N/A 2022-05-23 caplacizumab 230001 Cablivi Sanofi-Aventis Canada Inc. N/A 2020-02-28 2026-02-28 N/A 2028-02-28 carfilzomib 184479 Kyprolis Amgen Canada Inc.

N/A 2016-01-15 2022-01-15 N/A 2024-01-15 carglumic acid 171358 Carbaglu Recordati Rare Diseases N/A 2015-04-10 2021-04-10 Yes 2023-10-10 cedazuridine 234610 Inqovi Otsuka Pharmaceutical Co., Ltd. N/A 2020-07-07 2026-07-07 N/A 2028-07-07 ceftolozane 178006 Zerbaxa Merck Canada Inc. N/A 2015-09-30 2021-09-30 N/A 2023-09-30 cemiplimab 218718 Libtayo Sanofi-Aventis Canada Inc.

N/A 2019-04-10 2025-04-10 N/A 2027-04-10 cenegermin 218145 Oxervate Dompé farmaceutici S.p.A. N/A 2019-02-08 2025-02-08 N/A 2027-02-08 ceritinib 175702 Zykadia Novartis Pharmaceuticals Canada Inc. N/A 2015-03-27 2021-03-27 N/A 2023-03-27 cerliponase alfa 216539 Brineura Biomarin International Limited N/A 2018-12-19 2024-12-19 Yes 2027-06-19 coagulation factor IX (recombinant), albumin fusion protein (rIX-FP) 180793 Idelvion CSL Behring Canada Inc.

N/A 2016-01-26 2022-01-26 Yes 2024-07-26 coagulation factor IX (recombinant), pegylated (nonacog beta pegol) 201114 Rebinyn Novo Nordisk Canada Inc. N/A 2017-11-29 2023-11-29 Yes 2026-05-29 coagulation factor IX, Fc fusion protein 163614 Alprolix Sanofi-Aventis Canada Inc. N/A 2014-03-20 2020-03-20 Yes 2022-09-20 cobimetinib 182788 Cotellic Hoffmann-La Roche Limited N/A 2016-02-22 2022-02-22 N/A 2024-02-22 crisaborole 206906 Eucrisa Pfizer Canada Inc.

N/A 2018-06-07 2024-06-07 Yes 2026-12-07 cysteamine bitartrate 191347 Procysbi Horizon Pharma Ireland Ltd. N/A 2017-06-13 2023-06-13 Yes 2025-12-13 daclatasvir 172616 Daklinza Bristol-Myers Squibb Canada N/A 2015-08-13 2021-08-13 N/A 2023-08-13 daclizumab beta 190458 Zinbryta Biogen Canada Inc. N/A 2016-12-08 2022-12-08 N/A 2024-12-08 dacomitinib 214572 Vizimpro Pfizer Canada Inc.

N/A 2019-02-26 2025-02-26 N/A 2027-02-26 dalbavancin (supplied as dalbavancin hydrochloride) 212390 Xydalba Cipher Pharmaceuticals Inc. N/A 2018-09-04 2024-09-04 N/A 2026-09-04 dapagliflozin propanediol 160877 Forxiga AstraZeneca Canada Inc. XigduoQtern 2014-12-12 2020-12-12 N/A 2022-12-12 daratumumab 187648 Darzalex Janssen Inc.

Darzalex SC 2016-06-29 2022-06-29 N/A 2024-06-29 darolutamide 226146 Nubeqa Bayer Inc. N/A 2020-02-20 2026-02-20 N/A 2028-02-20 deferiprone 162924 Ferriprox Chiesi Canada Corp. N/A 2015-02-13 2021-02-13 Yes 2023-08-13 defibrotide sodium 200808 Defitelio Jazz Pharmaceuticals Ireland Limited N/A 2017-07-10 2023-07-10 Yes 2026-01-10 difluprednate 154517 Durezol Novartis Pharmaceuticals Canada Inc.

N/A 2013-11-04 2019-11-04 Yes 2022-05-04 dimethyl fumarate 154776 Tecfidera Biogen Idec Canada Inc. N/A 2013-04-03 2019-04-03 Yes 2021-10-03 dinutuximab 212066 Unituxin United Therapeutics Corporation N/A 2018-11-28 2024-11-28 Yes 2027-05-28 dolutegravir sodium 161084 Tivicay ViiV Healthcare ULC TriumeqJulucaDovato 2013-10-31 2019-10-31 Yes 2022-05-01 doravirine 211293 Pifeo Merck Canada Inc. Delstrigo 2018-10-12 2024-10-12 N/A 2026-10-12 dulaglutide 168671 Trulicity Eli Lilly Canada Inc.

N/A 2015-11-10 2021-11-10 N/A 2023-11-10 dupilumab 201285 Dupixent Sanofi-Aventis Canada Inc. N/A 2017-11-30 2023-11-30 Yes 2026-05-30 durvalumab 202953 Imfinzi AstraZeneca Canada Inc. N/A 2017-11-03 2023-11-03 N/A 2025-11-03 edaravone 214391 Radicava Mitsubishi Tanabe Pharma Corporation N/A 2018-10-03 2024-10-03 N/A 2026-10-03 edoxaban 187363 Lixiana Servier Canada Inc.

N/A 2016-11-04 2022-11-04 N/A 2024-11-04 efinaconazole 159416 Jublia Bausch Health, Canada Inc. N/A 2013-10-02 2019-10-02 N/A 2021-10-02 elagolix 209513 Orilissa AbbVie Corporation N/A 2018-10-05 2024-10-05 N/A 2026-10-05 elexacaftor 246955 Trikafta Vertex Pharmaceuticals (Canada) Incorporated N/A 2021-06-18 2027-06-18 Yes 2029-12-18 eliglustat tartrate 183050 Cerdelga Genzyme Canada, A division of Sanofi-aventis Canada Inc. N/A 2017-04-21 2023-04-21 N/A 2025-04-21 elosulfase alfa 170340 Vimizim Biomarin International Limited N/A 2014-07-02 2020-07-02 Yes 2023-01-02 elotuzumab 188144 Empliciti Bristol-Myers Squibb Canada N/A 2016-06-21 2022-06-21 N/A 2024-06-21 eluxadoline 190162 Viberzi Allergan inc.

N/A 2017-01-26 2023-01-26 N/A 2025-01-26 emicizumab 212635 Hemlibra Hoffmann-La Roche Limited N/A 2018-08-02 2024-08-02 Yes 2027-02-02 empagliflozin 162552 Jardiance Boehringer Ingelheim (Canada) Ltd. SynjardyGlyxambi 2015-07-23 2021-07-23 N/A 2023-07-23 enasidenib mesylate 217033 Idhifa Celgene Inc. N/A 2019-02-06 2025-02-06 N/A 2027-02-06 encorafenib 237413 Braftovi Pfizer Canada ULC N/A 2021-03-02 2027-03-02 N/A 2029-03-02 entrectinib 227517 Rozlytrek Hoffmann-La Roche Limited N/A 2020-02-10 2026-02-10 Yes 2028-08-10 eptinezumab 233288 Vyepti Lundbeck Canada Inc.

N/A 2021-01-11 2027-01-11 N/A 2029-01-11 erdafitinib 224529 Balversa Janssen Inc. N/A 2019-10-25 2025-10-25 N/A 2027-10-25 erenumab 208607 Aimovig Novartis Pharmaceuticals Canada Inc. N/A 2018-08-01 2024-08-01 N/A 2026-08-01 ertugliflozin 204724 Steglatro Merck Canada Inc.

SteglujanSegluromet 2018-05-09 2024-05-09 N/A 2026-05-09 eslicarbazepine acetate 165665 Aptiom Sunovion Pharmaceuticals Canada Inc. N/A 2014-07-08 2020-07-08 Yes 2023-01-08 estetrol monohydrate 236197 Nextstellis Searchlight Pharma Inc. N/A 2021-03-05 2027-03-05 N/A 2029-03-05 evolocumab 178234 Repatha Amgen Canada Inc.

N/A 2015-09-10 2021-09-10 Yes 2024-03-10 fedratinib (supplied as fedratinib hydrochloride) 229866 Inrebic Celgene Inc. N/A 2020-07-27 2026-07-27 N/A 2028-07-27 ferric pyrophosphate citrate 239850 Triferic Avnu Rockwell Medical Inc. N/A 2021-04-22 2027-04-22 Yes 2029-10-22 finafloxacin 172450 Xtoro MerLion Pharmaceuticals GmbH N/A 2016-03-11 2022-03-11 Yes 2024-09-11 flibanserin 189352 Addyi Searchlight Pharma Inc.

N/A 2018-02-27 2024-02-27 N/A 2026-02-27 florbetaben (18F) 193105 Neuraceq Isologic Innovative Radiopharmaceuticals Ltd. N/A 2017-02-22 2023-02-22 N/A 2025-02-22 follitropin delta 188743 Rekovelle Ferring Inc. N/A 2018-03-22 2024-03-22 N/A 2026-03-22 fostamatinib (supplied as fostamatinib disodium) 232078 Tavalisse Rigel Pharmaceuticals Inc.

N/A 2020-11-19 2026-11-19 N/A 2028-11-19 fremanezumab 226828 Ajovy Teva Canada Limited N/A 2020-04-09 2026-04-09 N/A 2028-04-09 gadoterate meglumine 186333 Dotarem Guerbet N/A 2016-11-26 2022-11-26 Yes 2025-05-26 galcanezumab 219521 Emgality Eli Lilly Canada Inc. N/A 2019-07-30 2025-07-30 N/A 2027-07-30 galsulfase 159020 Naglazyme BioMarin Pharmaceutical Inc. N/A 2013-09-16 2019-09-16 Yes 2022-03-16 gemtuzumab ozogamicin 223091 Mylotarg Pfizer Canada ULC N/A 2019-11-28 2025-11-28 Yes 2028-05-28 gilteritinib fumarate 227918 Xospata Astellas Pharma Canada Inc.

N/A 2019-12-23 2025-12-23 N/A 2027-12-23 givosiran (supplied as givosiran sodium) 237194 Givlaari Alnylam Netherlands B.V.. N/A 2020-10-09 2026-10-09 N/A 2028-10-09 glasdegib 225793 Daurismo Pfizer Canada ULC N/A 2020-04-28 2026-04-28 N/A 2028-04-28 glecaprevir, pibrentasvir 202233 Maviret AbbVie Corporation N/A 2017-08-16 2023-08-16 Yes 2026-02-16 glycerol phenylbutyrate 174219 Ravicti Horizon Pharma Ireland Ltd. N/A 2016-03-18 2022-03-18 Yes 2024-09-18 grazoprevir, elbasvir 185866 Zepatier Merck Canada Inc.

N/A 2016-01-19 2022-01-19 N/A 2024-01-19 guanfacine hydrochloride 150741 Intuniv XR Takeda Canada Inc. N/A 2013-07-05 2019-07-05 Yes 2022-01-05 guselkumab 200590 Tremfya Janssen Inc. N/A 2017-11-10 2023-11-10 N/A 2025-11-10 haemagglutinin strain A (H5N1) 115398 Arepanrix H5N1 ID Biomedical Corporation of Quebec N/A 2013-02-13 2019-02-13 Yes 2021-08-13 hemin 212276 Panhematin Recordati Rare Diseases Canada Inc.

N/A 2018-07-13 2024-07-13 N/A 2026-07-13 ibrutinib 174029 Imbruvica Janssen Inc. N/A 2014-11-17 2020-11-17 Yes 2023-05-17 icatibant acetate 162918 Firazyr Takeda Canada Inc. N/A 2014-06-04 2020-06-04 Yes 2022-12-04 icosapent ethyl 227235 Vascepa HLS Therapeutics Inc.

N/A 2019-12-30 2025-12-30 N/A 2027-12-30 idarucizumab 182503 Praxbind Boehringer Ingelheim (Canada) Ltd N/A 2016-04-29 2022-04-29 N/A 2024-04-29 idecabtagene vicleucel 244266 Abecma Celgene Inc. N/A 2021-05-26 2027-05-26 N/A 2029-05-26 idelalisib 172652 Zydelig Gilead Sciences Canada Inc. N/A 2015-03-27 2021-03-27 N/A 2023-03-27 inotersen sodium 214274 Tegsedi Akcea Therapeutics Inc.

N/A 2018-10-03 2024-10-03 N/A 2026-10-03 inotuzumab ozogamicin 204077 Besponsa Pfizer Canada Inc. N/A 2018-03-15 2024-03-15 N/A 2026-03-15 insulin degludec 198124 Tresiba Novo Nordisk Canada Inc. Xultophy 2017-08-25 2023-08-25 Yes 2026-02-25 ioflupane (123I) 201481 Datscan GE Healthcare Canada Inc.

N/A 2017-12-07 2023-12-07 N/A 2025-12-07 iron isomaltoside 1000 193890 Monoferric Pharmacosmos A/S N/A 2018-06-22 2024-06-22 N/A 2026-06-22 isatuximab 229245 Sarclisa Sanofi-Aventis Canada Inc. N/A 2020-04-29 2026-04-29 N/A 2028-04-29 isavuconazole (supplied as isavuconazonium sulfate) 208919 Cresemba Avir Pharma Inc. N/A 2018-12-19 2024-12-19 N/A 2026-12-19 ivabradine hydrochloride 166949 Lancora Servier Canada Inc.

N/A 2016-12-23 2022-12-23 Yes 2025-06-23 ivermectin 172733 Rosiver Galderma Canada Inc. N/A 2015-04-22 2021-04-22 N/A 2023-04-22 ixazomib (supplied as ixazomib citrate) 190498 Ninlaro Takeda Canada Inc. N/A 2016-08-04 2022-08-04 N/A 2024-08-04 ixekizumab 184993 Taltz Eli Lilly Canada Inc.

N/A 2016-05-25 2022-05-25 Yes 2024-11-25 lanadelumab 213920 Takhzyro Takeda Canada Inc. N/A 2018-09-19 2024-09-19 Yes 2027-03-19 larotrectinib (supplied as larotrectinib sulfate) 219998 Vitrakvi Bayer Inc. N/A 2019-07-10 2025-07-10 Yes 2028-01-10 latanoprostene bunod 211732 Vyzulta Bausch &.

Lomb Incorporated N/A 2018-12-27 2024-12-27 N/A 2026-12-27 ledipasvir 173180 Harvoni Gilead Sciences Canada Inc. N/A 2014-10-15 2020-10-15 Yes 2023-04-15 lefamulin acetate 233292 Xenleta Sunovion Pharmaceuticals Canada Inc. N/A 2020-07-10 2026-07-10 N/A 2028-07-10 lemborexant 231286 Dayvigo Eisai Limited N/A 2020-11-04 2026-11-04 N/A 2028-11-04 lenvatinib mesylate 180877 Lenvima Eisai Limited N/A 2015-12-22 2021-12-22 N/A 2023-12-22 letermovir 204165 Prevymis Merck Canada Inc.

N/A 2017-11-01 2023-11-01 N/A 2025-11-01 levomilnacipran hydrochloride 167319 Fetzima Allergan Inc. N/A 2015-05-08 2021-05-08 N/A 2023-05-08 lifitegrast 199810 Xiidra Novartis Pharmaceuticals Canada Inc. N/A 2017-12-22 2023-12-22 N/A 2025-12-22 linaclotide 161056 Constella Forest Laboratories Canada Inc.

N/A 2013-12-02 2019-12-02 N/A 2021-12-02 lixisenatide 193862 Adlyxine Sanofi-aventis Canada Inc. Soliqua 2017-05-25 2023-05-25 N/A 2025-05-25 lomitapide mesylate 160385 Juxtapid Aegerion Pharmaceuticals Canada Ltd. N/A 2014-02-04 2020-02-04 N/A 2022-02-04 lorlatinib 215733 Lorbrena Pfizer Canada ULC N/A 2019-02-22 2025-02-22 N/A 2027-02-22 lubiprostone 179333 Amitiza Sucampo Pharma Americas LLC N/A 2015-10-14 2021-10-14 N/A 2023-10-14 lumacaftor 181715 Orkambi Vertex Pharmaceuticals (Canada) Incorporated N/A 2016-01-26 2022-01-26 Yes 2024-07-26 luspatercept 236441 Reblozyl Celgene Inc.

N/A 2020-09-25 2026-09-25 N/A 2028-09-25 lutetium177 Lu oxodotreotide 217184 Lutathera Advanced Accelerator Applications USA, Inc. N/A 2019-01-09 2025-01-09 N/A 2027-01-09 macitentan 161372 Opsumit Janssen Inc. N/A 2013-11-06 2019-11-06 Yes 2022-05-06 mecasermin 235023 Increlex Ipsen Biopharmaceuticals Canada Inc.

N/A 2020-12-17 2026-12-17 Yes 2029-06-17 mepolizumab 179850 Nucala GlaxoSmithKline Inc. N/A 2015-12-03 2021-12-03 Yes 2024-06-03 midostaurin 201101 Rydapt Novartis Pharmaceuticals Canada Inc. N/A 2017-07-21 2023-07-21 Yes 2026-01-21 mifepristone 160063 Mifegymiso Linepharma International Limited N/A 2015-07-29 2021-07-29 Yes 2024-01-29 migalastat hydrochloride 196956 Galafold Amicus Therapeutics UK LTD N/A 2017-09-05 2023-09-05 N/A 2025-09-05 modified vaccinia zithromax (ankara-bavarian nordic) 144762 Imvamune Bavarian Nordic A/S N/A 2013-11-21 2019-11-21 N/A 2021-11-21 naloxegol oxalate 167790 Movantik Knight Therapeutics Inc.

N/A 2015-06-02 2021-06-02 N/A 2023-06-02 necitumumab 193689 Portrazza Eli Lilly Canada Inc. N/A 2017-03-16 2023-03-16 N/A 2025-03-16 neisseria meningitidis serogroup A polysaccharide, neisseria meningitidis serogroup C polysaccharide, neisseria meningitidis serogroup W-135 polysaccharide, neisseria meningitidis serogroup Y polysaccharide, conjugated to tetanus toxoid carrier protein 154290 Nimenrix Pfizer Canada Inc. N/A 2013-03-05 2019-03-05 Yes 2021-09-05 neisseria meningitidis serogroup B recombinant lipoprotein 2086 (rLP2086) subfamily A and Neisseria meningitidis serogroup B recombinant lipoprotein 2086 (rLP2086) subfamily B 195550 Trumenba Pfizer Canada Inc.

N/A 2017-10-05 2023-10-05 Yes 2026-04-05 neratinib maleate 218224 Nerlynx Knight Therapeutics Inc. N/A 2019-07-16 2025-07-16 N/A 2027-07-16 netupitant 196495 Akynzeo Elvium Life Sciences N/A 2017-09-28 2023-09-28 N/A 2025-09-28 nintedanib (supplied as nintedanib esilate) 176043 Ofev Boehringer Ingelheim (Canada) Ltd N/A 2015-06-25 2021-06-25 N/A 2023-06-25 niraparib 216792 Zejula GlaxoSmithKline Inc. N/A 2019-06-27 2025-06-27 N/A 2027-06-27 nivolumab 180828 Opdivo Bristol-Myers-Squibb Canada N/A 2015-09-25 2021-09-25 Yes 2024-03-25 nusinersen 200070 Spinraza Biogen Canada Inc.

N/A 2017-06-29 2023-06-29 Yes 2025-12-29 obeticholic acid 198418 Ocaliva Intercept Pharmaceuticals Inc. N/A 2017-05-24 2023-05-24 N/A 2025-05-24 obiltoxaximab 230825 Anthim Elusys Therapeutics, Inc. N/A 2020-07-30 2026-07-30 N/A 2028-07-30 obinutuzumab 168227 Gazyva Hoffmann-La Roche Limited N/A 2014-11-25 2020-11-25 N/A 2022-11-25 ocrelizumab 198094 Ocrevus Hoffmann-La Roche Limited N/A 2017-08-14 2023-08-14 N/A 2025-08-14 ocriplasmin 161356 Jetrea ThromboGenics N.V.

N/A 2013-08-13 2019-08-13 N/A 2021-08-13 olaparib 182823 Lynparza AstraZeneca Canada Inc. N/A 2016-04-29 2022-04-29 N/A 2024-04-29 olaratumab 203478 Lartruvo Eli Lilly Canada Inc. N/A 2017-11-23 2023-11-23 N/A 2025-11-23 ombitasvir, paritaprevir, dasabuvir sodium 174739 Holkira Pak Abbvie Corporation Technivie 2014-12-22 2020-12-22 N/A 2022-12-22 onasemnogene abeparvovec 239719 Zolgensma Novartis Pharmaceuticals Canada Inc.

N/A 2020-12-15 2026-12-15 Yes 2029-06-15 osimertinib mesylate 188171 Tagrisso AstraZeneca Canada buy generic zithromax no prescription Inc. N/A 2016-07-05 2022-07-05 N/A 2024-07-05 ozanimod (supplied as ozanimod hydrochloride) 232761 Zeposia Celgene Inc. N/A 2020-10-02 2026-10-02 N/A 2028-10-02 ozenoxacin 192925 Ozanex Ferrer Internacional, S.A.

N/A 2017-05-01 2023-05-01 Yes 2025-11-01 palbociclib 182048 Ibrance Pfizer Canada Inc. N/A 2016-03-16 2022-03-16 N/A 2024-03-16 pasireotide diaspartate 145005 Signifor Novartis Pharmaceuticals Canada Inc. Signifor Lar 2013-09-23 2019-09-23 N/A 2021-09-23 patiromer sorbitex calcium 210368 Veltassa Vifor Fresenius Medical Care Renal Pharma Ltd.

N/A 2018-10-03 2024-10-03 N/A 2026-10-03 patisiran (as patisiran sodium) 221896 Onpattro Alnylam Netherlands B.V. N/A 2019-06-07 2025-06-07 N/A 2027-06-07 peginterferon beta-1a 166974 Plegridy Biogen Idec Canada Inc. N/A 2015-08-10 2021-08-10 N/A 2023-08-10 pembrolizumab 175884 Keytruda Merck Canada Inc.

N/A 2015-05-19 2021-05-19 Yes 2023-11-19 peramivir 191280 Rapivab BioCryst Pharmaceuticals Inc. N/A 2017-01-05 2023-01-05 N/A 2025-01-05 perampanel 153747 Fycompa Eisai Limited N/A 2013-04-04 2019-04-04 Yes 2021-10-04 pitolisant hydrochloride 238175 Wakik Endo Ventures Ltd. N/A 2021-05-25 2027-05-25 N/A 2029-05-25 plecanatide 215288 Trulance Bausch Health, Canada Inc.

N/A 2019-10-10 2025-10-10 N/A 2027-10-10 polatuzumab vedotin 232303 Polivy Hoffmann-La Roche Limited N/A 2020-07-09 2026-07-09 N/A 2028-07-09 polidocanol 177359 Varithena Provensis Ltd. N/A 2015-08-04 2021-08-04 N/A 2023-08-04 pomalidomide 165891 Pomalyst Celgene Inc. N/A 2014-01-20 2020-01-20 Yes 2022-07-20 pralatrexate 207545 Folotyn Servier Canada Inc.

N/A 2018-10-26 2024-10-26 N/A 2026-10-26 pralsetinib 243731 Gavreto Hoffmann-La Roche Limited N/A 2021-06-30 2027-06-30 N/A 2029-06-30 prasterone 198822 Intrarosa Endoceutics Inc. N/A 2019-11-01 2025-11-01 N/A 2027-11-01 ponatinib hydrochloride 165121 Iclusig Ariad Pharmaceuticals Inc. N/A 2015-04-02 2021-04-02 N/A 2023-04-02 ponesimod 239537 Ponvory Janssen Inc.

N/A 2021-04-28 2027-04-28 N/A 2029-04-28 propiverine hydrochloride 188323 Mictoryl / Mictoryl Pediatric Duchesnay Inc. N/A 2017-01-05 2023-01-05 Yes 2025-07-05 radium - 223 dichloride 161312 Xofigo Bayer Inc. N/A 2013-12-12 2019-12-12 N/A 2021-12-12 ramucirumab 176810 Cyramza Eli Lilly Canada Inc.

N/A 2015-07-16 2021-07-16 N/A 2023-07-16 ravulizumab 217955 Ultomiris Alexion Pharma GmbH N/A 2019-08-28 2025-08-28 N/A 2027-08-28 recombinant haemagglutinin protein-strain A (H1N1) recombinant haemagglutinin protein-strain A (H3N2) recombinant haemagglutinin protein-strain B (Victoria) recombinant haemagglutinin protein-strain B (Yamagata) 235672 Supemtek Sanofi Pasteur Limited N/A 2021-01-14 2027-01-14 N/A 2029-01-14 recombinant human papillomazithromax types 31, 33, 45, 52 and 58 170006 Gardasil 9 Merck Canada Inc. N/A 2015-02-05 2021-02-05 Yes 2023-08-05 recombinant neisseria meningitidis group B NHBA fusion protein, recombinant neisseria meningitidis group B NadA protein, recombinant neisseria meningitidis group B FHBP fusion protein, outer membrane vesicle (neisseria meningitidis group B NZ98/254 strain) 147275 Bexsero GlaxoSmithKline Inc. N/A 2013-12-06 2019-12-06 Yes 2022-06-06 recombinant porcine factor VIII (antihemophilic factor (recombinant), porcine sequence) 177290 Obizur Takeda Canada Inc.

N/A 2015-10-14 2021-10-14 N/A 2023-10-14 regorafenib monohydrate 157970 Stivarga Bayer Inc. N/A 2013-03-11 2019-03-11 Yes 2021-09-11 remdesivir 240551 Veklury Gilead Sciences Canada, Inc. N/A 2020-07-27 2026-07-27 N/A 2028-07-27 reslizumab 185873 Cinqair Teva Canada Limited N/A 2016-07-20 2022-07-20 Yes 2025-01-20 ribociclib (supplied as ribociclib succinate) 203884 Kisqali Novartis Pharmaceuticals Canada Inc.

N/A 2018-03-02 2024-03-02 N/A 2026-03-02 rifaximin 161256 Zaxine Salix Pharmaceuticals Inc. N/A 2013-08-13 2019-08-13 N/A 2021-08-13 riociguat 162761 Adempas Bayer Inc. N/A 2013-09-19 2019-09-19 N/A 2021-09-19 ripretinib 234688 Qinlock Deciphera Pharmaceuticals, LLC N/A 2020-06-19 2026-06-19 N/A 2028-06-19 risankizumab 215753 Skyrizi AbbVie Corporation N/A 2019-04-17 2025-04-17 N/A 2027-04-17 risdiplam 242373 Evrysdi Hoffman-La Roche Limited N/A 2021-04-14 2027-04-14 Yes 2029-10-14 romidepsin 152293 Istodax Celgene Inc.

N/A 2013-10-16 2019-10-16 N/A 2021-10-16 romosozumab 197713 Evenity Amgen Canada Inc. N/A 2019-06-17 2025-06-17 N/A 2027-06-17 rupatadine (supplied as rupatadine fumarate) 186488 Rupall Medexus Pharmaceuticals Inc. N/A 2016-07-20 2022-07-20 Yes 2025-01-20 sacubitril 182734 Entresto Novartis Pharmaceuticals Canada Inc.

N/A 2015-10-02 2021-10-02 N/A 2023-10-02 safinamide (as safinamide mesylate) 207115 Onstryv Valeo Pharma Inc. N/A 2019-01-10 2025-01-10 N/A 2027-01-10 sarilumab 191745 Kevzara Sanofi-aventis Canada Inc. N/A 2017-01-12 2023-01-12 N/A 2025-01-12 satralizumab 233642 Enspryng Hoffmann-La Roche Limited N/A 2020-06-01 2026-06-01 Yes 2028-12-01 sebelipase alfa 204085 Kanuma Alexion Pharma GmbH N/A 2017-12-15 2023-12-15 Yes 2026-06-15 secukinumab 170732 Cosentyx Novartis Pharmaceuticals Canada Inc.

N/A 2015-02-27 2021-02-27 Yes 2023-08-27 selexipag 182114 Uptravi Janssen Inc. N/A 2016-01-20 2022-01-20 N/A 2024-01-20 selpercatinib 243748 Retevmo Loxo Oncology Inc. N/A 2021-06-15 2027-06-15 Yes 2029-12-15 semaglutide 202059 Ozempic Novo Nordisk Canada Inc.

Rybelsus 2018-01-04 2024-01-04 N/A 2026-01-04 siltuximab 174291 Sylvant EUSA Pharma (UK) Limited N/A 2014-12-03 2020-12-03 N/A 2022-12-03 simeprevir 164021 Galexos Janssen Inc. N/A 2013-11-18 2019-11-18 N/A 2021-11-18 siponimod 223225 Mayzent Novartis Pharmaceuticals Canada Inc. N/A 2020-02-20 2026-02-20 N/A 2028-02-20 sodium zirconium cyclosilicate 218799 Lokelma AstraZeneca Canada Inc.

N/A 2019-07-25 2025-07-25 N/A 2027-07-25 sofosbuvir 165043 Sovaldi Gilead Sciences Canada Inc. HarvoniEpclusaVosevi 2013-12-13 2019-12-13 N/A 2021-12-13 solriamfetol hydrochloride 237511 Sunosi Jazz Pharmaceuticals Ireland Ltd. N/A 2021-05-13 2027-05-13 N/A 2029-11-13 sonidegib phosphate 229407 Odomzo Sun Pharma Global FZE N/A 2020-06-12 2026-06-12 N/A 2028-06-12 sucroferric oxyhydroxide 201492 Velphoro Vifor Fresenius Medical Care Renal Pharma Ltd.

N/A 2018-01-05 2024-01-05 N/A 2026-01-05 sugammadex sodium 180385 Bridion Merck Canada Inc. N/A 2016-02-05 2022-02-05 N/A 2024-02-05 suvorexant 196367 Belsomra Merck Canada Inc. N/A 2018-11-29 2024-11-29 N/A 2026-11-29 tafamidis meglumine 228368 Vyndaqel Pfizer Canada ULC Vyndamax 2020-01-20 2026-01-20 N/A 2028-01-20 tafluprost 165596 Saflutan Purdue Pharma N/A 2014-05-26 2020-05-26 N/A 2022-05-26 talazoparib (supplied as talazoparib tosylate) 220584 Talzenna Pfizer Canada ULC N/A 2019-09-06 2025-09-06 N/A 2027-09-06 taliglucerase alfa 140854 Elelyso Pfizer Canada Inc.

N/A 2014-05-29 2020-05-29 Yes 2022-11-29 tedizolid phosphate 173603 Sivextro Merck Canada Inc. N/A 2015-03-17 2021-03-17 N/A 2023-03-17 teduglutide 180223 Revestive Takeda Canada Inc. N/A 2015-09-04 2021-09-04 Yes 2024-03-04 telotristat ethyl (as telotristat etiprate) 208730 Xermelo Ipsen Biopharmaceuticals Canada Inc.

N/A 2018-10-10 2024-10-10 N/A 2026-10-10 tenapanor hydrochloride 224850 Ibsrela Knight Therapeutics Inc. N/A 2020-04-15 2026-04-15 N/A 2028-04-15 tenofovir alafenamide hemifumarate 181399 Genvoya Gilead Sciences Canada Inc. DescovyOdefseyVemlidySymtuzaBiktarvy 2015-11-27 2021-11-27 Yes 2024-05-27 tepotinib (supplied as tepotinib hydrochloride) 242300 Tepmetko EMD Serono, a Division of EMD Inc., Canada N/A 2021-05-27 2027-05-27 N/A 2029-05-27 teriflunomide 160646 Aubagio Genzyme Canada a division of Sanofi-aventis Canada Inc.

N/A 2013-11-14 2019-11-14 Yes 2022-05-14 tesamorelin 131836 Egrifta Theratechnologies Inc. N/A 2014-04-29 2020-04-29 N/A 2022-04-29 tezacaftor 211292 Symdeko Vertex Pharmaceuticals (Canada) Incorporated N/A 2018-06-27 2024-06-27 Yes 2026-12-27 tildrakizumab 224036 Ilumya Sun Pharma Global FZE N/A 2021-05-19 2027-05-19 N/A 2029-05-19 tisagenlecleucel 213547 / 213698 Kymriah Novartis Pharmaceuticals Canada Inc. N/A 2018-09-05 2024-09-05 Yes 2027-03-05 tofacitinib 154642 Xeljanz Pfizer Canada Inc.

N/A 2014-04-17 2020-04-17 Yes 2022-10-17 trametinib 157665 Mekinist Novartis Pharmaceuticals Canada Inc. N/A 2013-07-18 2019-07-18 N/A 2021-07-18 trastuzumab deruxtecan 242104 Enhertu AstraZeneca Canada Inc. N/A 2021-04-15 2027-04-15 N/A 2029-04-15 trastuzumab emtansine 162414 Kadcyla Hoffmann-La Roche Limited N/A 2013-09-11 2019-09-11 N/A 2021-09-11 trifarotene 221945 Aklief Galderma Canada Inc.

N/A 2019-11-25 2025-11-25 Yes 2028-05-25 tipiracil hydrochloride 205852 Lonsurf Taiho Pharma Canada Inc. N/A 2018-01-25 2024-01-25 N/A 2026-01-25 triheptanoin 242196 Dojolvi Uagenyx Pharmaceutical Inc. N/A 2021-02-15 2027-02-15 Yes 2029-08-15 tucatinib 235295 Tukysa Seagen Inc.

N/A 2020-06-05 2026-06-05 N/A 2028-06-05 turoctocog alfa 170796 Zonovate Novo Nordisk Canada Inc. N/A 2014-12-08 2020-12-08 Yes 2023-06-08 umeclidinium bromide 161585 Anoro Ellipta GlaxoSmithKline Inc. Incruse Ellipta 2013-12-23 2019-12-23 N/A 2021-12-23 upadacitinib 223734 Rinvoq AbbVie Corporation N/A 2019-12-23 2025-12-23 N/A 2027-12-23 varicella-zoster zithromax glycoprotein E (gE) 200244 Shingrix GlaxoSmithKline Inc.

N/A 2017-10-13 2023-10-13 N/A 2025-10-13 vedolizumab 169414 Entyvio Takeda Canada Inc. N/A 2015-01-29 2021-01-29 Yes 2023-07-29 velpatasvir 190521 Epclusa Gilead Sciences Canada Inc. Vosevi 2016-07-11 2022-07-11 Yes 2025-01-11 venetoclax 190761 Venclexta AbbVie Corporation N/A 2016-09-30 2022-09-30 N/A 2024-09-30 vernakalant hydrochloride 190817 Brinavess Cipher Pharmaceuticals Inc.

N/A 2017-03-13 2023-03-13 N/A 2025-03-13 vilanterol trifenatate 157301 Breo Ellipta GlaxoSmithKline Inc. Anoro ElliptaTrelegy Ellipta 2013-07-03 2019-07-03 Yes 2022-01-03 vilazodone hydrochloride 176820 Viibryd Allergan Inc. N/A 2015-07-16 2021-07-16 Yes 2024-01-16 von willebrand factor (recombinant) (vonicog alfa) 213188 Vonvendi Takeda Canada Inc.

N/A 2019-01-10 2025-01-10 N/A 2027-01-10 vorapaxar sulfate 179320 Zontivity Toprol Acquisition LLC N/A 2016-05-13 2022-05-13 N/A 2024-05-13 voretigene neparvovec 233097 Luxturna Novartis Pharmaceuticals Canada Inc. N/A 2020-10-13 2026-10-13 Yes 2029-04-13 vortioxetine hydrobromide 159019 Trintellix Lundbeck Canada Inc. N/A 2014-10-22 2020-10-22 Yes 2023-04-22 voxilaprevir 202324 Vosevi Gilead Sciences Canada Inc.

N/A 2017-08-16 2023-08-16 N/A 2025-08-16 zanubrutinib 242748 Brukinsa BeiGene Switzerland GmbH N/A 2021-03-01 2027-03-01 N/A 2029-03-01On this page June 2021Product Monograph Brand Safety Updates June 2021(PDF, 101 KB, 4 pages) June 2021 Brand Name Submission Number Ingredient(s) Manufacturer Contraindications Warnings &. Precautions Serious Warnings &. Precautions Adverse Reactions Drug Interactions Dosage &.

Administration Overdosage Consumer Information Altace HCT 246597 Hydrochlorothiazide, Ramipril Bausch Health, Canada Inc No Yes No Yes No No No Yes Aspirin 81 mg, Aspirin 81 mg Quick Chews, Aspirin Regular Strength, Aspirin Extra Strength 248124 Acetylsalicylic Acid Bayer Inc No Yes No Yes Yes No No No Bricanyl Turbuhaler 239089 Terbutaline Sulfate AstraZeneca Canada Inc Yes Yes No No No No No Yes Cellcept, Cellcept I.V. 248429 Mycophenolate Mofetil Hoffmann-La Roche Limited No Yes No No No No No Yes Cipro XL 248371 Ciprofloxacin Hydrochloride Bayer Inc Yes No No No No Yes No Yes Cipro, Cipro Oral Suspension 248370 Ciprofloxacin Hydrochloride Bayer Inc Yes No No No No Yes No Yes Clozaril 247538 Clozapine HLS Therapeutics Inc No Yes Yes No No Yes No Yes Combogesic 248697 Ibuprofen, Acetaminophen Biosyent Pharma Inc No No No Yes No Yes No No Efudex 246337 Fluorouracil Bausch Health, Canada Inc Yes Yes Yes Yes Yes Yes Yes Yes Epclusa 247195 Velpatasvir, Sofosbuvir Gilead Sciences Canada Inc No No No Yes No No No Yes Erleada 241210 Apalutamide Janssen Inc No Yes No Yes No Yes No Yes Harvoni 247194 Ledipasvir, Sofosbuvir Gilead Sciences Canada Inc No No No Yes No No No Yes Hemangiol 247151 Propranolol Hcl Pierre Fabre Dermo-Cosmetique Canada Inc No Yes No Yes No No No Yes Idamycin PFS 249085 Idarubicin Hcl Pfizer Canada ULC No No No Yes No No No Yes Imbruvica 248172 Ibrutinib Janssen Inc No Yes No Yes No No No Yes Inderal-LA 248972 Propranolol Hcl Pfizer Canada ULC No No No Yes No No No Yes Jakavi 247787 Ruxolitinib Phosphate Novartis Pharmaceuticals Canada Inc No Yes No Yes No No No Yes Lorbrena 247174 Lorlatinib Pfizer Canada ULC No Yes No Yes No Yes No Yes Lynparza 249369 Olaparib AstraZeneca Canada Inc No No No Yes No No No Yes Manerix 246047 Moclobemide Bausch Health, Canada Inc Yes Yes No Yes Yes Yes Yes Yes Maxidol Liquid Gels 248432 Naproxen Sodium Bayer Inc No No No Yes No No No Yes Nerlynx 242449 Neratinib Maleate Knight Therapeutics Inc No Yes No Yes Yes Yes No Yes Ofev 241747 Nintedanib Boehringer Ingelheim (Canada) Ltd Ltee No Yes No No Yes No No Yes Orgalutran 248614 Ganirelix Acetate Organon Canada Inc Yes Yes No Yes No Yes No Yes Pat-Galantamine ER 248978 Galantamine Hydrobromide Janssen Inc No Yes No Yes No Yes No Yes Piqray 248616 Alpelisib Novartis Pharmaceuticals Canada Inc No Yes No Yes No No No Yes Ralivia 246159 Tramadol Hcl Bausch Health, Canada Inc No Yes No Yes No No Yes Yes Retrovir (AZT) 249459 Zidovudine ViiV Healthcare ULC No Yes Yes No Yes Yes Yes Yes Rinvoq 241253 Upadacitinib Abbvie Corporation No Yes No Yes No Yes No Yes Rivotril 245341 Clonazepam Hoffmann-La Roche Limited No Yes Yes Yes Yes Yes No Yes Rydapt 247829 Midostaurin Novartis Pharmaceuticals Canada Inc No No No Yes No No No Yes Sandoz Zopiclone Tablet 247527 Zopiclone Sandoz Canada Incorporated No Yes Yes Yes No Yes No Yes Sovaldi 247196 Sofosbuvir Gilead Sciences Canada Inc No No No Yes No No No Yes Synalar 247002 Fluocinolone Acetonide Bausch Health, Canada Inc No Yes No Yes No No No Yes Tapazole 246350 Methimazole Paladin Labs Inc No Yes No No No No Yes Yes Toviaz 248542 Fesoterodine Fumarate Pfizer Canada ULC Yes Yes No Yes Yes Yes No No Trileptal 247670 Oxcarbazepine Novartis Pharmaceuticals Canada Inc No Yes No No No Yes No Yes Valium 245343 Diazepam Hoffmann-La Roche Limited No Yes Yes Yes Yes Yes No Yes Vaseretic 247516 Enalapril Maleate, Hydrochlorothiazide Organon Canada Inc No Yes No No Yes No No Yes Vasotec 247519 Enalapril Maleate Organon Canada Inc No Yes No No Yes No No Yes Wellbutrin XL 247849 Bupropion Hcl Bausch Health, Canada Inc Yes Yes No Yes Yes Yes Yes Yes Zyban 247564 Bupropion Hcl Bausch Health, Canada Inc Yes Yes No Yes Yes Yes Yes Yes Zyvoxam 248930 Linezolid Pfizer Canada ULC No Yes No Yes No Yes No Yes May 2021Product Monograph Brand Safety Updates May 2021(PDF, 90 KB, 2 pages) May 2021 Brand Name Submission Number Ingredient(s) Manufacturer Contraindications Warnings &. Precautions Serious Warnings &.

Precautions Adverse Reactions Drug Interactions Dosage &. Administration Overdosage Consumer Information Afinitor, Afinitor Disperz 247570 Everolimus Novartis Pharmaceuticals Canada Inc No Yes No Yes No No No Yes Androcur, Androcur Depot 245903 Cyproterone Acetate Bayer Inc No Yes No Yes No No No Yes Apo-Clobazam 245505 Clobazam Apotex Inc No Yes Yes Yes Yes Yes No Yes Ativan 245317 Lorazepam Pfizer Canada ULC No Yes Yes Yes Yes Yes No Yes Aubagio 247354 Teriflunomide Sanofi Genzyme, A Division of Sanofi-Aventis Canada Inc No No No Yes No No No Yes Biktarvy 240953 Emtricitabine, Bictegravir Sodium, Tenofovir Alafenamide Hemifumarate Gilead Sciences Canada Inc No Yes No Yes No Yes No Yes Ceftriaxone Sodium for Injection 246728 Ceftriaxone Sodium Teva Canada Limited No No No Yes No No No Yes Depakene 247699 Valproic Acid BGP Pharma ULC No Yes No Yes No No No Yes Diastat 245322 Diazepam Valeant Pharmaceuticals North America Llc No Yes Yes Yes Yes Yes No Yes Diazepam Injection USP 245324 Diazepam Sandoz Canada Incorporated Yes Yes Yes Yes Yes Yes No Yes Epival 247581 Divalproex Sodium BGP Pharma ULC No Yes No Yes No No No Yes Eucrisa 240171 Crisaborole Pfizer Canada ULC No No No No Yes No No Yes Lorazepam Injection USP 245339 Lorazepam Sandoz Canada Incorporated No Yes Yes Yes Yes Yes No Yes Mayzent 245078 Siponimod Novartis Pharmaceuticals Canada Inc No Yes No Yes No No No Yes Ofev 247352 Nintedanib Boehringer Ingelheim (Canada) Ltd Ltee No Yes No Yes Yes Yes Yes Yes Prinivil 247696 Lisinopril Merck Canada Inc No Yes No No Yes No No Yes Sevorane AF 246821 Sevoflurane Abbvie Corporation No Yes No Yes No No No Yes Soliqua 247226 Lixisenatide, Insulin Glargine Sanofi-Aventis Canada Inc No Yes No Yes No Yes No Yes Tegretol 247229 Carbamazepine Novartis Pharmaceuticals Canada Inc Yes Yes Yes Yes Yes Yes Yes Yes Toloxin 246803 Digoxin Pendopharm Division of Pharmascience Inc No No No No No Yes No Yes Topamax 247698 Topiramate Janssen Inc Yes Yes No No Yes Yes Yes Yes Trelegy Ellipta 240101 Umeclidinium Bromide, Fluticasone Furoate, Vilanterol Trifenatate GlaxoSmithKline Inc Yes Yes No Yes Yes Yes Yes Yes Vitrakvi 241249 Larotrectinib Sulfate Bayer Inc No Yes No Yes Yes Yes No No Vosevi 247191 Voxilaprevir, Velpatasvir, Sofosbuvir Gilead Sciences Canada Inc No No No Yes No No No Yes Xanax,Xanax TS 245344 Alprazolam Upjohn Canada ULC No Yes Yes Yes Yes Yes No Yes Xylocard 246218 Lidocaine Hcl Aspen Pharmacare Canada Inc. Yes Yes No No No Yes Yes Yes April 2021Product Monograph Brand Safety Updates April 2021(PDF, 84.6 KB, 2 pages) April 2021 Brand Name Submission Number Ingredient(s) Manufacturer Contraindications Warnings &.

Precautions Serious Warnings &. Precautions Adverse Reactions Drug Interactions Dosage &. Administration Overdosage Consumer Information Avalide 246609 Hydrochlorothiazide, Irbesartan Sanofi-Aventis Canada Inc No Yes No Yes No No No Yes Avapro 246866 Irbesartan Sanofi-Aventis Canada Inc No No No Yes No No No Yes Docetaxel Injection USP 246984 Docetaxel Pfizer Canada ULC No Yes Yes Yes No No No Yes Duodopa 245733 Levodopa, Carbidopa Monohydrate AbbVie Corporation No Yes No No No Yes No Yes Hydromorphone Hydrochloride Injection USP 237401 Hydromorphone Hcl Sandoz Canada Incorporated No No No No No Yes Yes No Iressa 246584 Gefitinib AstraZeneca Canada Inc No No No Yes No No No Yes Kazano 243901 Metformin Hcl, Alogliptin Benzoate Takeda Canada Inc No No No Yes No No No Yes Naproxen Capsules200 Mg 245549 Naproxen Catalent Ontario Limited No Yes No Yes Yes No No Yes Nesina 243900 Alogliptin Benzoate Takeda Canada Inc No Yes No Yes No No No Yes Nexplanon 247049 Etonogestrel Organon Canada Inc.

No Yes No No No No No Yes Opsumit 246750 Macitentan Janssen Inc No No No No Yes No No Yes Reactine Fast Melt Junior 246339 Cetirizine Hydrochloride McNeil Consumer Healthcare Division of Johnson &. Johnson Inc No No No No No No No Yes Sandostatin, Sandostatin LAR 247160 Octreotide Novartis Pharmaceuticals Canada Inc No No No Yes No No Yes No Seroquel, Seroquel XR >246849 Quetiapine Fumarate AstraZeneca Canada Inc No Yes Yes Yes Yes Yes No Yes Sinemet 246915 Carbidopa Monohydrate, Levodopa Organon Canada Inc. No No No No No Yes No Yes Vosevi >245142 Voxilaprevir, Velpatasvir, Sofosbuvir Gilead Sciences Canada Inc No Yes No Yes No No No Yes Xeloda 247293 Capecitabine Hoffmann La Roche Limited No No No Yes No No No Yes Zenhale 239493 Formoterol Fumarate Dihydrate, Mometasone Furoate Organon Canada Inc.

No Yes No Yes No Yes No Yes March 2021Product Monograph Brand Safety Updates March 2021(PDF, 108 KB, 3 pages) March 2021 Brand Name Submission Number Ingredient(s) Manufacturer Contraindications Warnings &. Precautions Serious Warnings &. Precautions Adverse Reactions Drug Interactions Dosage &.

Administration Overdosage Consumer Information Abilify Maintena 237149 Aripiprazole Otsuka Pharmaceutical Co Ltd No Yes No No No Yes No Yes Accuretic 244863 Hydrochlorothiazide, Quinapril Hcl Pfizer Canada ULC No Yes No Yes No No No Yes Aldactazide 25, Aldactazide 50 244911 Hydrochlorothiazide, Spironolactone Pfizer Canada ULC No Yes No Yes No No No Yes Alunbrig 237680 Brigatinib Takeda Canada Inc No Yes No Yes No No No Yes Asacol 245536 Mesalazine Allergan Inc No Yes No Yes Yes No No Yes Asacol 800 245722 Mesalazine Allergan Inc No Yes No Yes Yes No No Yes Balversa 245919 Erdafitinib Janssen Inc No No No No Yes No No No Belsomra 244781 Suvorexant Merck Canada Inc No Yes No Yes No No No Yes Buscopan 245198 Hyoscine Butylbromide Sanofi Consumer Health Inc Yes Yes No No No No Yes Yes Cellcept 245034 Mycophenolate Mofetil Hydrochloride, Mycophenolate Mofetil Hoffmann La Roche Limited No No No Yes No No No Yes Children's Advil 244560 Ibuprofen GlaxoSmithkKine Consumer Healthcare ULC No Yes No No No Yes No Yes Cymbalta 245810 Duloxetine Hcl Eli Lilly Canada Inc No Yes No No No No No Yes Flovent HFA, Flovent Diskus 243742 Fluticasone Propionate GlaxoSmithkKine Inc No Yes No Yes No Yes Yes Yes Gemcitabine Injection 245820 Gemcitabine Hcl Pfizer Canada ULC No Yes No Yes No No No No Glatect 244549 Glatiramer Acetate Pharmascience Inc No Yes No Yes No No No Yes Glyxambi 243907 Linagliptin, Empagliflozin Boehringer Ingelheim (Canada) Ltd Ltee No No No Yes No No No Yes Imbruvica 238064 Ibrutinib Janssen Inc No Yes No Yes Yes No No Yes Invanz 245199 Ertapenem Sodium Merck Canada Inc No No No Yes No No No Yes Jentadueto 243906 Metformin Hcl, Linagliptin Boehringer Ingelheim (Canada) Ltd Ltee No No No Yes No No No Yes Jorveza 238101 Budesonide Avir Pharma Inc No No No Yes No Yes No Yes Lynparza 246316 Olaparib AstraZeneca Canada Inc No Yes No Yes No No No Yes Maviret 245141 Pibrentasvir, Glecaprevir Abbvie Corporation Yes Yes No Yes No No No Yes Mekinist 245843 Trametinib Novartis Pharmaceuticals Canada Inc No Yes No Yes No No No Yes Motrin Liquid Gels 200 Mg, Motrin Liquid Gels 400 Mg 244305 Ibuprofen McNeil Consumer Healthcare Division of Johnson &. Johnson Inc No Yes No No No No No Yes Neupro 245289 Rotigotine UCB Canada Inc No Yes No Yes No No No Yes Nolvadex-D 243317 Tamoxifen Citrate AstraZeneca Canada Inc Yes Yes No Yes Yes No No No Octostim 244562 Desmopressin Acetate Ferring Inc Yes Yes No Yes Yes Yes Yes Yes Onbrez Breezhaler 245077 Indacaterol Maleate Novartis Pharmaceuticals Canada Inc No Yes No Yes Yes No No Yes Onpattro 245256 Patisiran Sodium Alnylam Netherlands B.V. No Yes No Yes No No No Yes PMS-Methadone 241778 Methadone Hydrochloride Paladin Labs Inc Yes Yes Yes Yes Yes Yes Yes Yes Prevacid, Prevacid Fastab 241989 Lansoprazole Takeda Pharmaceuticals America Inc No Yes No Yes No No No No Radicava 245593 Edaravone Mitsubishi Tanabe Pharma Corporation No No No No No Yes No No Sandoz Methylphenidate SR 244991 Methylphenidate Hcl Sandoz Canada Incorporated No Yes No Yes No Yes No Yes Sandoz Perindopril Erbumine/Indapamide LD, Sandoz Perindopril Erbumine/Indapamide, Sandoz Perindopril Erbumine/Indapamide HD 244537 Indapamide, Perindopril Erbumine Sandoz Canada Incorporated Yes Yes No Yes Yes No No Yes Septra Injection 245929 Trimethoprim, Sulfamethoxazole Aspen Pharmacare Canada Inc.

No Yes Yes Yes No No No Yes Serevent Diskus 243734 Salmeterol Xinafoate GlaxoSmithKline Inc Yes Yes No Yes Yes Yes No Yes Solu-Medrol, Solu-Medrol Act-O-Vials 245362 Methylprednisolone Pfizer Canada ULC No Yes No No No No No No Somatuline Autogel 245315 Lanreotide Ipsen Biopharmaceuticals Canada Inc Yes Yes Yes Yes Yes Yes No Yes Tafinlar 245834 Dabrafenib Novartis Pharmaceuticals Canada Inc No Yes No Yes No No No Yes Thalomid 244994 Thalidomide Celgene Inc No Yes No Yes No No No Yes Trintellix 237793 Vortioxetine Hydrobromide Lundbeck Canada Inc No Yes No Yes No No No Yes Viibryd 237588 Vilazodone Hydrochloride Allergan Inc No Yes No Yes No Yes No No Vocabria, Cabenuva 238803 Rilpivirine, Cabotegravir ViiV Healthcare ULC Yes Yes No Yes Yes Yes No Yes Zepatier 245140 Grazoprevir, Elbasvir Merck Canada Inc No Yes No Yes No No No Yes February 2021Product Monograph Brand Safety Updates February 2021(PDF, 83 KB, 2 pages) February 2021 Brand Name Submission Number Ingredient(s) Manufacturer Contraindications Warnings &. Precautions Serious Warnings &. Precautions Adverse Reactions Drug Interactions Dosage &.

Administration Overdosage Consumer Information Abilify 242200 Aripiprazole Otsuka Pharmaceutical Co Ltd No Yes No Yes No No No Yes Aleve Caplets 243112 Naproxen Sodium Bayer Inc No No No No No Yes No Yes Aubagio 243821 Teriflunomide Sanofi Genzyme, A Division of Sanofi-Aventis Canada Inc No Yes No Yes No No No Yes Belkyra 242465 Deoxycholic Acid Kythera Biopharmaceuticals Inc No Yes No Yes No No No Yes Biktarvy 237235 Emtricitabine, Bictegravir Sodium, Tenofovir Alafenamide Hemifumarate Gilead Sciences Canada Inc No No No Yes No No No Yes Bridion 237151 Sugammadex Merck Canada Inc No Yes No Yes No No No No Clobex Spray 244309 Clobetasol Propionate Galderma Canada Inc Yes Yes No Yes No Yes Yes Yes Definity 242706 Perflutren Lantheus MI Canada Inc No Yes No No No No No No Depo-Medrol 245381 Methylprednisolone Acetate Pfizer Canada ULC No No No No No Yes No No Diflucan One 244031 Fluconazole Pfizer Canada ULC No No No No Yes No No Yes Metadol 241772 Methadone Hydrochloride Paladin Labs Inc No Yes No Yes Yes Yes No Yes Metadol-D 241773 Methadone Hydrochloride Paladin Labs Inc No Yes No Yes Yes Yes No Yes Mycobutin 244143 Rifabutin Pfizer Canada ULC No Yes No Yes No No No Yes Myleran 243043 Busulfan Aspen Pharmacare Canada Inc. No Yes No Yes No No No Yes Ninlaro 244191 Ixazomib Citrate Takeda Canada Inc No No No No No No Yes Yes Pomalyst 243491 Pomalidomide Celgene Inc No Yes Yes Yes Yes Yes Yes Yes Revatio 237407 Sildenafil Citrate Upjohn Canada ULC No No No Yes No No No No Sabril 244467 Vigabatrin Lundbeck Pharmaceuticals LLC No Yes No No No Yes No No Salofalk 242059 Mesalazine Aptalis Pharma Canada ULC No Yes No Yes Yes Yes No Yes Salofalk 242468 Mesalazine Aptalis Pharma Canada ULC No Yes No Yes Yes No No Yes Salofalk 242774 Mesalazine Aptalis Pharma Canada ULC No Yes No Yes Yes No No Yes Seasonale 245618 Levonorgestrel, Ethinyl Estradiol Teva Canada Limited Yes Yes Yes No No No No Yes Seasonique 245619 Levonorgestrel, Ethinyl Estradiol Teva Canada Limited Yes Yes Yes No No No No Yes Stieva-A 244142 Tretinoin GlaxoSmithKline Inc No Yes No No No Yes No Yes Symbicort Turbuhaler 244507 Formoterol Fumarate Dihydrate, Budesonide AstraZeneca Canada Inc No Yes No Yes Yes Yes Yes Yes Teveten Plus 244660 Hydrochlorothiazide, Eprosartan Mesylate BGP Pharma ULC No Yes No Yes No No No Yes Trajenta 243905 Linagliptin Boehringer Ingelheim (Canada) Ltd Ltee No No No Yes No No No Yes Trintellix 243819 Vortioxetine Hydrobromide Lundbeck Canada Inc No Yes No Yes Yes No No Yes Vfend 243931 Voriconazole Pfizer Canada ULC Yes No No No Yes No No Yes January 2021Product Monograph Brand Safety Updates January 2021(PDF, 83 KB, 2 pages) January 2021 Brand Name Submission Number Ingredient(s) Manufacturer Contraindications Warnings &. Precautions Serious Warnings &.

Precautions Adverse Reactions Drug Interactions Dosage &. Administration Overdosage Consumer Information Addyi 229727 Flibanserin Searchlight Pharma Inc Yes Yes Yes Yes Yes Yes No Yes Aptivus 242983 Tipranavir Boehringer Ingelheim (Canada) Ltd Ltee No No No No Yes Yes No Yes Entocort Enema 242607 Budesonide Tillotts Pharma GmbH Yes Yes No No Yes Yes Yes Yes Fycompa 235549 Perampanel Eisai Limited No Yes No No Yes No No No Kyleena 243730 Levonorgestrel Bayer Inc No Yes No No No Yes No Yes Kyprolis 237196 Carfilzomib Amgen Canada Inc No Yes No Yes No Yes No Yes Micardis Plus 242123 Telmisartan, Hydrochlorothiazide Boehringer Ingelheim (Canada) Ltd Ltee Yes No No Yes Yes No No No Monistat Derm Cream 242581 Miconazole Nitrate Insight Pharmaceuticals LLC No Yes Yes No No No Yes Yes Omnipaque 180, Omnipaque 240, Omnipaque 300, Omnipaque 350 242219 Iohexol GE Healthcare Canada Inc No No No No No Yes No Yes Retin-A 235656 Tretinoin Bausch Health, Canada Inc. Yes Yes No Yes No Yes No Yes Rozlytrek 242028 Entrectinib Hoffmann La Roche Limited No No No Yes No Yes No Yes Sinemet 240018 Carbidopa, Levodopa Merck Canada Inc No No No No No Yes No No Tagrisso 243288 Osimertinib Mesylate AstraZeneca Canada Inc No Yes No Yes No Yes No Yes Tivicay 235583 Dolutegravir Sodium ViiV Healthcare ULC No Yes No Yes Yes Yes No Yes Trelstar 239594 Triptorelin Pamoate Knight Therapeutics Inc.

No No No No No No No Yes Venclexta 243474 Venetoclax Abbvie Corporation No Yes No No No Yes No Yes Xarelto 234756 Rivaroxaban Bayer Inc Yes Yes No Yes Yes Yes Yes Yes Xylac 243159 Loxapine Succinate Pendopharm Division of Pharmascience Inc No Yes Yes Yes Yes Yes No Yes Ziagen 243476 Abacavir Sulfate ViiV Healthcare ULC No No No No Yes No No Yes Zytiga 244273 Abiraterone Acetate Janssen Inc No Yes No Yes No No No Yes December 2020Product Monograph Brand Safety Updates December 2020(PDF, 103 KB, 3 pages) December 2020 Brand Name Submission Number Ingredient(S) Manufacturer Contraindications Warnings &. Precautions Serious Warnings &. Precautions Adverse Reactions Drug Interactions Dosage &.

Administration Overdosage Consumer Information Abilify Maintena 242346 Aripiprazole Otsuka Pharmaceutical Co Ltd No Yes No Yes No No No No Accel-Sevelamer 239213 Sevelamer Carbonate Accel Pharma Inc No Yes No No No Yes Yes Yes Adderall XR 241496 Amphetamine Aspartate, Dextroamphetamine Saccharate, Amphetamine Sulfate, Dextroamphetamine Sulfate Takeda Canada Inc No Yes No No Yes No No Yes Advagraf 241431 Tacrolimus Astellas Pharma Canada Inc No No No No Yes No No Yes Asmanex Twisthaler 241482 Mometasone Furoate Merck Canada Inc No Yes No No No Yes Yes Yes Biktarvy 242750 Emtricitabine, Bictegravir Sodium, Tenofovir Alafenamide Hemifumarate Gilead Sciences Canada Inc No No No Yes No No No Yes Caduet 241827 Atorvastatin Calcium, Amlodipine Besylate Upjohn Canada ULC Yes Yes No No Yes No No Yes Caripul 241742 Epoprostenol Sodium Janssen Inc No Yes No No No No No Yes Dexilant 241999 Dexlansoprazole Takeda Canada Inc No Yes No Yes No No No No Duotrav PQ 242431 Travoprost, Timolol Maleate Novartis Pharmaceuticals Canada Inc No No No Yes No No No Yes Erythrocin I.V. 241362 Erythromycin Lactobionate Amdipharm Limited Yes Yes Yes Yes Yes No No Yes Gilenya 242144 Fingolimod Hydrochloride Novartis Pharmaceuticals Canada Inc No Yes No Yes Yes Yes No Yes Idhifa 242218 Enasidenib Mesylate Celgene Inc No No No No Yes No No No Imbruvica 235706 Ibrutinib Janssen Inc No Yes No Yes No Yes No Yes Invanz 238455 Ertapenem Sodium Merck Canada Inc No Yes No No No No No Yes Invega 241812 Paliperidone Janssen Inc No Yes No Yes No No No Yes Invega Sustenna 241862 Paliperidone Palmitate Janssen Inc No Yes No Yes No No No Yes Invega Trinza 241830 Paliperidone Palmitate Janssen Inc No Yes No Yes No No No Yes Keppra 242697 Levetiracetam UCB Canada Inc No Yes No Yes No No No Yes Kisqali 237555 Ribociclib Succinate Novartis Pharmaceuticals Canada Inc No No No Yes No No No No Lenvima 242453 Lenvatinib Mesylate Eisai Limited No Yes No Yes Yes Yes No Yes Lipitor 241951 Atorvastatin Calcium Upjohn Canada ULC Yes Yes No No Yes No No Yes Luvox 238347 Fluvoxamine Maleate BGP Pharma ULC No Yes No No No No No No Mavenclad 238626 Cladribine EMD Serono a Division of EMD Inc Canada Yes Yes No No No No No Yes Moviprep 238575 Polyethylene Glycol 3350, Sodium Chloride, Potassium Chloride, Ascorbic Acid, Sodium Ascorbate, Sodium Sulfate Anhydrous Aralez Pharmaceuticals Canada Inc No Yes No No No No No Yes Olmetec 241065 Olmesartan Medoxomil Merck Canada Inc Yes Yes No Yes Yes No No Yes Olmetec Plus 241145 Hydrochlorothiazide, Olmesartan Medoxomil Merck Canada Inc Yes Yes No No Yes No Yes Yes Onivyde 243509 Irinotecan Sucrose Octasulfate Servier Canada Inc No Yes No No No No No Yes Onstryv 242236 Safinamide Valeo Pharma Inc No No No Yes No No No Yes Pantoloc 242003 Pantoprazole Takeda Canada Inc No Yes No Yes No No No No Pediapred 243283 Prednisolone Sodium Phosphate Sanofi-Aventis Canada Inc No Yes No Yes No No No Yes Prograf 241489 Tacrolimus Astellas Pharma Canada Inc No No No No Yes Yes No Yes Prolensa 238790 Bromfenac Sodium Sesquihydrate Bausch &. Lomb Inc No Yes No Yes No No No Yes Remeron 242352 Mirtazapine Merck Canada Inc No Yes No Yes No No No Yes Remeron RD 242354 Mirtazapine Merck Canada Inc No Yes No Yes No No No Yes Rexulti 242419 Brexpiprazole Otsuka Pharmaceutical Co Ltd No Yes No Yes No No No Yes Rifadin 241843 Rifampin Sanofi-Aventis Canada Inc No No No No Yes No No Yes Risperdal 241861 Risperidone Janssen Inc No Yes No Yes No No No Yes Risperdal Consta 241839 Risperidone Janssen Inc No Yes No Yes No No No Yes Stribild 238174 Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat, Elvitegravir Gilead Sciences Canada Inc Yes No No No No No No Yes Tecta 242002 Pantoprazole Magnesium Takeda Canada Inc No Yes No Yes No No No No Teva-Loperamide 240985 Loperamide Hcl Teva Canada Limited No Yes No No No No Yes Yes Uam 241841 Tramadol Hcl Janssen Inc No Yes No Yes No No No Yes November 2020Product Monograph Brand Safety Updates November 2020(PDF, 91 KB, 2 pages) November 2020 Brand Name Submission Number Ingredient(S) Manufacturer Contraindications Warnings &.

Precautions Serious Warnings &. Precautions Adverse Reactions Drug Interactions Dosage &. Administration Overdosage Consumer Information Adlyxine 240740 Lixisenatide Sanofi-Aventis Canada Inc No No No No No Yes No Yes Advil Cold &.

Sinus Convenience Pack 240564 Ibuprofen, Pseudoephedrine Hcl, Chlorpheniramine Maleate GlaxoSmithKline Consumer Healthcare Inc Yes Yes No No Yes No No Yes Advil Day/Night Convenience Pack 240575 Ibuprofen, Diphenhydramine Hcl GlaxoSmithKline Consumer Healthcare Inc Yes Yes No Yes Yes No Yes Yes Auro-Cefixime 239750 Cefixime Auro Pharma Inc No Yes No No No No No Yes Avalide 241361 Hydrochlorothiazide, Irbesartan Sanofi-Aventis Canada Inc No Yes No Yes Yes No No Yes Avapro 241360 Irbesartan Sanofi-Aventis Canada Inc No Yes No Yes Yes No No Yes Azarga 242484 Timolol Maleate, Brinzolamide Novartis Pharmaceuticals Canada Inc No Yes No Yes No No No Yes Carbaglu 227936 Carglumic Acid Recordati Rare Diseases No Yes No Yes Yes Yes Yes Yes Claritin Kids Rapid Dissolve 228699 Loratadine Bayer Inc No No No No No Yes No Yes Cold + Sinus Daytime Cold + Sinus Nighttime 239435 Ibuprofen, Pseudoephedrine Hcl Vita Health Products Inc Yes Yes Yes No Yes No No Yes Depakene 242654 Valproic Acid BGP Pharma ULC No Yes No No No No No Yes Descovy 234525 Emtricitabine, Tenofovir Alafenamide Gilead Sciences Canada Inc No Yes Yes Yes No Yes No Yes Epclusa 233923 Velpatasvir, Sofosbuvir Gilead Sciences Canada Inc No Yes No Yes No Yes No Yes Epival 242651 Divalproex Sodium BGP Pharma ULC No Yes No No No No No Yes Erleada 241921 Apalutamide Janssen Inc No No No Yes No No No Yes Genvoya 238172 Emtricitabine, Tenofovir Alafenamide Hemifumarate, Cobicistat, Elvitegravir Gilead Sciences Canada Inc Yes No No No Yes No No Yes Jakavi 241484 Ruxolitinib Phosphate Novartis Pharmaceuticals Canada Inc No Yes No Yes Yes No No Yes Lolo 238799 Ethinyl Estradiol, Norethindrone Acetate Allergan Inc No No No No No Yes No Yes Lonsurf 235999 Tipiracil Hydrochloride, Trifluridine Taiho Pharma Canada, Inc. No Yes No Yes No Yes No Yes Lupron, Lupron Depot 241744 Leuprolide Acetate Abbvie Corporation Yes Yes Yes Yes Yes Yes Yes Yes Micro+6 Concentrate 237994 Manganese Sulfate, Chromic Chloride, Cupric Sulfate, Selenious Acid, Zinc Sulfate Heptahydrate, Sodium Iodide Sandoz Canada Incorporated No Yes No No No Yes Yes No Mirena 243721 Levonorgestrel Bayer Inc No Yes No No No Yes No Yes PMS-Fluticasone Propionate/Salmeterol DPI 242762 Fluticasone Propionate, Salmeterol Xinafoate Pharmascience Inc No No No No No No No Yes Ravicti 241398 Glycerol Phenylbutyrate Horizon Therapeutics Ireland DAC No No No No No No No Yes Rydapt 241284 Midostaurin Novartis Pharmaceuticals Canada Inc No Yes No No No Yes No No Sandostatin LAR, Sandostatin 240998 Octreotide, Octreotide Acetate Novartis Pharmaceuticals Canada Inc No Yes No Yes Yes Yes No Yes Sandoz Metoprolol SR 240568 Metoprolol Tartrate Sandoz Canada Incorporated No No No No Yes No No Yes Sofracort 240569 Dexamethasone Sodium Metasulphobenzoate, Gramicidin, Framycetin Sulfate Sanofi-Aventis Canada Inc Yes Yes No Yes Yes No Yes Yes Tagrisso 242157 Osimertinib Mesylate AstraZeneca Canada Inc No No No Yes No No No Yes Tasigna 242015 Nilotinib Hydrochloride Monohydrate Novartis Pharmaceuticals Canada Inc No No No Yes No No No Yes Tiazac XC 238542 Diltiazem Hcl Valeant Canada LP Valeant Canada S.E.C. Yes Yes No Yes No No Yes Yes Xarelto 233166 Rivaroxaban Bayer Inc No Yes No Yes No Yes No Yes Zytiga 241627 Abiraterone Acetate Janssen Inc No Yes No Yes Yes No No Yes October 2020Product Monograph Brand Safety Updates October 2020(PDF, 70KB, 1 page) October 2020 Brand Name Submission Number Ingredient(S) Manufacturer Contraindications Warnings &.

Precautions Serious Warnings &. Precautions Adverse Reactions Drug Interactions Dosage &. Administration Overdosage Consumer Information Aubagio 239626 Teriflunomide Sanofi Genzyme, A Division of Sanofi-Aventis Canada Inc No Yes No Yes Yes No No Yes Elmiron 239842 Pentosan Polysulfate Sodium Janssen Inc Yes Yes Yes Yes No No No Yes Ibuprofen Liquid Filled Capsules, Extra Strength Ibuprofen Liquid Filled Capsules 240415 Ibuprofen Apotex Inc Yes Yes No No Yes No No Yes Imovane 240565 Zopiclone Sanofi-Aventis Canada Inc Yes Yes Yes Yes Yes No No Yes Ketalar 238402 Ketamine Hydrochloride ERFA Canada 2012 Inc Yes Yes No Yes No Yes No No Kisqali 233623 Ribociclib Succinate Novartis Pharmaceuticals Canada Inc No Yes No Yes No Yes No No Maviret 234362 Pibrentasvir, Glecaprevir Abbvie Corporation No No No No No Yes No No Plavix 239831 Clopidogrel Bisulfate Sanofi-Aventis Canada Inc No Yes No No Yes No No Yes Prezcobix 240107 Darunavir Ethanolate, Cobicistat Janssen Inc No No No No Yes No No Yes Prezista 240039 Darunavir Ethanolate Janssen Inc No No No No Yes No No Yes Renagel 238457 Sevelamer Hydrochloride Sanofi-Aventis Canada Inc No Yes No Yes No No No Yes Renvela 238461 Sevelamer Carbonate Sanofi-Aventis Canada Inc No Yes No Yes No No No Yes Salazopyrin, Salazopyrin En-Tabs 239257 Sulfasalazine Pfizer Canada ULC No No No Yes No No No No Symtuza 240432 Darunavir Ethanolate, Emtricitabine, Cobicistat, Tenofovir Alafenamide Hemifumarate Janssen Inc No No No No Yes No No Yes Tagrisso 234607 Osimertinib Mesylate AstraZeneca Canada Inc No Yes No Yes No Yes No No Talzenna 234108 Talazoparib Pfizer Canada ULC No Yes No Yes Yes Yes No No Tenormin 239845 Atenolol AstraZeneca Canada Inc No Yes No No No No No No Teva-Mexiletine 238065 Mexiletine Hcl Teva Canada Limited No Yes No No No No No No Twynsta 239007 Telmisartan, Amlodipine Besylate Boehringer Ingelheim (Canada) Ltd Ltee Yes Yes No Yes Yes No Yes Yes Zejula 237670 Niraparib GlaxoSmithKline Inc No Yes No Yes Yes Yes No Yes Zerbaxa 238477 Ceftolozane Sulfate, Tazobactam Sodium Merck Canada Inc No Yes No No No No No Yes Zofran, Zofran ODT 240200 Ondansetron Hydrochloride Dihydrate Novartis Pharmaceuticals Canada Inc No Yes No No No No No Yes September 2020Product Monograph Brand Safety Updates September 2020(PDF, 72 KB, 1 page) September 2020 Brand Name Submission Number Ingredient(s) Manufacturer Contraindications Warnings &.

Precautions Serious Warnings &. Precautions Adverse Reactions Drug Interactions Dosage &. Administration Overdosage Consumer Information Aubagio 231739 Teriflunomide Sanofi Genzyme, A Division of Sanofi-Aventis Canada Inc No Yes No Yes No No No Yes Dovato 233469 Dolutegravir, Lamivudine ViiV Healthcare ULC No No No Yes No No No No Heartburn Control 238026 Omeprazole Apotex Inc Yes Yes No Yes Yes Yes Yes Yes Imbruvica 233164 Ibrutinib Janssen Inc No Yes No No No Yes No No Incruse Ellipta 222505 Umeclidinium Bromide GlaxoSmithKline Inc No No No No No No No Yes Narcan Nasal Spray 234832 Naloxone Hcl Adapt Pharma Operations Limited No No No No No No No Yes Plaquenil 238801 Hydroxychloroquine Sulfate Sanofi-Aventis Canada Inc Yes Yes No Yes Yes Yes Yes Yes Saphris 238694 Asenapine Merck Canada Inc No Yes No No No No No No Soliqua 232504 Lixisenatide, Insulin Glargine Sanofi-Aventis Canada Inc No No No Yes No Yes No Yes Synthroid 238350 Levothyroxine Sodium BGP Pharma ULC Yes Yes No No Yes Yes No Yes Targin 237753 Naloxone Hcl, Oxycodone Hcl Purdue Pharma Yes Yes Yes Yes Yes Yes Yes Yes Venclexta 234504 Venetoclax Abbvie Corporation No No No Yes No Yes No No Zytiga 236834 Abiraterone Acetate Janssen Inc No No No Yes No No No No August 2020Product Monograph Brand Safety Updates August 2020(PDF, 82 KB, 2 pages) August 2020 Brand Name Submission Number Ingredient(s) Manufacturer Contraindications Warnings &.

Precautions Serious Warnings &. Precautions Adverse Reactions Drug Interactions Dosage &. Administration Overdosage Consumer Information Brilinta 231818 Ticagrelor AstraZeneca Canada Inc No Yes No Yes No Yes No Yes Butrans 237701 Buprenorphine Purdue Pharma Yes Yes Yes Yes Yes Yes Yes Yes Clinimix E, Clinimix 239475 Nitrogen, Amino Acids, Dextrose Baxter Corporation No Yes No No No Yes No No Codeine Contin 237940 Codeine, Codeine Sulfate Purdue Pharma Yes Yes Yes Yes Yes Yes Yes Yes Epuris 238793 Isotretinoin Cipher Pharmaceuticals Inc No Yes No Yes No No No No Hepsera 236397 Adefovir Dipivoxil Gilead Sciences Canada Inc No Yes No No Yes No No Yes Invokamet 232307 Metformin Hcl, Canagliflozin Janssen Inc No Yes No Yes No Yes No Yes Lokelma 231794 Sodium Zirconium Cyclosilicate AstraZeneca Canada Inc No Yes No Yes No Yes No Yes Lotriderm 237862 Betamethasone Dipropionate, Clotrimazole Merck Canada Inc Yes Yes No Yes Yes Yes Yes Yes Lynparza 235698 Olaparib AstraZeneca Canada Inc No Yes No Yes Yes No No Yes Mezavant 238836 Mesalazine Shire Pharma Canada ULC No No No Yes No No Yes Yes Mirapex 234378 Pramipexole Dihydrochloride Monohydrate Boehringer Ingelheim (Canada) Ltd Ltee No Yes No Yes No Yes No Yes MS Contin 237930 Morphine Sulfate Purdue Pharma Yes Yes Yes Yes Yes Yes Yes Yes MS IR 237978 Morphine Sulfate Purdue Pharma Yes Yes Yes Yes Yes Yes Yes Yes Otezla 233030 Apremilast Amgen Canada Inc No Yes No Yes No Yes No Yes Oxy.IR 237807 Oxycodone Hcl Purdue Pharma Yes Yes Yes Yes Yes Yes Yes Yes Oxyneo 237808 Oxycodone Hcl Purdue Pharma Yes Yes Yes Yes Yes Yes Yes Yes Sonovue 231944 Sulfur Hexafluoride Bracco Imaging Canada No Yes No Yes No Yes No No Sprycel 229858 Dasatinib Bristol-Myers Squibb Canada No Yes No Yes Yes Yes No Yes Sudafed Sinus Advance 237300 Ibuprofen, Pseudoephedrine Hcl McNeil Consumer Healthcare Division of Johnson &.

Buy zithromax canada

More Americans are vaccinated against buy antibiotics everyday, but that's buy zithromax canada not the only reason antibiotics cases in the U.S. Keep falling, buy zithromax canada Dr. Scott Gottlieb told CNBC on Friday.In an interview on "Closing Bell," the former Food and Drug Administration commissioner said additional factors contributing to declining levels include warming weather and the fact that a portion of the unvaccinated population has already been infected with buy antibiotics.Gottlieb's comments Friday came as the country's seven-day average of daily new antibiotics s fell below 30,000 for the first time in almost a year.

In late March, that figure was around 66,000.The case decline has coincided with buy zithromax canada an expansion of treatment availability. As of buy zithromax canada Friday, nearly 50% of the U.S. Population has received at least one buy antibiotics treatment dose, according to the Centers for Disease Control and Prevention.

In late March, that number was slightly less than 30%.However, the percentage of Americans who have some immunity against antibiotics is higher than the vaccination rates, Gottlieb buy zithromax canada said, estimating that at least one-third of the population has been infected. The U.S buy zithromax canada. Has had around 33 million total confirmed buy antibiotics cases, but Gottlieb has repeatedly said the official tally is an undercount."We don't have data on this, but my guess would be that the level among the unvaccinated population is probably higher because a lot of people probably aren't getting the treatment because they knew they were previously infected," Gottlieb said.People who have recovered from buy antibiotics do have natural antibodies, but the CDC and other experts recommend they also get the treatment.

In fact, people who had the disease and receive the buy antibiotics shot may develop stronger protection against zithromax buy zithromax canada variants.People who have yet to be vaccinated might have been less concerned about the zithromax during the zithromax and spent less time at home as a result, Gottlieb added."So, if you assume that the percent of prior among the unvaccinated population is more than that third, and it probably is, and you assume that we've given at least one dose to around half the population right now, we're approaching pretty high levels of immunity," said Gottlieb, who led the FDA from 2017 to 2019 in the Trump administration. He now serves on the board of treatment maker Pfizer.And while states are lifting many zithromax-era restrictions, such as capacity limits at restaurants, Gottlieb said, some people have not returned buy zithromax canada to their pre-buy antibiotics behavior, which is helping with case reductions."People are being more cautious, generally, even though we're starting to take masks off and go out and about," Gottlieb said. "People are more cautious about their interactions, so some of that is still having a downward effect on transmission."Gottlieb predicted the country's case counts will continue to decline in the coming weeks, while cautioning the zithromax is unlikely to be declared "over." He added, "I think we're going to have a very quiet summer with respect to antibiotics spread and then have to contend with it again as we head into the winter."Disclosure.

Scott Gottlieb is a CNBC contributor and is a member of the boards of Pfizer, genetic testing start-up buy zithromax canada Tempus, health-care tech company Aetion and biotech company Illumina. He also serves as co-chair of Norwegian Cruise Line Holdings' and Royal Caribbean's "Healthy Sail Panel.".

More Americans are vaccinated against buy antibiotics everyday, but that's not the only buy zithromax pill reason antibiotics cases in the U.S http://www.ec-louvois-strasbourg.ac-strasbourg.fr/wp/?page_id=3372. Keep falling, buy zithromax pill Dr. Scott Gottlieb told CNBC on Friday.In an interview on "Closing Bell," the former Food and Drug Administration commissioner said additional factors contributing to declining levels include warming weather and the fact that a portion of the unvaccinated population has already been infected with buy antibiotics.Gottlieb's comments Friday came as the country's seven-day average of daily new antibiotics s fell below 30,000 for the first time in almost a year. In late March, that buy zithromax pill figure was around 66,000.The case decline has coincided with an expansion of treatment availability. As of Friday, nearly 50% buy zithromax pill of the U.S.

Population has received at least one buy antibiotics treatment dose, according to the Centers for Disease Control and Prevention. In late March, that number was slightly less than 30%.However, the percentage of Americans buy zithromax pill who have some immunity against antibiotics is higher than the vaccination rates, Gottlieb said, estimating that at least one-third of the population has been infected. The U.S buy zithromax pill navigate to this web-site. Has had around 33 million total confirmed buy antibiotics cases, but Gottlieb has repeatedly said the official tally is an undercount."We don't have data on this, but my guess would be that the level among the unvaccinated population is probably higher because a lot of people probably aren't getting the treatment because they knew they were previously infected," Gottlieb said.People who have recovered from buy antibiotics do have natural antibodies, but the CDC and other experts recommend they also get the treatment. In fact, people buy zithromax pill who had the disease and receive the buy antibiotics shot may develop stronger protection against zithromax variants.People who have yet to be vaccinated might have been less concerned about the zithromax during the zithromax and spent less time at home as a result, Gottlieb added."So, if you assume that the percent of prior among the unvaccinated population is more than that third, and it probably is, and you assume that we've given at least one dose to around half the population right now, we're approaching pretty high levels of immunity," said Gottlieb, who led the FDA from 2017 to 2019 in the Trump administration.

He now serves on the board of treatment maker Pfizer.And while states are lifting buy zithromax pill many zithromax-era restrictions, such as capacity limits at restaurants, Gottlieb said, some people have not returned to their pre-buy antibiotics behavior, which is helping with case reductions."People are being more cautious, generally, even though we're starting to take masks off and go out and about," Gottlieb said. "People are more cautious about their interactions, so some of that is still having a downward effect on transmission."Gottlieb predicted the country's case counts will continue to decline in the coming weeks, while cautioning the zithromax is unlikely to be declared "over." He added, "I think we're going to have a very quiet summer with respect to antibiotics spread and then have to contend with it again as we head into the winter."Disclosure. Scott Gottlieb is a CNBC buy zithromax pill contributor and is a member of the boards of Pfizer, genetic testing start-up Tempus, health-care tech company Aetion and biotech company Illumina. He also serves as co-chair of Norwegian Cruise Line Holdings' and Royal Caribbean's "Healthy Sail Panel.".